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SUMMARY
A radioimmunoassay has been developed for the major metabolite of melatonin, 
6-sulphatoxymelatonin (aMT6s). The assay is specific, sensitive and is d irect fo r both 
urine and plasma samples. Classical validation procedures have been employed and the 
urinary assay has been compared with an established gas chromatographic/mass 
spectrometric assay.
A number of physiological studies have been carried out. A marked diurnal 
rhythm in both urinary and plasma aMT6s excretion was found which correlated closely 
w ith plasma melatonin values. There were large inter-individual variations in aMT6s 
excretion but its production was consistent for any one volunteer over a four-day 
period. No evidence was obtained for the episodic secretion of melatonin or aMT6s 
when blood samples were taken every th irty  seconds for ten minutes. Adm inistration 
of a peripheral 8-blocker to volunteers, resulted in the abolition of the night-tim e rise 
in aMT6s excretion.
In a seasonal study, a small but highly significant change in the acrophase of the 
aMT6s rhythm was found during the year w ith a phase advance in summer compared to 
winter. Changes in aMT6s excretion with age were also investigated. Total urinary 
aMT6s excretion was re la tive ly constant in fo rty  children aged 2-20 years. However, 
when aMT6s excretion was expressed as a function of body weight highly significant 
age-related changes were observed. In ninety adult volunteers aged 20-80 years there 
was a significant decline in to ta l 24h aMT6s excretion w ith age, w ith significantly 
lower excretion in elderly subjects. No relationships were found between to ta l 24h 
aMT6s excretion and body weight, height or pineal ca lcification.
In addition to the above physiological studies, the pharmacokinetics of melatonin 
and aMT6s were investigated following the oral administration of melatonin to normal 
volunteers.
ACKNOWLEDGEMENTS
I would like to express my gratitude to my supervisor, Dr Josephine Arendt, fo r 
her enthusiastic help and support in all aspects of this work. I also thank Professor 
Vincent Marks. I am grateful to Dr John Wright for his help w ith all the clin ical 
projects. Many thanks to all my colleagues, past and present, in laboratories 25AY19 
and 26AY19 for their technical, clinical and moral support. I am greatly indebted to 
my cohort of long-suffering volunteers fo r their generous donation of body fluids: 
without them none of this work would have been possible. I thank Miss Tracey Bakall 
fo r her expertise in the typing and word-processing of this manuscript, and Jolanta 
Bojkowska-Walmsley and Dr Peter Walmsley for proof-reading. I wish to thank the 
Wellcome Trust and the MRC for funding this work.
Finally, I wish to express my special gratitude to my parents fo r the ir unfailing 
love and support throughout my education.
ABBREVIATIONS
ADP Adenosine diphosphate
aMT6G 6-glucuronide melatonin
aMT6s 6-sulphatoxymelatonin
APS Adenosine-5-phosphosulphate
ATP Adenosine triphosphate
AUC Area under the curve
BSA Bovine serum albumin
cAMP Cyclic 3,,5,-adenine monophosphate
CNBr Cyanogen bromide
CNS Central nervous system
cpm Counts per minute
CSF Cerebrospinal flu id
CV C oefficient of variation
df Degrees of freedom
DMBA Dimethylbenz(a)anthracene
EC Electron capture
GABA y -amino-n-butyric acid
GC/MS Gas chromatography/Mass spectrometry
h Hour(s)
HIOMT Hydroxyindole-O-methyltransf erase
HPLC High performance liquid chromatography
HSA Human serum albumin
IgG Immunoglobulin G
K Equilibrium constant
L-Dopa L-3,4-dihydroxyphenylalanine
MAO Monoamine oxidase
min Minute(s)
NADPH 8-Nicotinamide adenine dinucleotide phosphate (reduced form)
NAS N-acetylserotonin
PAPS 3'-Phosphoadenosine-5'-phosphosulphate
PET Positive emission tomography
PPi Inorganic phosphate
RIA Radioimmunoassay
rpm Revolutions per minute
s Seconds
SCN Suprachiasmatic nucleus
TG Thyroglobulin
TLC Thin layer chromatography
vol Volume
VIP Vasoactive intestinal peptide
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Hard students are commonly troubled w ith gowts, 
catarrhs, rheums, cachexia, bradypepsia, bad eyes, stone, 
and collick, crudities, oppilations, vertigo, winds, 
consumption, and all such diseases as come by over-much 
sitting: they are most part lean, dry, ill-coloured ... and 
all through immoderate pains and extraordinary studies. 
I f  you w ill not believe the tru th of this, look upon great 
Tostatus and Thomas Aquainas' works; and te ll me 
whether these men took pains.
Burton's Anatomy of Melancholy, p.i.s.2
CHAPTER 1 
LITERATURE REVIEW
THE PINEAL GLAND
1. Introduction
Herophilos (325-280BC) an anatomist at the University of Alexandria, is 
credited with being the f irs t to discover the human pineal. I t  was Galen who later 
coined the term 'soma konoeides' or 'konareion' fo r the pineal, because in a number 
of species i t  is shaped like a pine cone (Kappers, 1981). The function of the pineal 
gland has remained an enigma and i t  is only w ithin the last twenty years that its role 
has begun to be understood.
1.1 Phylogenetic Development
The pineal gland exists in all classes of vertebrates, however, i t  has 
undergone major changes in the course of phylogenetic development. In lower 
vertebrates the epiphyseal complex (pineal gland) can consist of two components, 
the pineal organ proper and the parietal organ (or third eye). In the pineal gland of 
these species the outer segments of the sensory cells resemble re tinal cones and are 
directly photosensitive. In birds and reptiles the pineal is d irectly  responsive to 
ligh t, but i t  also has a secretory function. In the course of phylogenetic 
development the pineal organ has changed from a predominantly photoreceptive 
organ in lower vertebrates to a gland, which, in mammalian species is dependent on 
photic information conducted via the lateral eyes and the sympathetic nervous 
system and is probably entirely secretory in nature (Vollrath, 1981; Collin and 
Oksche, 1981; Reiter, 1983).
1.2 Anatomy
Embryologically, the mammalian pineal gland develops from  the 
diencephalic ependymal area, usually between the habenular and posterior 
commissures. There are great inter-species differences with respect to pineal shape
and position. In man, the pineal lies near the posterior margin of the diencephalic 
roof and occupies the depression between the superior co llicu lli of the 
mesencephalon. Proximally the organ is intim ately related to the th ird cerebral 
ventricle an evagination of which penetrates into the organ as the pineal recess. 
The weight of the pineal is about lOOmg in man and i t  is attached to the brain by 
means of a stalk. In humans, the pineal gland appears to be located outside of the 
blood-brain barrier (Arendt et al., 1983a) and pineal blood flow is one of the highest 
in the body (Vollrath, 1981).
1.3 Histology
The major cellular components of the pineal organ are the pinealocytes, 
which account for 80-90% of the cells. Mammalian pinealocytes consist of cell 
bodies w ith long cytoplasmic processes and they contain various organelles including 
dense-core vesicles, synaptic ribbons and synaptic spherules (Vollrath, 1981; 
Karasek, 1983; Vollrath, 1985). In addition to pinealocytes, glial cells are also 
present in varying numbers and astrocytes have been identified in some species. 
Occasionally, nerve cells, fibroblasts, mast cells, plasma cells and pigment- 
containing cells have been observed in the pineal glands of some species (Vollrath, 
1981).
1.4 Innervation
The mammalian pineal gland is innervated by three groups of nerve fibres: 
sympathetic, commissural and parasympathetic fibres. The major anatomical, and 
physiologically most important innervation is by the sympathetic postganglionic 
fibres from the paired superior cervical ganglia (Kappers, 1960). The neural 
pathway by which ligh t information reaches the pineal involves the retina, the 
retinohypothalamic trac t, the hypothalamic suprachiasmatic nuclei (SCN) and the 
paraventricular nuclei. Nerve impulses then traverse fibres in the median forebrain
bundle and re ticu la r formation to the intermediolateral cell column of the spinal 
cord. They then pass to the preganglionic adrenergic fibres of the sympathetic 
nervous system which synapse in the superior cervical ganglion. The pineal is fina lly  
innervated by sympathetic postganglionic fibres arising from the superior cervical 
ganglion (Moore, 1978). There is good evidence that the major aspects of pineal 
synthetic and functional ac tiv ity  are dependent upon the sympathetic innervation.
In addition to sympathetic fibres the mammalian pineal is also innervated 
by fibres from the posterior ahd habenular commissures (Korf and Moller, 1984). 
These fibres are thought to be peptidergic and electrophysiological evidence 
suggests that the direct connections from the central nervous system (CN5) to the 
pineal may be of functional significance. A parasympathetic innervation of the 
pineal has been shown (Kenny, 1961), however, there is l it t le  experimental evidence 
to suggest that these fibres have an e ffect on pinealocyte function (Vollrath, 1981).
1.5 Secretory Products
There are two main chemical classes of presumptive secretory substances 
in the pineal. These are the indoleamines and the peptides. The most intensely 
studied pineal product is the indoleamine, N-acetyl-5-methoxytryptam ine 
(melatonin). There are several other indoles which have been identified in the pineal 
and may have a possible hormonal role; these include 5-methoxytryptophol, 5- 
methoxytryptamine, N-acetylserotonin (NAS) and 8-carbolines. Many peptides are 
also present w ithin the pineal and may have a physiological function (Pevet, 1985).
1.6 Synthesis of Melatonin
A major breakthrough in pineal research occurred when Lerner and 
colleagues (1958) isolated and identified the active principle which caused blanching 
of amphibian skin. This active principle was melatonin. Melatonin is synthesized
within the pineal gland from the amino acid, tryptophan. Tryptophan is taken up by 
the pinealocytes and is hydroxylated to form 5-hydroxytryptamine (serotonin). The 
enzyme, serotonin N-acetyltransferase, converts 5-hydroxytryptamine to NAS and 
the specific enzyme, hydroxyindole-O-methyltransferase (HIOMT), converts NAS to 
melatonin (Klein et al., 1981). Most synthesis and secretion takes place at night in a 
normal environment. This synthetic pathway, together w ith that of other indoles, is 
shown in Figure 1.1. The metabolism of melatonin is outlined in Section 1.17.
The pineal is not the only site of melatonin biosynthesis. Other reported 
sites of synthesis are the retina, the Harderian gland (Pang et al., 1977) and the gut 
(Raikhlin et al., 1975). In most mammals, pinealectomy leads to undetectable levels 
of melatonin in the plasma (Arendt et al., 1980; Markey and Buell, 1982; Tetsuo et 
al., 1982a; Neuwelt and Lewy, 1983) suggesting that any effects of melatonin 
derived from non-pineal sites are local.
1.7 Control of Melatonin Synthesis
As suggested previously, light plays an important role in the function of 
the pineal gland. The sequence of events which controls the synthesis of melatonin 
is as follows. A fte r the onset of darkness the sympathetic nerves fire  w ith the 
subsequent release of the neurotransmitter, noradrenaline. Noradrenaline interacts 
with a post-synaptic 8-receptor on the pinealocyte cell membrane. The adenyl 
cyclase system is activated, an increase in cyclic 3',5’-adenosine monophosphate 
(cAMP) follows which, via a cAMP dependent protein kinase, brings about 
phosphorylation and increased protein transcription and translation. A t night there 
is a 70-100 fold increase in N-acetyltransferase activ ity  (in the ra t) ( Klein and 
Weller, 1970) and a small increase in HIOMT activ ity . These mechanisms result in 
the marked diurnal variation in melatonin synthesis; see Figure 1.2 (Klein et al., 
1981).
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Figure 1.2 Circadian Rhythms in Indole Metabolism
in the Rat Pineal Gland
The shaded area represents the dark period of the lighting cycle (Klein et al., 1981)
Recent evidence has shown that the control of melatonin synthesis is 
more complicated than outlined above. Noradrenaline has been shown to act on 
receptors to potentiate the e ffect of 8-adrenergic stimulation on cAMP levels 
(Vanecek et al., 1985) and diacylglycerol has been suggested as a possible secondary 
messenger of this mechanism (Sugden et al., 1985). In addition to the adrenergic 
receptors, pinealocytes also contain receptor sites for glutamate, #-amino-n-butyric 
acid (GABA), dopamine, benzodiazepines and serotonin. Various putative 
neurotransmitters, including GABA, vasoactive intestinal peptide (VIP) and 
substance P, have also been identified w ithin the pineal gland. The possible function 
of these receptors and neurotransmitters w ithin the pineal remains a mystery (Ebadi 
and Govitrapong, 1986).
1.8 Rhythmic Melatonin Production
Melatonin is produced with an endogenous rhythm which persists in
complete darkness and has a free-running period in man slightly longer than 24h
(Wever, 1986). The melatonin rhythm (at least in the ra t and monkey) is generated 
by the SCN of the hypothalamus (Klein and Moore, 1979; Reppert et al., 1981; Klein 
et al., 1983), the central rhythm-generating centre of the brain (Moore and Klein, 
1974). Light has a dual role in controlling the melatonin rhythm. F irs tly , ligh t 
entrains the rhythm to 24h (Lynch et al., 1978) and secondly, ligh t of a suitable 
wavelength and intensity w ill suppress the production of melatonin (Lewy et al., 
1980; Reiter, 1985; Bojkowski et al., 1987). Thus, in most species the duration of 
melatonin secretion correlates closely with the length of the night (Arendt, 1985).
1.9 Secretion of Melatonin
Melatonin has not been found in granules in the pineal gland and appears 
to exist in the cytosol. (Klein et al., 1981). Whether melatonin is d irectly  secreted 
into the cerebrospinal flu id  (CSF) remains uncertain and evidence suggests that
under normal circumstances melatonin is secreted prim arily into the systemic 
circulation (Arendt at al., 1977a; Rollag et al., 1978a; Brown et al., 1979; 
Withyachumnarnkul and Knigge, 1980).
1.10 Exogenous Factors Influencing Pineal Function
The function of the pineal has been described as that of a 'neuroendocrine 
transducer' (Wurtman and Axelrod, 1965). Unlike other endocrine organs the pineal 
is more or less d irectly influenced by environmental factors. The light-dark cycle is 
of primary importance in the control of pineal function (Sections 1.7 and 1.8). 
However, other environmental factors can also influence pineal function, 
particularly in lower vertebrates. These include temperature, humidity and 
nutritional factors (Vivien-Roels and Pevet, 1983; Vivien-Roels, 1985). Magnetic 
fields have also been shown to influence the pineal (Semm et al., 1980; Welker et al., 
1983).
1.11 Pineal Gland and Mammalian Photoperiodism
The mammalian pineal gland is a major endocrine component in the 
regulation of photoperiodic responses. Many mammalian species exhibit seasonal 
changes in, for example, body weight, pelage and reproductive behaviour. In most 
species the environmental cue which controls these changes is the annual change in 
day-length or photoperiod. The regulation of the reproductive cycle has been 
studied in most detail and w ill be discussed further.
A particular photoperiod can have d iffe rent effects in d iffe ren t species, 
fo r example, a short-day photoperiod is stimulatory in sheep (short-day breeder), 
whereas i t  is inhibitory in hamsters (long-day breeder). Pinealectomy or superior 
cervical ganglionectomy have been shown to disrupt breeding cycles; animals either 
continue permanently in one breeding condition or continue to exhibit cycles in
fe r t il ity , however, these changes are unrelated to photoperiod. These experiments 
demonstrate that the pineal gland is necessary for co-ordinating the reproductive 
system with photoperiod. Disruption of the circadian system by lesioning the SCN 
has also been shown to produce a similar e ffect (Rusak and Morin, 1976; Stetson and 
Watson-Whitmyre, 1976; Tamarkin et al., 1985a; Arendt, 1986a).
I t  has now been shown that the photoperiodic message is translated into 
an endocrine signal by the secretion of melatonin. Much early work on the role of 
melatonin made use of continuous release implants (Tamarkin et al., 1985a). I t  was 
not until i t  was realised that the tim ing of melatonin secretion was of crucial 
importance to its biological effects that the functions of melatonin were understood 
(Tamarkin et al., 1976). Various workers have demonstrated how the duration of the 
melatonin signal can vary w ith the prevailing photoperiod (Rollag et al., 1978b; 
Arendt, 1979; Arendt et al., 1981a; Skene £ t al., 1987). I t  is possible to administer 
melatonin in a variety of ways in order to mimic long or short photoperiods. Most 
recently the role of the melatonin signal in translating photoperiodic information 
has been elegantly demonstrated in experiments involving timed subcutaneous or 
intravenous infusions to pinealectomized hamsters or ewes (Carter and Goldman, 
1983; Bittman et al., 1983). These experiments have suggested that i t  is the 
duration of the melatonin signal which is the c ritica l parameter in bringing about 
reproductive changes related to photoperiod. The daily feeding of melatonin to 
in tact ewes in the late afternoon from mid-June, in such a way as to m imic a w inter 
night, w ill advance the onset of oestrus (Kennaway et al., 1982; Arendt et al., 
1983). A sim ilar e ffec t is observed w ith constant release implants (Nowak and 
Rodway, 1985; English et al., 1986; Arendt, 1986a).
1.12 Mechanism of Action of Melatonin
Two theories are used to explain photoperiodic time measurement. One 
theory is the 'duration1 hypothesis, whereby the day-length is used as an interval 
timer. A lternatively, there is evidence that circadian rhythms are involved in day- 
length perception. In the 'external coincidence' model, a circadian rhythm in 
photosensitivity has been proposed whilst in the 'internal coincidence' model i t  is 
suggested that the phase-relationships between different circadian rhythms are 
critica l (Pittendrigh, 1972; Pittendrigh, 1976).
Most evidence suggests that the duration of the nocturnal melatonin pulse 
indicates photoperiod length (Bittman et al., 1983; Goldman, 1983; Goldman and 
Darrow, 1983; Hastings et al., 1985a). No conclusive proof is available as yet and it  
is important to bear in mind that other properties of the melatonin signal may be of 
importance in the action of the hormone. These properties may include: (i) the 
amplitude of the nocturnal peak, (ii) the phase relationship of the peak to the ligh t- 
dark cycle or to other physiological rhythms, (iii) the duration of nocturnal 
secretion, (iv) the tota l amount secreted (Goldman, 1983).
1.13 Sites of Action of Melatonin
The means by which melatonin exerts its effects have yet to be identified.
Most workers have concentrated on possible sites of action in the brain. A specific
area of the anterior hypothalamus involved w ith photoperiodic responses has been
identified (Hastings et al., 1985b). Studies using putative melatonin binding sites
T 1251have in the past yielded equivocal results. Recently, I j-iodomelatonin has become 
available and binding sites have been identified in the brain (Laudon and Zisapel, 
1986; Laudon and Zisapel, 1987) including sites in the SCN and the median eminence 
(Vanecek et al., 1987). A specific melatonin antagonist which appears to be active 
ini v itro  and in vivo has been developed and this may prove to be a useful tool for 
elucidating this problem (Zisapel and Laudon, 1987).
In addition to a possible action on the brain, melatonin may also have a 
direct action on peripheral sites such as the ovaries. It has also been suggested that 
i t  may have a feedback effect on the pineal to modify the release of other 
compounds.
1.14 Other Target Organs of Pineal Substances
Many workers have studied the e ffect of the pineal gland on other target 
sites and endocrine glands, however, the results are largely contradictory and no 
convincing evidence has emerged. An interrelationship between the pineal and the 
thyroid gland has been suggested (Vriend, 1983). The pineal exerts a largely 
inhibitory influence on thyroid function though some studies have suggested a 
stimulatory e ffect (Vriend, 1983).
Interrelationships with other glands, including the parathyroids, the 
adrenals and the pancreas have been reported (Vollrath, 1981), however, no clear 
picture has emerged and a detailed discussion of this is beyond the scope of this 
thesis.
1.15 Circadian Rhythms and the Pineal
Many body rhythms are capable of self-sustaining oscillations under 
constant environmental conditions, ie, they are endogenous rhythms. Under these 
constant conditions many circadian rhythms exhibit a periodicity which does not 
correspond exactly to 24h. The main environmental signal that 'entrains' the 
endogenous oscillations to the 24h day is light. The anatomical pathway which is 
involved with the entrainment of circadian rhythms involves the eyes, the 
retinohypothalamic trac t and the SCN. The dominant central circadian pacemaker 
is located in the SCN of the hypothalamus (Moore and Klein, 1974; Rusak and 
Zucker, 1979). An island of SCN isolated from its neural surroundings in the ra t s till 
shows a persistent circadian rhythm of neural ac tiv ity  while similar rhythm ic ity  no 
longer occurs elsewhere in the brain (Inouye and Kawamura, 1979).
The exact role of the pineal gland in the mammalian circadian system is 
not resolved at present. In some birds there are at least two clock systems, one lies 
in the SCN and regulates the pineal via the usual multi-synaptic pathway through 
the superior cervical ganglion; the other in, for example, house sparrows, lies in the 
pineal itse lf (Zimmerman and Menaker, 1979). This 'clock* localized in the pineal is 
present in other vertebrates, for example, certain species of iguanid lizards 
(Underwood, 1977; Menaker and Wisner, 1983); however, i t  is absent in mammals 
(Follet et al., 1985).
There is nevertheless some evidence suggesting a role of the pineal gland 
in mammalian circadian rhythms. Pinealectomy leads to a more rapid re- 
entrainment of certain circadian rhythms in rats following an acute phase shift 
(Quay, 1970). In rodents the pharmacological administration of melatonin has been 
shown to have entraining or 'zeitgeber' properties (Redman et al., 1983; Murakami et 
al., 1983). These studies have been extended to humans and prelim inary results 
suggest that melatonin can help alleviate the symptoms of jet-lag, possibly via its 
entraining properties (Arendt £ t al., 1987).
1.16 Melatonin in Humans
Although a role for the pineal and melatonin has been established in 
seasonal breeders there is as yet l it t le  evidence for a major physiological role of the 
human pineal gland. To investigate the function of the human pineal gland most 
workers have concentrated on measuring the physiological and pathological 
variations in the concentrations of melatonin and its principal metabolites.
1.16.1 Variations in C irculating Melatonin Levels
Circulating plasma melatonin has been shown to be a good index of pineal 
function. Following pinealectomy, plasma levels are undetectable (Neuwelt and 
Lewy, 1983). During the day circulating levels are low and increase at night to 
reach a maximum around 0300h (Arendt et al., 1977a).
1.16.1.1 Light
Experiments on subjects in environmental isolation have shown that bright 
light (>25001ux) entrains human circadian rhythms (Wever et al., 1983). L ight also 
has a suppressive effect on the nocturnal production of melatonin. Lewy and 
colleagues (1980) demonstrated that light of an intensity of 25001ux would suppress 
melatonin production in humans, whereas light of an intensity of 5001ux was 
ineffective. Recent work has shown that when administered under the right 
conditions, light of an intensity as low as 3001ux w ill suppress melatonin production 
in man (Bojkowski et al., 1987).
1.16.1.2 Menstrual Cycles
When serum samples were taken at 0900h from five women through the 
menstrual cycle, melatonin was found to fa ll during the fo llicu lar phase and rise to a 
peak during the luteal phase (Wetterberg et al., 1976). Whether these changes 
represent differences in the phase or the amplitude of the melatonin rhythm is 
uncertain. Measuring 6-sulphatoxymelatonin (aMT6s) Fellenberg and colleagues 
reported no variation in excretion throughout the menstrual cycle (Fellenberg et al., 
1980; Fellenberg et al., 1982). Recently, possible phase-shifts and/or an increase in 
the amplitude of the rhythm during the luteal phase have been reported 
(Hariharasubramanian and Nair, 1983; Webley and Leidenberger, 1986). C learly, 
more evidence is required before the possible variations in melatonin secretion 
during the menstrual cycle are established.
1.16.1.3 Drug Effects
A number of drugs have been shown to affect plasma melatonin 
concentrations. 8-Blocking drugs decrease melatonin concentrations (Section 3.3). 
Drugs which increase noradrenaline and/or serotonin levels, such as the anti- 
depressant, desipramine, and the monoamine oxidase (MAO) inhib itor,
tranylcypromine, increase plasma melatonin levels (Wirz-Justice et al., 1980; Franey 
et al., 1986; Oxenkrug et al., 1986). The e ffec t of desipramine was shown not to be 
due t o . the inhibition of the hepatic metabolism of melatonin. S im ilarly, the 
phosphodiesterase inhibitor, rolipram, which increases cAMP levels, increased 
urinary aMT6s excretion from 2400-0600h (Checkley et al., 1987). Not all MAO 
inhibitors have been found to increase plasma melatonin. Two- to three-fold 
elevations in daytime plasma melatonin occurred in depressed patients treated with 
clorgyline or tranylcypromine but not those treated w ith the MAO-B inhibitor, 
deprenyl (Murphy et al., 1986). Conflicting results have been obtained w ith the 
agonist, clonidine. Lewy et al., (1986) reported a decrease in plasma melatonin 
levels, however, this has not been confirmed by Grasby and Cowen (1987a). The 
neuroleptic drug, chlorpromazine, was shown to increase serum melatonin 
concentrations, however, this was not due to a stimulation of the pineal but due to 
inhibition of hepatic metabolism (Smith et al., 1979). The peptide, destyrosine 
gamma endorphin, increased the urinary excretion of melatonin (C laustrat et al., 
1981). The effects of a variety of other drugs and hormones including L-3,4- 
dihydroxyphenylalanine (L-dopa), luteinizing hormone, thyroid-stim ulating hormone 
and 5-methoxypsoralen on melatonin levels in man have been studied (for a review 
see Vaughan, 1984; Souetre et al., 1987), but no consensus of opinion has emerged as 
to their effects as yet.
1.16.1.4 Depression
Various workers have suggested that melatonin levels are decreased in 
patients w ith depressive disorders (for a review see Grasby and Cowen, 1987b). 
Many of these studies have used a lim ited number of subjects, and control subjects 
and patients have not been well-matched with respect to a number of variables. A 
recent study has reported no differences in the plasma melatonin concentrations 
between patients w ith depression and well-matched control subjects (Thompson et 
al., 1988). The exact role of the pineal gland in depression needs to be resolved with 
further studies.
A great deal of interest was generated by the possible connection of the 
pineal w ith the psychiatric condition known as 'seasonal a ffective  disorder'. This 
small group of patients suffer depressive episodes during the w inter months. Lewy 
and Rosenthal considered that 'seasonal affective disorder' was a photoperiod 
related phenomenon, because the behavioural changes observed were so dependent 
on the season, and treated the symptoms with bright ligh t given as a summer 
skeleton photoperiod (Lewy et al., 1982; Rosenthal et al., 1984). The intensity of 
light used was that required for suppression of melatonin secretion (>25001ux). As 
melatonin conveys photoperiodic information in animals via its duration of 
secretion, i t  was logical to presume that bright light compression of the melatonin 
profile to a summer pattern would be an effective treatm ent. In fac t, recent 
evidence suggests that melatonin is not of major importance in seasonal a ffective
j
disorder as ligh t treatm ent given in the middle of the day is an e ffec tive  treatm ent 
and the suppression of melatonin secretion by atenolol is not always an effective  
treatment (Wehr et al., 1986; Rosenthal et al., 1986). Recently, W irz-Justice and 
colleagues (1986) have reported that both dim yellow light (2501ux) and bright white 
light (25001ux) treatments were effective. This whole area is currently very 
controversial w ith the use of evening bright light or morning bright ligh t being 
variously reported as more effective. Notably, Lewy et al., (1987) have proposed 
that morning bright ligh t treatment corrects the tim ing of the melatonin rhythm, 
delayed in their patients, via its phase-advancing properties.
1.16.1.5 Cancer
For many years a relationship between the pineal gland and malignant 
growth has been suggested, however, the results of early experiments were 
contradictory (Starr, 1970; Lapin, 1979). Results of more recent experiments have 
shown that tumour growth can be influenced by both photoperiod and tim e of day of 
melatonin administration (Bartsch and Bartsch, 1981; Stanberry et al., 1983). In
1981, Tamarkin et al., provided compelling evidence that pinealectomy increased 
and melatonin dramatically decreased the incidence of dimethylbenz(a)anthracene 
(DMBA)-induced mammary tumours in the rat. Recently, both melatonin and the 
conjugated metabolites of melatonin have been shown to inhib it the growth of 
cancer cells in v itro  (Tamarkin et al., 1985b; Leone et al., 1987a).
Clinical evidence has also suggested a relationship between pineal 
function and breast cancer and possibly other malignancies. The best evidence 
demonstrated low plasma melatonin levels in hormone-dependent breast cancer, 
w ith a correlation between plasma melatonin concentration and tumour oestrogen 
receptor concentration (Tamarkin et al., 1982a). However, there was no correlation 
between melatonin levels and other hormones studied, nor w ith risk status for breast 
cancer (Danforth et al., 1985). The exact role of the pineal in endocrine-related 
cancers remains to be clarified in future studies.
1.16.1.6 Seasonal Variations
Although i t  is well established that the pattern of melatonin secretion can 
vary throughout the year in many animal species, re lative ly few studies have 
examined the annual changes in human melatonin secretion. The studies which have 
been carried out have been largely incomplete due to methodological problems.
Some studies have only used one or two sampling points throughout the 
24h period. Annual variations have nevertheless been found with peaks in summer 
and winter and troughs in spring and autumn (Arendt et al., 1977b; Arendt et al., 
1979) and peaks in December and May with a nadir in August (Martikainen et al., 
1985). Similar results to Arendt and colleagues were reported by Birau et al., (1981) 
when blood samples were taken at six-hourly intervals for 24h from one hundred and 
seventy four subjects. The same subjects, however, were only studied on two 
occasions.
Touitou et al., (1984) examined plasma melatonin at d ifferent times of the 
year, in d ifferent age groups and in patients with senile dementia. The only 
consistent result was the stab ility of the peak-time for plasma melatonin. Other 
workers have found no seasonal differences in tota l melatonin production at 
d ifferent times of the year (Beck-Friis et al., 1984; G riffiths et al., 1986; Sack et 
al., 1986).
In studies with hourly blood sampling over 24h at two d iffe rent times of 
the year (winter and summer), the tota l melatonin production was the same. 
However, a phase-shift was observed. Illnerova et al., (1985) reported a phase 
advance of the summer profile by 1.5h compared to the winter profile in urbanized 
man in Czechoslovakia, while in the Antarctic there was a 2h phase advance of the 
summer profile relative to the winter profile (Arendt and Broadway, 1986). The 
data of Beck-Friis et al., (1984) also suggests a summer phase advance. Employing 
the RIA described in this thesis, Kennaway and Royles (1986) also investigated the 
circadian rhythm in aMT6s at two time points (winter and summer) and confirmed a 
phase advance of the summer profile.
1.16.1.7 Puberty
Pinealectomy hastens pubertal development in a number of species, 
whereas exogenous melatonin administration can delay sexual maturation in 
experimental animals (Lang, 1986). When lambs were implanted w ith melatonin 
there was a significant delay in the onset of puberty (Kennaway and Gilmore, 1984).
The role of the pineal and of melatonin in human sexual development 
remains unclear. Two lines of evidence suggest a relationship between pineal 
function and human puberty. Around 1900 Heubner reported a case of precocious 
puberty in a boy with a pinealoma and this led Marburg to suggest that the human
pineal gland was an endocrine organ which inhibited the function of the 
hypothalamus and thus the development of the reproductive system (Kappers, 1981). 
Destructive pineal tumours have been associated with precocious puberty and 
delayed puberty has been observed in boys with hyperactive pineal tumours (K itay,
1954). Most of the tumours are not pinealocytomas but dysgerminomas secreting 
human chorionic gonadotrophin (Sklar et al., 1981) and therefore i t  is d iff ic u lt to 
determine the exact role of the pineal gland.
Observations on the changes in circulating melatonin levels from infancy 
to adulthood also indicate that there may be a relationship between the pineal and 
sexual maturation in humans. A great deal of controversy, however, remains in this 
area largely due to methodological problems. In many of the studies carried out 
comparing plasma melatonin levels in prepubertal and pubertal children, blood 
samples were collected during the daytime yielding data of questionable value 
(Silman et al., 1979; Lenko et al., 1982; Gupta et al., 1983).
Silman and colleagues (1979) reported a significant difference between 
the daytime plasma melatonin levels of prepubertal and pubertal boys. However, 
these findings have never been replicated by other workers. Contradictory results 
have also been reported in studies which have used night-time blood sampling. 
Workers have found no changes in the plasma melatonin profile  w ith pubertal 
development (Ehrenkranz et al., 1982; Tamarkin et al., 1982b; Sizonenko et al., 
1985) or a decrease with sexual maturation (Gupta et al., 1983; Waldhauser et al., 
1984a; Attanasio et al., 1985).
No change in the excretion of urinary melatonin w ith pubertal 
development has been reported (Sizonenko et al., 1985), whereas Penny (1982) found 
an increase in melatonin excretion during puberty. An increase in 6-
hydroxymelatonin excretion in Tanner Stage II girls was reported by Tetsuo and 
colleagues (1982b), however, this particular group of subjects continued to show high 
levels throughout their development (unpublished observation, Tamarkin, 1985). No 
other changes in 6-hydroxymelatonin excretion during development were observed. 
In this study no correction for differences in body weight was made. Studies on 
children with abnormal pubertal development have also yielded contradictory results 
(Tamarkin et al., 1982b; Lissoni et al., 1983; Attanasio et al., 1984).
To date, the most extensive studies which have been carried out w ith well 
validated methodology are those of Waldhauser and colleagues (Waldhauser and 
Steger, 1986). Plasma samples were taken from two hundred and eighty subjects of 
all ages and no variation in daytime melatonin levels with age was found, whereas 
night-time levels were low during the firs t few months of life , increasing to peak 
values between 1-3 years and then progressively dropping until early adulthood.
1.16.1.8 Age and Body Parameters
A number of variables including age, sex, body weight and body height, 
have been reported to influence melatonin production in healthy subjects. In 
addition to the changes in melatonin production during childhood (see Section 
1.16.1.7) melatonin levels have also been demonstrated to decrease with age in 
adults in plasma (Touitou et al., 1981; Iguchi et al., 1982b; Beck-Friis et al., 1984; 
Nair et al., 1986; Waldhauser and Steger, 1986), CSF (Brown et al., 1979) and in 
urine (Sack et al., 1986).
The published reports on the relationship between melatonin production 
and body height/weight in adults have been contradictory. In a population which 
included both normal volunteers and subjects with major affective disorders, Beck- 
Friis and colleagues (1984) found a significant negative correlation between plasma 
melatonin and height. In contrast, Sack and co-workers (1986) w ith  a population of
sixty normal volunteers (age range 22-94 years), reported a significant positive 
correlation between urinary 6-hydroxymelatonin excretion and height, which was no 
longer significant when height was adjusted for age.
A positive correlation between plasma melatonin and weight was 
reported by Arendt et al., (1982) in women and by Ferrier et al., (1982) in men. Sack 
et al., (1986) found no relationship between 6-hydroxymelatonin excretion and 
weight. These workers also found differences between the sexes, w ith a negative 
association between 6-hydroxymelatonin levels and obesity in women and an 
opposite association for men. Recently, in an extensive and well-controlled study 
Nair and colleagues (1986) reported a significant decrease in melatonin levels w ith 
age but no relationship between melatonin levels and body height, body weight or 
obesity index.
1.16.2 Administration of Melatonin
Melatonin was administered to normal, and epileptic subjects 
intravenously, in doses ranging from 0.25mg/kg - 1.25mg/kg body weight, and 
increased sleep and a feeling of well-being and elation were found (Anton-Tay et al., 
1971). When two Parkinsonians received 1.2g melatonin orally fo r four weeks, a 
marked improvement in their symptoms was detected. No undesirable effects were 
observed (Anton-Tay et al., 1971). However, later studies on the administration of 
melatonin to Parkinson's patients demonstrated that daily oral doses (starting with 
lOOmg per day and increasing to lg  per day in divided doses) had no e ffect on 
Parkinsonian disabilities. Melatonin was well tolerated and transitory sedation was 
the only noticeable adverse reaction (Shaw et al., 1973).
Following the daily feeding of lg  of melatonin fo r 25-30 days to five 
human subjects w ith hyperpigmented skin, skin lightening was observed in one 
patient w ith untreated adrenogenital syndrome. There was no e ffec t on patients 
with idiopathic hyperpigmentation (Nordlund and Lerner, 1977). Melatonin appeared 
to depress the levels of serum luteinizing hormone and all subjects noted increased 
drowsiness. No evidence of tox ic ity  was observed (Nordlund and Lerner, 1977).
Other workers have also shown that pharmacological doses of melatonin 
induce sedation and sleep (Cramer et al., 1974; Vollrath et al., 1981) and a ffec t 
prolactin and growth hormone secretion (Smythe and Lazarus, 1974; Waldhauser et 
al., 1987). When 240mg of melatonin were given orally to normal volunteers over a 
2h period a decrease in self-reported alertness and increased sleepiness were 
observed. The effects were brief and there was no e ffect on sustained free motor 
performance, memory or visual sensitivity (Lieberman et al., 1984). Daily feeding 
of 2mg of melatonin in the late afternoon for one month had no e ffec t on growth 
hormone, luteinizing hormone, testosterone, thyroxine and cortiso l whereas the 
tim ing of prolactin secretion was slightly modified (Wright et al., 1986). The same 
dosing regimen significantly advanced the 'self-rated fatigue' rhythm and also phase 
advanced its own endogenous rhythm (Arendt et al., 1984; Arendt et al., 1985b). 
Recently, pharmacological doses of melatonin have been shown to alleviate the 
symptoms of je t-lag  and i t  has been suggested that this may be due to the hypnotic 
and synchronizing properties of melatonin (Arendt et al., 1986; Arendt et al., 1987).
METABOLISM OF MELATONIN
1.17 General Metabolism
The major pathway for melatonin metabolism was elucidated by Kopin and 
colleagues (Kopin et al., 1960; Kopin et al., 1961). Melatonin, labelled on either the 
methoxy group or the N-acetyl group, was injected into the ta il veins of rats, and 
urine and faeces were collected. 60-70% of the radioactivity was recovered in the 
urine and 15% in the faeces. The urinary metabolites were separated and 
quantitated with paper chromatography. The major metabolite, accounting for 70- 
80% of the radioactivity, was the sulphate conjugate of 6-hydroxymelatonin (6- 
sulphatoxymelatonin aMT6s) whereas the glucuronide conjugate of 6- 
hydroxymelatonin (aMT6G) represented only 5% of the administered rad ioactiv ity. 
An unidentified metabolite represented 12% of the radioactivity (Figure 1.3). The 
administration of radioactive melatonin to mice showed that melatonin is rapidly 
metabolized (ha lf-life  of approximately 2min) and a small portion is bound and 
retained (ha lf-life  of about 35min). An enzyme which hydroxylated melatonin in 
position six was found in rat liver microsomes (Kopin et al., 1961).
CPM aMT6s
6 0 0 0
4 0 0 0
2000 1 2 . 5
0 . 5 1.0
R f
Figure 1-3 Chromatogram of the Radioactive Metabolites of
r3 iH Melatonin
Percentages of excreted radioactivity of various metabolites are shown at top of 
bars.
(Kopin et al., 1961)
The above results were confirmed by Kveder and Mclsaac (1961). A fte r 
administration of [ ^ c  ] melatonin to rats, 70% and 20% of the ac tiv ity  was 
excreted in the urine and faeces, respectively. Analysis of radioactive
chromatograms showed that aMT6s accounted fo r 55%, the aMT6G fo r 30%, and 
other minor metabolites for 15% of the activ ity  in the urine. The major metabolic 
product of melatonin was identified as aMT6s by colour reactions, sulphate analysis, 
and by its hydrolysis to the free phenol. 5-Methoxyindoleacetic acid was found to be 
a metabolite of melatonin, but to account for only 2% of the dose. These authors 
also reported the presence of at"least two metabolites which did not react w ith 
Ehrlich's reagent.
A later study confirmed that the major metabolite of melatonin in ra t 
urine was indeed aMT6s (Taborsky et al., 1965). In addition, these workers reported 
that the th ird unidentified metabolite in the original study of Kopin et al., (1961) 
was free 6-hydroxymelatonin.
The firs t study on the metabolism of exogenous melatonin in humans was 
carried out by Jones et al., (1969). Radioactive melatonin was administered to five 
male patients. Three of the volunteers were schizophrenic, one had Huntington's 
Chorea and the f if th  had brain damage. Analysis of the rad ioactiv ity  in the urine 
showed that the general pattc n of metabolism was sim ilar in humans to that in rats. 
The major melatonin metabolites were aMT6s (59-79% of the recovered 
radioactivity) and aMT6G (13-29% of the recovered rad ioactiv ity). Some free 6- 
hydroxymelatonin was also excreted together w ith an unidentified acidic metabolite.
A d iffe rent metabolic pathway of melatonin exists in the CNS (H irata et 
al., 1974). A partia lly  purified enzyme from rabbit brain was shown to catalyse the 
cleavage of the indole ring, yielding N-acetyl-N-formyl-5-methoxykynurenamine,
which was further degraded to N-acetyl-5-methoxykynurenamine by the action of 
formidase. When [ ^ C  ] melatonin was injected intracisternally, the major 
metabolite in ra t brain was shown to be N-acetyl-5-methoxykynurenamine. A fte r 
intravenous administration of radioactive melatonin to rats, 15% of the tota l 
radioactivity was recovered as N-acetyl-5-methoxykynurenamine.
The deacetylation of melatonin to form 5-methoxytryptamine has been 
confirmed as a very minor metabolic pathway (Rogawski et al., 1979; Beck and 
Jonsson, 1981). The jn  v itro  incubation of liver slices with melatonin led to a 0.3- 
0.8% conversion to 5-methoxytryptamine. Rapid deamination follows and the final 
product is 5-methoxyindoleacetic acid.
Gas chromatography/mass spectrometry (GC/MS) was used by Leone and 
Silman (1984) to identify a new melatonin metabolite. When deuterated melatonin 
was administered to rats, GC/MS analysis of the urine showed the presence of 
deuterated 6-hydroxymelatonin and deuterated NAS, proving that NAS was 
metabolized directly from melatonin. The demethylation of melatonin to form NAS 
was also reported to occur in man, following the intravenous injection of deuterated 
melatonin (Young et al., 1985). The NAS metabolite is excreted as either the 
sulphate or glucuronide conjugate. The importance of this demethylation pathway 
for the metabolism of endogenous melatonin remains to be established.
Recently Vakkuri and colleagues (1987) have identified a novel metabolite 
of melatonin. This metabolite was isolated by chloroform extraction and reverse 
phase high performance liquid chromatography (HPLC) from human and ra t urine 
after administration of synthetic melatonin. This metabolite was shown to be 1- 
acetyl-l,2,3,3a,8,8a-hexahydro-8a-hydroxy-5-methoxypyrrolo 2,3-6 indole, a cyclic 
isomer of 2-hydroxymelatonin, by means of mass and proton magnetic resonance.
Studies with tritia ted  melatonin showed that this metabolite accounted for 5% of 
the urinary metabolites of melatonin in the rat. It remains to be determined 
whether this metabolite is formed from endogenously produced melatonin.
The metabolism of melatonin is summarized in Figure 1.4.
1.18 Sulphate Conjugation
Drug metabolism (and the metabolism of endogenous compounds) is 
normally divided into two phases: phase I (or functionalization reactions) and phase 
II (or conjugative reactions). Aromatic hydroxylation is a very common phase I 
reaction. The hydroxylation of melatonin yields a final product, 6- 
hydroxymelatonin, containing a chemically reactive functional group (-OH) which is, 
in the correct chemical state to be acted upon by the phase II or conjugative 
enzymes. In general, the main function of phase I metabolism is to prepare a 
compound for phase II metabolism.
Phase II metabolism (conjugation) involves a diverse group of enzymes (for 
example, UDP-glucuronyltransferases, UDP-glycosyltransferases, sulphotransferases 
and glutathione-S-transferase) which act on compounds to produce water-soluble 
products which can be excreted in urine or bile. The major conjugation pathway for 
melatonin is sulphation. 3'-Phosphoadenosine-5'-phosphosulphate (PAPS) is required 
as an 'active' donor. The production of PAPS from adenosine triphosphate (ATP) and 
inorganic sulphate is illustrated below:
S O ^ + ATP ATP-sulphurylasq^ /\( jenosine-5'-phosphosulphate + PPi
(APS) Inorganic phosphate
APS + ATP 3'-phosphoadenosine-5'-phosphosulphate + ADP
(PAPS) Adenosine diphosphate
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Sulphation of 6-hydroxymelatonin occurs by its interaction with PAPS in 
the presence of cytosolic sulphotransferase. For many endogenous compounds there 
is competition between the glucuronidation pathway and the sulphation pathway. In 
general, sulphate conjugation predominates at low substrate concentrations and 
glucuronide conjugation at high substrate concentrations (Gibson and Skett, 1986).
1.19 Biological Activity of Melatonin Metabolites
Very few studies have been carried out on the biological ac tiv ity  of 
melatonin metabolites. 6-Hydroxymelatonin was reported to be the only indole 
besides melatonin to produce a specific e ffect at a low dose on amphibian 
melanophores (Quay and Bagnara, 1964; Quay, 1968). Blinding adult male golden 
hamsters led to involution of the testes and accessory sex organs and to a regression 
in p itu itary prolactin levels within eight weeks. Subcutaneous implantations of 
either melatonin or 6-hydroxymelatonin were equipotent in preventing these 
changes, whereas NAS and 5-hydroxytryptophol were ineffective (Reiter and 
Vaughan, 1975). Another study demonstrated that five indoles, including 6- 
hydroxymelatonin and melatonin, decreased both the absolute and the relative 
ovarian and uterine weights of immature female mice pre-treated with human 
chorionic gonadotrophin (Vaughan et al., 1976a). N-Acetyl-5-methoxykynurenamine 
has also been shown to be biologically active. This melatonin brain metabolite was 
shown to be ten times more potent in inhibiting [^H ] diazepam binding to ra t brain 
synaptosomal membranes thanrmelatonin (Marangos et al., 1981). This metabolite 
was also demonstrated to have a marked and time-dependent inhibiting e ffect on 
prostaglandin biosynthesis in v itro , whereas melatonin was ineffective (Kelly et al., 
1984).
The influence of six pineal indoles on the sexual maturation of the male 
ra t was investigated by Lang and colleagues (1985). In addition to melatonin, only 5-
methoxytryptamine and 6-hydroxymelatonin inhibited the neuroendocrine axis during 
sexual maturation. These indoles were active when injected in the late afternoon 
and were inactive when injected in the morning. NAS, serotonin, 5- 
hydroxytryptophol and 5-methoxytryptophol were all inactive. The activ ity  of 5- 
methoxytryptamine was perhaps partly due to its conversion to melatonin in vivo. 
When injected in the late afternoon the potency of 6-hydroxymelatonin was 
approximately one tenth that of melatonin.
Recent evidence has emerged that the conjugated metabolites of 6- 
hydroxymelatonin are also biologically active. The potency of various indoles in 
inhibiting the growth of two human ovarian carcinoma cell lines was tested (Leone 
et al., 1987a). Melatonin was shown to inhibit ovarian tumour cell growth in v itro . 
The 6-hydroxylated melatonin metabolites were all more potent than melatonin. 
The most active compounds were 6-hydroxymelatonin and aMT6G. This is the firs t 
evidence to show that the conjugated metabolites of melatonin are biologically 
active.
ASSAY OF MELATONIN
1.20 Bioassay
The firs t methods used to measure melatonin were bioassays which relied 
upon the ab ility  of melatonin to aggregate melanin granules within the dermal 
melanophores of amphibian skin, thereby lightening the skin (McCord and Allen, 
1917). Lerner and colleagues used a bioassay to follow the isolation of melatonin 
from bovine pineal glands (Lerner et al., 1958; Lerner and Wright, 1960). The 
bioassay was sensitive and apparently specific (Quay and Bagnara, 1964). Ralph and 
Lynch (1970) developed another bioassay using tadpoles. The lower sensitivity lim it 
of this assay was lOOpg/ml. Pineal melatonin could be measured d irectly. However 
to measure circulating melatonin, serum had to be extracted and urine samples were 
concentrated by Amberlite XAD-2 column chromatography. A diurnal rhythm of a 
'melatonin-like substance' in plasma and urine in normal volunteers was 
demonstrated (Pelham £ t al., 1973; Lynch et al., 1975). This assay was also used to 
demonstrate that the urinary melatonin rhythm was not abolished by 28h of constant 
a rtific ia l light (Jimerson et al., 1977).
The bioassays suffered from the disadvantages that animal breeding 
fac ilities were required, they involved tedious and lengthy extractions, and they had 
poor precision and specificity. Residual amounts of organic solvents used in 
extraction were reported to interfere with the assays (Wilson e ta l., 1977).
The bioassays have been largely replaced by more sensitive, specific and 
convenient radioimmunoassays (RIAs) (Section 1.22). Rollag and White (1986) have 
recently applied the tadpole bioassay to screen for high a ffin ity  melatonin receptor 
agonists and antagonists. These authors have also started to investigate the 
molecular mechanism of the action of melatonin, by testing melatonin interaction 
with the components of the hormone-sensitive adenylate cyclase complex in a 
Xenopus dermal melanophore bioassay (White e ta l., 1987).
1.21 Spectrophotofluorometry
A ll 5-hydroxy and 5-methoxyindoles have a distinctive fluorescence in 
strong mineral acid at 540-550nm when activated at 295nm (Udenfriend et al.,
1955). A selective extraction procedure was necessary to separate 5-hydroxyindoles 
from 5-methoxyindoles. This approach was used by Quay (1963) to measure 
melatonin and a variety of d iffe rent indoles, and to demonstrate a circadian rhythm 
in rat pineal content (Quay, 1964). Maickel and M iller (1968) enhanced the 
fluorescence of indole derivatives by reaction with O-phthalaldehyde. The 
sensitivity of the method was suffic ient only to measure pineal gland melatonin or 
exogenously administered melatonin (Ozaki et al., 1976). Dreux (1969) reported a 
method for the measurement of melatonin in urine or pineal gland.
The above assays had problems with specific ity, since closely-related 
indoles could not be separated from melatonin, and extraction solvents, including 
chloroform, were reported to interfere (Wilson et al., 1977). The fluorom etric 
assays were largely replaced by RIAs which were more specific and sensitive.
1.22 Radioimmunoassay
1.22.1 Principle of RIA
In the late 1950s, patients treated w ith insulin were found to have 
developed antibodies which could bind both circulatory and iodinated insulin, in vivo 
and m vitro  (Berson et al., 1956). Both labelled and unlabelled hormone would' 
compete for the antibody binding sites. This competitive binding formed the 
theoretical basis for the principle of RIA, described by Yalow and Berson in 1960.
To perform a RIA the following are required: an antiserum binding the
ligand w ith high specific ity , standard cold ligand, labelled ligand and a method to 
separate bound and free ligand without disrupting the equilibrium. To assay
melatonin by RIA, an antibody specific fo r melatonin (Ab) and a radioactive ligand 
(Ag*) which can compete with melatonin (Ag) for the antibody binding sites, are 
required. I f  the number of antibody binding sites and the amount of radioactive 
antigen are kept constant the amount of radioactivity associated with the antibody 
is a quantitative function of the concentration of non-radioactive melatonin present 
in each tube.
Labelled
Antigen
Ag*
(free)
Specific
Antibody
Ab
Ag
/
V
Ag - Ab 
Unlabelled Antigen- 
Antibody Complex
Unlabelled Antigen 
in Known Standard 
Solutions or Unknown 
Samples
Labelled Antigen 
Antibody Complex
Ag* - Ab (bound)
When equilibrium is reached, bound and free ligand are separated. Either 
the bound radioactivity or the free radioactivity is counted. The concentration of 
unknown samples is determined by comparing the radioactivity measured to that 
observed in a standard curve where increasing known amounts of cold ligand have 
been added.
1.22.2 Production of Antiserum
A molecule as small as melatonin (molecular weight 232) is not antigenic. 
To e lic it an immune response, and to induce antibody formation, melatonin has to be 
conjugated to a large carrier protein. A number of d ifferent methods have been 
employed to couple melatonin or one of its analogues to d ifferent carrier molecules 
(see Table 1.1). The particular immunogen used plays an important role in 
determining the specificity of the antiserum produced (Brown e ta l., 1983).
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1.22.3 Radiolabel
The firs t published assays used tritia ted  melatonin (Arendt et al., 1975; 
Levine and Riceberg, 1975). Most of the RIAs published use commercially available 
tritia ted  melatonin, 35-80Ci/mM, available from New England Nuclear, Boston 
(USA) and Amersham International (UK) (Kennaway et al., 1977; Wetterberg et al., 
1978; Grota et al., 1981; Fraser et al., 1983a and Webley et al., 1985). Rollag and 
Niswender (1976) developed a RIA which had a sensitivity of 2-3pg/tube using 
radioiodinated melatonin analogue, iodinated N-3-(4-hydroxyphenyl)-propionyl-5- 
methoxytryptamine. An iodinated label has the advantage of increased sensitivity. 
Expensive and cumbersome liquid scintillation counting is also avoided. These 
advantages may be at the expense of specificity. Rollag and Niswender's assay has 
been improved by Claustrat et al., (1984) by using an iodinated tracer formed by 
reaction of Bolton Hunter's reagent (Bolton and Hunter, 1973) and 5- 
methoxytryptamine). Vakkuri et al., (1984) reported a technique by which melatonin 
was iodinated directly. The assay appears to have achieved excellent sensitivity 
together with the high degree of specificity required.
1.22.4 Preparation of Samples
To some extent the way samples have to be treated depends on the 
specificity of the antibody and the nature of the sample. Most of the melatonin 
RIAs published have required tedious extraction of the sample with organic solvents 
before assay. These extraction stages have typically included alkaline extraction 
with chloroform followed by petroleum ether (Arendt et al., 1977a); extraction with 
ethyl acetate (Jenkin et al., 1980) and extraction with water-saturated 
chloromethane (Wetterberg et al., 1978).
Kennaway et al., (1977) followed chloroform extraction of the samples by 
further purification on Lipidex 5000 columns. Similarly, following chloroform
extraction, Ozaki and colleagues (1978) purified urine and plasma samples by thin 
layer chromatography (TLC) before quantitation by RIA. An a ffin ity
chromatography method has been used by Thoresen (1978), where antibody has been 
coupled to Sepharose 4B to purify samples prior to assay. Baker reverse-phase C-18 
columns were used by Sieghart and co-workers (1987) to extract melatonin from 
serum. With a very specific antibody it  is possible to measure melatonin directly in 
plasma with no extraction stage. This assay has been applied to human (Fraser et 
al., 1983a), ovine (English et al., 1986) and rat plasma (Webley et al., 1985).
1.22.5 Separation of Samples
Samples are either incubated for a short period, for example, at 37°C for 
lh  (Wetterberg et al., 1978) or, more usually, they are incubated overnight at 4°C. 
Antibody-bound melatonin is usually separated from the free fraction by any one of 
three techniques; ammonium sulphate precipitation, separation with dextran-coated 
charcoal or precipitation using a double-antibody. A dialysis technique was used by 
Geffard and co-workers (1982). Following the addition of ammonium sulphate, 
Sieghart and colleagues (1987) replaced centrifugation with a filtra tio n  step 
involving Whatman GF/B glass-fibre filte rs.
1.22.6 Current Melatonin RIAs
RIAs are now extensively used for the measurement of melatonin in both 
tissues and body fluids in a variety of species. Melatonin has been assayed tissues 
and body fluids of many species, for examples, the pineal gland, retina, Harderian 
gland, brain and serum of rats and chickens (Pang et al., 1977); the plasma of man, 
sheep, rat, chicken, pig, donkey, cow, camel and scinzid lizard (Kennaway et al.,
1977); in human serum and C5F (Arendt et al., 1977a); human urine (Lang et al., 
1981), saliva (Vakkuri et al., 1985) and fo llicu lar flu id (Webley et al., 1985; 
Brzezinski e ta l., 1987).
D iffe rent RIAs have variable specificity and so i t  is important to validate 
new methods by comparison with as many other methods as possible. The firs t 
melatonin RIA was validated by comparison w ith the bioassay (Arendt et al., 1975). 
Chromatographic identity of immunoreactivity with melatonin in d iffe rent solvent 
systems has been used to validate assays by TLC (Arendt, 1978; Ozaki et al., 1976) 
and HPLC (Tamarkin et al., 1982b; Vakkuri et al., 1984). The firs t RIA to be 
validated by GC/MS was that of Kennaway and co-workers (1977). Other assays 
have been sim ilarly validated (Grota et al., 1981; Fraser et al., 1983b).
A collaborative study to compare methods of measuring melatonin in 
human plasma was organised by Wetterberg and Eriksson (1981). Twenty 
laboratories were asked to participate, out of which twelve (all using RIA 
methodology) co-operated. Most of the laboratories using RIA methods reported 
comparable results. This study showed that melatonin could be accurately measured 
using d ifferent RIA methods.
Reliable GC/MS methods to measure melatonin have been developed (for 
example, Lewy and Markey, 1978). The theoretical absolute specific ity  of this 
technique has meant that the values obtained by this method are used as a 
'standard', against which RIAs and other methods are compared. There is now 
general agreement that in normal human volunteers, daytime plasma melatonin 
levels are low (l-10pg/m l) w ith a nocturnal peak of about 30-100pg/ml. The earliest 
melatonin RIAs lacked complete specificity and the measured values were somewhat 
higher than the GC/MS values. There is now good agreement between the recently 
developed, very specific RIAs and GC/MS values (Fraser et al., 1983b; C laustrat et 
al., 1984; Waldhauser et al., 1984a; Vakkuri et al., 1984). However, in recent 
literature there has s till been a considerable variation in the reported levels of 
melatonin. Daytime human plasma melatonin levels of around 100-200pg/ml have
been reported by Birkeland (1982), whereas the majority of workers using RIA 
technology find daytime human plasma melatonin levels to be <20pg/ml. This 
illustrates one of the problems with RIA, that is despite extensive validation 
procedures, problems with cross-reactivity can occur. Both heparin (Johansson et 
al., 1984) and dimethylphthalate (Wetterberg et al., 1984) have been reported to 
interfere with melatonin RIA, yielding anomalous melatonin values. RIAs using the 
same antibody have to be extensively validated for each new application, whether 
this involves measuring melatonin in a new species or in a new tissue/body fluid. 
Even after extensive validation, the results obtained may depend on the skill of the 
individual operator.
These problems w ill not be resolved until an international quality control 
system for melatonin measurement is adopted. Where controversial results are 
obtained and/or very high endogenous melatonin levels are reported, workers in the 
field should be encouraged to exchange samples between groups so that the 
methodology employed can be validated.
1.23 Assay of Urinary Melatonin
The majority of RIAs described above have been validated to measure 
melatonin in body fluids, such as plasma and CSF, which obviously lim its  the type of 
clin ical studies which can be carried out. A small proportion of melatonin secreted 
by the pineal gland is excreted unmetabolized (Kopin et al., 1961). Human urinary 
melatonin has been measured by some workers as a non-invasive way of studying 
pineal function.
Lynch and colleagues (1978) applied the RIA of Levine and Riceberg 
(1973) to the measurement of urinary melatonin in man. Two methods were used to 
concentrate melatonin from urine; either Amberlite XAD-2 column chromatography
was used, or urine was directly extracted into chloroform. It was then necessary to 
further purify the urine samples by using the TLC method originally developed by 
Ozaki and co-workers (1978). The urinary melatonin levels measured using the RIA 
were sim ilar to those established by bioassay (Table 1.2). The method was used to 
demonstrate that 5-7 days were required to re-entrain rhythmic melatonin excretion 
to a 12h phase sh ift in the lighting schedule (Lynch et al., 1978). When nine blood 
samples were obtained from three volunteers it  was shown that urinary melatonin 
reflected circulating melatonin levels (r = 0.88, p<0.01).
Another RIA for urinary melatonin was developed by Wetterberg et al., 
(1978). Urine samples were extracted with chloromethane and washed with sodium 
hydroxide. Following oral administration of a melatonin solution only a small 
amount of the administered dose was measured in urine, indicating extensive 
metabolism of melatonin in man (Wetterberg et al., 1978). The correlation 
coefficient between serum melatonin levels at 0200h and the morning urine 
concentration of melatonin in twenty-four patients and healthy controls was 0.89 
(Wetterberg, 1978). The correlation between tota l urinary melatonin output and 
plasma melatonin levels measured with this assay, has not been reported. The 
urinary assay has been used to study the re-entrainment of the melatonin rhythm 
following an eastward fligh t and a 9h tim e-shift (Wetterberg, 1978), to study the 
e ffect of propranolol on melatonin output (Wetterberg, 1978), to investigate 
melatonin production during sleep deprivation (Akerstedt et al., 1979) and to 
compare urinary melatonin levels found in women with breast cancer to those found 
in controls (Bartsch et al., 1981). Representative urinary melatonin values reported 
using this assay are given in Table 1.2.
A decrease in urinary melatonin excretion from birth to adulthood was 
demonstrated by Lemaitre and colleagues (1981). The antiserum used was reported 
to be specific (Lemaitre and Hartmann, 1980) and urine samples were extracted
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using the method developed by Arendt et al., (1977a) for plasma samples. The assay 
was validated by chromatographic identity of immunoreactivity on TLC with one 
solvent system.
The firs t RIA for the measurement of urinary melatonin which has been 
extensively validated was reported by Lang and colleagues (1981). The specific ity of 
urinary melatonin measurements were confirmed by both TLC and GC/MS. These 
authors found that urine, unlike blood, contained many interfering substances which 
inhibited binding of the label to the antibody. Chloroform extraction alone did not 
remove all these cross-reacting derivatives from urine. In order to remove these 
interfering substances i t  proved necessary to wash the chloroform extract w ith 0.1M 
sodium hydroxide. A good correlation between plasma melatonin levels at midnight 
and nocturnal excretion of melatonin (2100-0700h) in thirteen adult volunteers was 
reported (r = 0.74, p<0.01).
The radioiodinated assay of Vakkuri et al., (1984) has also been applied to 
the measurement of urinary melatonin. Validation of the assay by HPLC 
demonstrated that the m ajority of urine immunoreactivity co-eluted w ith synthetic 
melatonin, but 7-23% contaminating immunoreactivity was observed. Urine samples 
were extracted w ith chloroform and, despite the incomplete specific ity  of the assay 
for urine determination, a diurnal rhythm for urinary melatonin excretion was 
observed.
Another radioiodinated assay, that of Rollag and Niswender (1976), has 
also been applied to the measurement of urinary melatonin (C laustrat et al., 1981). 
To attain specific ity improved iodination, extraction and separation methods were 
used. The validation procedures employed are described by Brun et al., (1983). 
However, extensive validation of the urinary assay has not been reported. This 
assay has been used to study the effects of destyrosine gamma endorphin on urinary 
melatonin levels (Chazot et al., 1983).
Urinary melatonin only represents a small percentage of secreted 
melatonin, consequently urine concentrations of melatonin are extremely low (Kopin 
et al., 1961; Lang et al., 1981). A number of factors are present in urine which can 
cause inhibition of binding. In view of the extremely low levels and problems with 
cross-reactivity, i t  is essential that methods to measure melatonin in urine are 
thoroughly validated. It is not sufficient to validate a RIA for plasma measurements 
and then apply the techniques to urine. Very few of the methods reported above 
have been extensively validated and the specificity of the measurements made has 
to be questioned. A summary of the human urinary melatonin levels reported in the 
literature using some of the above mentioned methods is given in Table 1.2.
1.24 Assay of Salivary Melatonin
A useful non-invasive method to study pineal function is to measure 
salivary melatonin. Using an iodinated melatonin label, Vakkuri (1983) has 
developed a salivary melatonin assay which has been validated by HPLC. Using six- 
hourly sampling, a circadian variation with a nocturnal peak has been demonstrated. 
The same assay was used to study the distribution of melatonin in human serum, 
saliva and urine following the oral administration of lOOmg of melatonin (Vakkuri et 
al., 1985). The results suggested that melatonin is passively secreted into saliva and 
they showed that salivary melatonin closely reflects changes in serum melatonin. 
The salivary melatonin concentrations corresponded to 21-56% of the serum 
concentrations.
Another salivary assay, modelled on the direct plasma method of Fraser 
and colleagues (1983a), has been developed (Miles et al., 1985). Their findings 
confirm the observations of Vakkuri. Paired plasma and saliva samples, taken hourly 
from six volunteers between 2000h and 0800h, correlated well (r = 0.971, p<0.001). 
The mean concentration of melatonin in saliva was 24% of the corresponding 
concentration in plasma.
Most recently, McIntyre and co-workers (1987) have also adapted the RIA 
of Fraser et al., (1983a) to the measurement of salivary melatonin. Melatonin was 
found to correlate in plasma and saliva, described by a linear regression equation: y
= 0.55x - 2.6 (r=0.90). In four subjects, the nocturnal rhythm in saliva was parallel
to that observed in plasma. When one subject was challenged by exposure to 30001ux 
of light for lh  at 2400h a good correlation between plasma and salivary melatonin 
was also observed.
Further work needs to be carried out to determine the e ffect of changes 
in salivary flow-rate on melatonin levels. Extensive validation has to be carried out 
to ensure that artefactual results are not obtained. It has been reported that 
toothpaste, coffee (Laitinen and Harma, 1987) and potato crisps (McIntyre et al., 
1987) can interfere with salivary melatonin RIAs.
The preliminary results with the salivary assays indicate that the method 
w ill prove to be very useful, particularly when blood samples are d iff ic u lt to obtain.
1.25 Non-Isotopic Immunoassays
1.25.1 Chemiluminescence Immunoassay
Gupta and co-workers (1985) reported a chemiluminescent assay for the 
measurement of serum melatonin. The stable tracer is formed by reacting 
aminobutylethyl isoluminol with melatonin. A fte r overnight incubation at 4°C, 
charcoal separation is used to separate bound and free antigens. Aliquots of 
supernatant are taken and luminescence initiated by oxidation of the label w ith a 
hydrogen peroxide-microperoxidase system at pH 8. The method has a sim ilar 
sensitivity (standard curve range 4-500pg per tube), specificity and precision as the 
Rollag and Niswender RIA (1976).
The method is fa irly  rapid, the tracer is stable and presents none of the 
hazards associated with radioactivity. This method does have the disadvantage that 
prior extraction of the plasma sample is required.
1.25.2 Enzyme-Linked Immunoassay
A enzyme immunoassay to measure melatonin in serum, CSF and pineal 
gland has been developed (Ferrua and Masseyeff, 1985). Though not extensively 
validated, the assay is sensitive, fa irly  specific and values for sera were in the 
'expected' range. The assay is based on the measurement of the distribution of an 
enzyme-labelled anti-hapten antibody (anti-melatonin - immunoglobulin G (IgG) 
coupled to horseradish peroxidase) between solid phase - hapten (human serum 
albumin-5-methoxytryptamine hemisuccinate conjugate physically absorbed onto 
polystyrene spheres) and liquid phase hapten. The assay has the advantages that it  is 
simple to perform, the label is easy to prepare and chloroform extracted samples 
can be measured. Further evaluation of the method is necessary to confirm its 
specificity. The assay promises to be very useful, particularly i f  the sensitivity is 
further increased by the use of a fluorogenic substrate.
1.26 High Performance Liquid Chromatography
HPLC is a very powerful separation technique. Liquid chromatography 
involves the passage of a mobile liquid phase over a solid stationary phase. In 
HPLC, the close packed nature of the particulate stationary phase offers rapid 
resolution and high chromatographic efficiency but requires re lative ly high-pressure 
pumping systems to establish and maintain flow of the mobile phase through the 
column. For most HPLC methods 'reverse phase' chromatography is used, which 
involves the use of a non-polar stationary phase and a polar eluent (the mobile 
phase). Following separation of compounds by HPLC, detection of compounds is 
accomplished either by fluorometric or by electrochemical detection.
An assay using a cation exchange resin with electrochemical detection 
was developed by Goldman and colleagues (1980). A to ta l of fourteen indoles were 
tested, including melatonin and 6-hydroxymelatonin. A reversed phase HPLC with 
electrochemical detection to measure tryptophan and other indole metabolites 
(including melatonin and 6-hydroxymelatonin) was developed by Mefford and Barchas 
(1980). Not all the peaks obtained from the tissue supernatants were identified and 
so the specificity of the method has to be questioned. The assay was later modified 
by using a more e ffic ient column, a slightly higher pH, and by incorporating 
acetonitrile instead of methanol in the mobile phase (Mefford et al., 1983).
A fluorometric method, which was validated by using a fluorom etric 
detector and a electrochemical detector in series, was developed by Anderson and 
co-workers (1982). A total of six indoles, including melatonin, could be assayed. 
The use of two detectors improved the specificity of the method: in order to 
interfere, a compound would have to have the same retention time and the same 
ratio of response on the two detectors as the indole of interest.
The next major advance was the incorporation of internal standards to 
reduce the errors during extraction procedures and to increase analytical precision. 
A dual detection method using 4-aminoantipyrine, an ultraviolet-absorbing 
substance, as an internal standard has been reported (Wakabayashi et al., 1983). The 
method was simplified by using veratric acid as an internal standard and a 
fluorom etric detection system (Wakabayashi et al., 1986). Another system, which 
also included an internal standard, was reported by McNulty and colleagues (1983). 
The internal standard was 3-hydroxy-4,3-dimethoxybenzoic acid and electrochemical 
detection was used. In a modification of the system, using a column w ith 3pm 
reverse phase C18 particles, eleven indoles (including melatonin) could be measured 
in one pineal in a single run (McNulty et al., 1986).
HPLC has the major advantages that i t  is possible to measure a number of 
compounds in a single sample, the technique is specific and re la tive ly inexpensive; 
sample preparation is minimal. The application of HPLC to the measurement of 
melatonin has, however, been restricted to measuring pineal melatonin. A t the 
moment the detection systems are not suffic iently sensitive to measure melatonin in 
body fluids. An area in which HPLC has proved to be extremely valuable is in the 
validation of RIAs (Tamarkin et al., 1982b; Vakkuri et al., 1984).
1.27 Thin Layer Chromatoqraphy/Radiospectrometry
TLC coupled w ith radiospectrometry is a very useful technique to study 
the metabolism of indoles. A radiolabelled indole is usually incubated in v itro  w ith 
pineal tissue for several hours. A TLC system is then used to separate the d iffe rent 
metabolites, the rad ioactiv ity across the plate is subsequently measured. The 
technique has the advantages that i t  is quick, re lative ly cheap and, i f  a good 
separation system is used, several indoles can be measured at once. To a certain 
extent, the results obtained depend on where the radioactive precursor under study 
is labelled and few workers monitor the recovery of added radiolabel. This method 
has been used to study the metabolism of indoles (Wainwright, 1977) and to 
demonstrate metabolic changes induced by pharmacological agents (Voisin et al., 
1983; Morton, 1983). The major disadvantage of the technique is that endogenous 
indole levels cannot be measured.
1.28 Gas Chromatography
Separation is achieved by GC because of a d iffe ren tia l distribution 
between a stationary liquid phase coated on an inert column packing material and a 
mobile gas phase, forced through the column. Prior to injection onto the column, 
biological samples require a laborious extraction stage. This is followed by chemical 
reaction to produce a melatonin derivative w ith an appropriate vapour pressure fo r 
GC and to fac ilita te  detection.
1.28.1 Gas Chromatography/Electron Capture Detection
The recombination of ions is the principle of operation of the electron 
capture detector. The detector has an ion chamber containing an ionizable gas, 
which is held at a potential sufficient for the collection of all free ions produced 
(the standing current of the detector). The introduction of the melatonin derivative, 
which has a high electron a ffin ity , into the chamber produces a change in the 
standing current which is recorded.
To measure melatonin in biological material prior extraction is necessary, 
followed by the formation of a halogenated derivative. Melatonin has been 
measured in both rat and human pineal glands (Degen et al., 1972; Greiner and Chan,
1978). The specificity of the method is based on the purification of the ionizable 
melatonin derivative on the GC column. The preliminary extraction step is 
important in order to separate melatonin from other indoles which may form the 
same halogenated derivatives. Interfering substances in biological samples can also 
effect the derivatization step and the gas chromatographic separation. GC with 
electron capture.detection has now been largely replaced by the much more specific 
method of GC/MS.
1.28.2 Gas Chromatography/Mass Spectrometry
This is, theoretically, the most specific method for the measurement of 
melatonin. Samples are separated on the GC column, concentrated and ionized. 
The charged fragments are accelerated through electric and magnetic fields which 
separate them on the basis of their charge and mass, and, theoretically, an absolute 
identification of the parent compound is achieved. Extensive purification of the 
biological samples is s till necessary prior to assay. A major advance in the GC/MS 
measurement of melatonin was the inclusion of deuterated melatonin as an internal 
standard (Kennaway et al., 1977). This enabled endogenous melatonin to be
measured w ith great accuracy. GC/MS has been used to quantitate and identify 
melatonin in body fluids (Kennaway et al., 1977; Wilson et al., 1977), various tissues 
(Kennaway et al., 1977) and to validate RIAs (Kennaway et al., 1977; Fraser et al., 
1983b).
Lewy and Markey (1978) were the firs t to use negative chemical- 
ionization for the measurement of melatonin, thereby greatly increasing the 
sensitivity of the method. Skene and co-workers (1983) developed a method using a 
double focussing magnetic mass spectrometer which increased resolution and 
reduced sample preparation to a minimum. Theoretically, several compounds at 
once can be measured by GC/MS in a single sample. Very few methods have been 
developed in which this has been achieved. However, Beck and colleagues (1981) 
reported a method fo r simultaneous measurement of melatonin and 5- 
methoxytrytophol in a single pineal extract.
The disadvantages of GC/MS are that it  is expensive to run, requires 
trained personnel and extensive sample purification. GC/MS is not suited to the 
large numbers of samples associated with clin ical work and research into rhythm ic 
physiological phenomenon, because of the low sample throughout.
ASSAY OF MELATONIN METABOLITES 
1.29 Assay of Melatonin Metabolites and General Considerations
Studies of human pineal function have been largely restricted by the 
methodology which has been available. As described above, most of the methods to 
measure melatonin in man rely on the measurement of melatonin in blood. In order 
to get meaningful results i t  is necessary to take blood samples over 24h, which 
obviously restricts the type of studies which can be carried out. Some workers have 
set up assays to measure melatonin in urine (Section 1.23). The disadvantage with 
this approach is that urinary melatonin only represents a small percentage of 
endogenously secreted melatonin (see Section 1.17). More recently salivary 
assays have been established (Section 1.24). Saliva samples are easier to obtain than 
plasma samples but, unless frequent sampling is undertaken they do not necessarily 
represent an integrated measure of endogenous melatonin production.
To circumvent the above problems workers have established assays to 
measure the major urinary metabolites of melatonin. These provide an integrated 
measure of endogenous melatonin production.
1.30 Radiospectrometry Coupled with Chromatographic Separation
In the pioneering studies on the metabolism of melatonin (Kopin et al., 
1961; Kveder and Mclsaac, 1961) mice and rats were injected w ith tr itia te d  
melatonin and urine was collected. The urinary metabolites were separated by paper 
chromatography and quantitative estimation of the metabolites was obtained by 
scanning the radioactive chromatograms (see Section 1.17). A sim ilar approach was 
adopted to study melatonin metabolism in human volunteers (Jones et al., 1969). 
Five male patients were injected with [ ^ C ]  melatonin and urine was collected. 
The urinary metabolites were separated by extraction with ethyl acetate followed 
by column chromatography of the aqueous portion on Sephadex G-10. The re lative
proportion of each metabolite was determined by measuring the percentage of 
radioactivity appearing in each peak. This technique has obvious lim itations for the 
measurement of urinary melatonin metabolites in humans and presents considerable 
ethical problems.
1.31 Spectrophotofluorometry
A recent report has appeared for the fluorometric determination of the 
daily urinary excretion of '6-oxymelatonin' (Grinevich and Labunetz, 1986). The 
method used was originally reported by Zubkov and co-workers (1974) in Russian, 
and is based on the spectrofluorometric method for the measurement of urinary 
melatonin of Dreux (1969).
Exactly which of the urinary metabolites of melatonin the measurement 
of '6-oxymelatonin' encompasses is not made clear in the methodology. The 
specificity of the method has to be questioned as extensive validation procedures do 
not appear to have been carried out. No indication of in ter- or intra-assay variations 
is given and the method has not been compared with any other existing assays. It is 
unfortunate that no circadian rhythm in excretion has been established using the 
assay, and only 24h urinary excretion values have been reported (Table 1.3). The 
values reported nevertheless, are in the range expected for the 6-hydroxylated 
metabolites of melatonin.
1.32 High Performance Liquid Chromatography
HPLC methods for the measurement of 6-hydroxymelatonin and NAS have 
been developed (Section 1.26 for example Mefford and Barchas, 1980), however, 
these methods have not been applied to the measurement of melatonin metabolites 
in urine.
No methods for the measurement of the conjugated melatonin metabolites 
have been reported. Recently, HPLC techniques for the measurement of the 
sulphate conjugates of various catecholamines and of serotonin-O-sulphate in urine 
samples have been developed. These techniques, a post-column hydrolysis technique 
and a dual-electrode electrochemical procedure (Elchisak, 1983a and b) could be 
applied to the measurement of the urinary conjugates of melatonin. The 
concentrations present in urine are relatively high and sample preparations would be 
minimal. With a suffic iently good separation system, all the conjugated melatonin 
metabolites could be measured in one run. Another important application of this 
technique would be to study the metabolism of melatonin in detail. The main 
disadvantage of the method is that it  is re latively expensive to establish and 
maintain HPLC equipment.
1.33 Gas Chromatography
Gas chromatographic methods for the determination of melatonin and 6- 
hydroxymelatonin have been developed. Retention times were established on one 
non-polar and three polar columns with an argon ionization detection system (Greer 
and Williams, 1967). Attempts to detect melatonin and 6-hydroxymelatonin (free or 
conjugated) in normal human urine and in the urine of two patients w ith 
parenchymatous pinealoma were unsuccessful. Based on the conditions of the 
analysis, the authors estimated that the normal excretion of free melatonin and free 
6-hydroxymelatonin was less than 10pg/day. It is likely that these authors failed to 
detect the metabolites in urine because of decomposition during sample preparation 
and derivatization.
6-Hydroxymelatonin was identified by GC/MS in normal human urine by 
Sisak and colleagues (1979). Urine was hydrolysed, extracted and 6- 
hydroxymelatonin was reacted to form the t-butyldimethylsilyl-pentafluoropropionyl 
derivative. The amount of 6-hydroxymelatonin detected was estimated at 20ng/ml.
The firs t quantitative assay for a urinary metabolite of melatonin was 
developed by Fellenberg and co-workers (1980), who developed a GC/MS method for 
the measurement of urinary aMT6s. aMT6s was chemically synthesized using the 
method of Baillie et al., (1973) and deuterated aMT6s, which served as an internal 
standard, was also prepared. The assay procedure involved isolation of aMT6s from 
urine using XAD-2 and F loris il columns, prior to derivatization to form a 
trim ethyls ily l derivative. The inter- and intra-assay variations of the method were 
good. A marked nocturnal rise in aMT6s excretion was established and the reported 
values are shown in Table 1.3.
Another quantitative assay for the measurement of urinary melatonin 
metabolites was reported by Tetsuo and co-workers (1981a). Deuterated aMT6s was 
added to a urine sample as an internal standard. The urine was hydrolysed 
enzymatically and free 6-hydroxymelatonin extracted and reacted to form  a stable 
t-butyldimethylsilylpentafluoropropionyl derivative. I t  was then separated by silica 
gel column chromatography, and quantitated using electron capture negative ion 
chemical ionization mass spectrometry. Inter- and intra-assay variations were good. 
This method measures the tota l free and conjugated 6-hydroxylated urinary 
metabolites of melatonin. Diurnal variations in melatonin metabolite excretion 
were demonstrated and the values reported are shown in Table 1.3.
An assay for the simultaneous measurement of aMT6s and aMT6G in 
human urine was developed by Francis and colleagues (1987). The conjugates are 
extracted on octadecylsilane-bonded silica cartridges and separated on silica 
cartridges. A fte r hydrolysing the separated conjugates enzym atically, free 6- 
hydroxymelatonin is determined by GC/MS. The recoveries were low and variable, 
which necessitated the addition of deuterated sulphate and glucuronide conjugates 
to the urines before extraction. The reported inter- and intra-assay variations were
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good. No values for the endogenous levels of either compound were reported in this 
paper and a diurnal rhythm in excretion has not been established. This method has 
also been adapted for the measurement of aMT6s in hamster urine where a two-fold 
day/night difference in excretion has been reported (Korenman et al., 1987).
The reported GC/MS methods are sensitive and specific. However, they 
suffer from the disadvantages that they require laborious sample preparation and 
are expensive to maintain. A quantitative GC/MS assay for 5-methoxyindole-3- 
acetic acid, a minor melatonin metabolite, in human urine has been recently 
reported (Higa and Markey, 1985). The daily pattern of excretion bore no 
relationship to that of 6-hydroxymelatonin, indicating that the major portion of 
urinary 5-methoxyindole-3-acetic acid does not derive from melatonin. GC/MS has 
also recently been used to identify new melatonin metabolites. Young and 
colleagues showed that melatonin could be metabolized to form NAS as well as 6- 
hydroxymelatonin in man (Young et al., 1985) (Section 1.17).
1.34 Project
In view of the constraints posed by measuring melatonin in plasma 
samples, the aim of the project was to set up a method to measure a urinary 
metabolite of melatonin. We decided to develop a RIA for aMT6s the major 
melatonin metabolite. RIA has the advantages of being quick, re latively inexpensive 
and is amenable for the measurement of the large numbers of samples associated 
with clinical work.
CHAPTER 2
DEVELOPMENT OF 6-SULPHATOXYMELATONIN RADIOIMMUNOASSAY
2 Introduction
To develop a RIA which is both sensitive and specific, i t  is necessary to 
raise antibodies which have a high avidity and specificity. A number of factors can 
affect the quality of the antiserum produced. The conjugation method used should 
not alter or mask the antigenic determinants of the hapten molecule, as to be 
specific the antibodies produced should re flect these characteristics. A number of 
other factors are also important; these include the choice of carrier protein, the use 
of adjuvants, the choice of species and the route of administration.
The chances of e liciting a good immune response are increased by the use 
of an adjuvant such as mineral oil. The adjuvant is mixed with an immunogen to 
form a stable emulsion. Adjuvants are believed to work by acting as a depot and 
releasing immunogens slowly, thereby preventing rapid uptake into the circulation 
and degradation of the immunogen by proteolytic enzymes. The adjuvant causes 
local and general stimulation of the reticuloendothelial system, assists phagocytosis 
and attracts macrophages to the site of injection (Hum and Landon, 1971). A 
modified Freund's adjuvant (Morris) was used which has the same properties as 
complete Freund's adjuvant without causing ulceration at the site of injection 
(Marks et al., 1975). The immune response of an animal to a particular compound is 
genetically determined and is dependent on both the species and the strain. It is 
best to immunize a species/strain of animal which is known to respond well to a 
particular immunogen or to very similar immunogens.
A t the commencement of this project, no methods for the direct 
iodination of melatonin had been published. The approach adopted to prepare an 
aMT6s radiolabel was the biological transformation and subsequent purification of 
commercially available tritia ted  melatonin. Although iodinated labels have a higher 
specific activ ity , the commercially available tritia ted  melatonin labels are of 
su ffic iently high specific activ ity  to permit the development of sensitive assays.
In order to make quantitative comparisons between laboratories i t  is 
necessary to have a common standard. Unfortunately no international aMT6s 
standard exists. A t the start of this project it  was necessary to chemically 
synthesize aMT6s within our laboratory. Following the development of the RIA 
described in this thesis, several aMT6s standards from other research laboratories 
have been made available to us and have been compared with our own standard.
I t  is important to compare a newly developed method with other 
established methods. A t the time of writing, no other RIAs for aMT6s had been 
published. The method has, however, been compared with a fu lly  established GC/MS 
method for to ta l 6-hydroxylated melatonin metabolites (Tetsuo et al., 1981a).
2.1 Chemicals, Reagents, Consumables and Equipment
Required Routinely in the Radioimmunoassay
Tricine
Sodium Chloride
Activated Charcoal
Gelatine
Dextran T-70
Optiphase Safe Scintillant
Scintillation Vials
LKB 1216 Rackbeta Liquid 
Scintillation Counter
LP3 Plastic Tubes 
Eppendorf Multip ipette 4780
Eppendorf Combitips 
Labco Glass Universals 
Elkay Pipette Tips
Gilson Adjustable Pipettes
Sigma Chemical Company Lim ited,
Poole, Dorset
BDH Chemicals Lim ited, Speke, Liverpool 
Pharmacia, M ilton Keynes, Buckinghamshire 
LKB Lim ited, Selsdon, Surrey
Luckham Lim ited, Haywards Heath, Sussex 
Eppendorf, Supplied by BDH Chemicals 
Lim ited
Labco Lim ited, Marlow, Buckinghamshire 
Elkay Laboratory Products Lim ited, 
Basingstoke, Hampshire 
Gilson, Supplied by Anachem, Luton, 
Bedfordshire
Beckman J-6B Centrifuge Beckman, High Wycombe, Buckinghamshire
r3, aMT6sSynthesis of HJ 
Tritia ted Melatonin NET-458 
RPM I
NADPH (8-Nicotinamide adenine 
dinucleotide phosphate, 
reduced form)
PAPS
Niacinamide
Glutathione
Phenobarbitone
Sephadex LH-20
Oxygen - 5% carbon dioxide 
Cylinder
Nitrogen Cylinder
LKB 2112 Fraction Collector
Berthold LB2842 TLC-Plate 
Scanner
Synthesis of aMT6s Standard 
6-Hydroxymelatonin 
N-N'-dicyclohexylcarbodiimide 
Dimethylformamide
NEN, Southampton 
Gibco Europe, Uxbridge 
Sigma
BDH
Pharmacia 
BOC, London SW19
LKB
Berthold UK Lim ited, Leeds
Sigma
Immunization 
Non-Ulcerative Freund's 
(Morris) incomplete 
Ovalbumin
Guildhay Antisera, University of Surrey, 
Guildford, Surrey 
BDH
Chromatography
Cellulose Plastic-Backed 
TLC Plates
Silica Gel Plastic-Backed 
TLC Plates
Whatmann No 3MM F ilte r Paper
Cyanogen-Bromide Activated 
Sepharose 4B
Amicon Disposable Columns
Ehrlich's Reagent (4-dimethyl- 
aminobenzaldehyde)
Merck, supplied by BDH 
Kodak, Liverpool
Whatmann Laboratory Sales, Maidstone, Kent 
Sigma
Amicon Lim ited, Stonehouse, Gloucestershire 
BDH
Gifts from Dr A M Leone 
St Bartholomew's Hospital, London
Gifts from Laboratories Plan, SA 
Geneva
Sigma
Amersham International, Amersham, Bucks
Zeitz F ilte r Carlson Ford Lim ited, Ashton Under Lyme
Whatmann No 1 F ilte r Whatmann Laboratory Sales
Sigma
Boehringer Mannheim, Lewes, East Sussex 
Roche Products Lim ited, Welwyn Garden C ity, 
Hertfordshire
Bufferfly-19 Cannulae Venisystems, supplied by Abbott Laboratories
Lim ited, Queensborough, Kent 
G riffiths and Nielson Plastics Lim ited, 
Billingshurst, Sussex 
G riffiths and Nielson Plastics L im ited 
Billingshurst, Sussex
Gallenkamp and Co Lim ited, Loughborough, 
Leicestershire
Stuart Pharmaceuticals Lim ited, Cheadle 
Cheshire
A ll other chemicals were commerically available and of analytical grade.
2.2 Synthesis of aMT6s
aMT6s is not available commercially and was synthesized at the 
University of Surrey. Full details of the synthesis are given elsewhere (Franey, 
1988). The method of Fellenberg and colleagues (1980) was used. B riefly, 6-
Heparinised Plastic Tubes 
Urine Containers 2.51 
Urine Containers 1.01 
Atenolol
Others
Melatonin
Creatinine K it No. 124192 
Cobas Bio Autoanalyser
Validation of Assay 
aMT6G
N-acetylserotonin sulphate
N-acetylserotonin glucuronide
N-acetyltryptophan
5-Methoxy tryptophan
5-methoxy-N-acetyl-tryptophan
Other indoles, steroids and 
Catecholamine Derivative
Tritiated Methoxy-j^Hj 
Melatonin
hydroxymelatonin and N,N'-dicyclohexylcarbodiimide were dissolved in anhydrous 
dimethylformamide. The reaction temperature was maintained at 0°C while 
concentrated sulphuric acid and anhydrous dimethylformamide were added. The 
reaction was terminated after 15min. The reaction is outlined below:
g h 3 o J Q [ - J C h 2 c h 2 n h c o c h 3  +  H 2 3 0 <  t
A dicyclohexylcarbodiimide (DCC)
HO
6-hydroxym elatonin
dimethylformamide
(DMF)
C H „ 0
IC H -C H -N H C O C H , 2 2 c
OSO.OH ^
6-sulphatoxym elatonin (aM T6s)
The Synthesis of aMT6s
The reaction products were purified on a Sephadex LH-20 column w ith 
potassium chloride saturated methanol/chloroform (1/1 by vol; filte red  until non- 
turbid) as the eluting solvent. aMT6s was further purified by TLC (Silica Gel plates, 
n-butanol saturated with water). The final product was stored at -20°C at a 
concentration of 48pg/ml in methanol containing 0.1% ascorbic acid. A completely 
pure crystalline preparation was not obtained. Qualitative GC/MS performed by Dr 
G King (Queen Charlotte's Maternity Hospital, London) gave a spectrum identical to 
that reported by Fellenberg and colleagues (1980).
This chemically synthesized aMT6s has been used throughout this thesis as 
a RIA and chromatographic standard.
2.2.1 Crude aMT6s Preparation
In addition to the chemically synthesized standard, aMT6s has also been 
purified from urine. A female volunteer was given an oral dose of 500mg of 
melatonin, in a corn oil preparation, at 2200h and overnight urine was collected. 
The urine was freeze-dried and extracted with methanol. The methanol extract was 
purified by repeated paper chromatography (Whatman No. 3MM, propan-2-ol/3% 
ammonia, 4/2 by vol). The portion corresponding to the aMT6s standard was cut out, 
eluted with methanol and concentrated under nitrogen gas at 37°C. This fraction 
was further purified by TLC on cellulose plates (n-butanol/glacial acetic acid/water, 
4/1/1.5 by vol). The portion corresponding to authentic aMT6s was cut out and 
eluted with methanol. From approximately one third of the original urine volume, 
lOmg of aMT6s were obtained.
2.3 Preparation of Conjugated aMT6s and Immunization of Animals
The conjugate was prepared and the animals immunized prior to the start 
of this project. The conjugate was prepared at the University of Surrey and fu ll 
details are given elsewhere (Franey, 1988). B riefly, the Mannich reaction (Grota and 
Brown, 1974), a formaldehyde condensation reaction, was used to conjugate aMT6s 
(<4mg) to ovalbumin (55mg). No estimate of the molar ratio of hapten conjugated to 
protein was made. Six Suffolk cross ewes were immunized, by subcutaneous, 
injection at six sites on the back and legs, w ith 500yg of conjugate emulsified in 3ml 
of Freund's modified adjuvant/saline (2:1 ratio) (Marks et al., 1973). The sheep 
were boosted seven months later with 200yg of conjugate emulsified in modified 
Freund's adjuvant, and were bled nine days after the booster injection.
2.4 Preparation of aMT6s
aMT6s radiolabel was prepared by the biological transformation and 
subsequent purification of tr itia ted  melatonin.
Wistar rats (150-200g) male/female were killed by cervical dislocation.
The liver was rapidly dissected out and cut into slices (<lmm).
g
600mg liver slices were incubated with approximately 1.2 x 10 cpm of 
p H  ] melatonin in 3ml of RPMI at 37°C under an atmosphere of 93% 
02:5% CO2 fo r 2h with gentle shaking.
The incubate was cooled, homogenized and extracted at least five times 
w ith 3ml of methanol.
The pooled supernatants were dried down under nitrogen at 37°C.
Paper chromatography of the crude extract (Whatmann No. 3MM, propan- 
2-ol/5% ammonia, 4 /2 'b y  vol) revealed three peaks corresponding to 
melatonin (Rf  = 0.84), aMT6s (Rf  = 0.67) and aMT6G (Rf  = 0.45) (Figure 
2.1).
The crude extract was reconstituted in lOOOyl of LH-20 column buffer 
(Section 2.2) and purified on a LH-20 column. 4g dry powder were used, 
the column dimensions were 40 x 1cm and 2ml fractions were collected.
The elution profile  of the LH-20 column is shown in (Figure 2.2).
The aMT6s fractions were pooled and dried down under nitrogen at 37°C. 
p H ]  aMT6s gave one peak chromatographically identical to authentic 
aMT6s (Figure 2.3). [^H] aMT6s was stored in methanol 0.1% ascorbate at 
-20°C and was stable for at least twelve months under these conditions.
15-25% of the starting p H ]  melatonin was converted to p H ]  aMT6s.
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Figure 2.1 Paper Chromatogram (Whatmann No. 3MM, Propan-2-ol/3% 
Ammonia, 4/2 by vol) of a Methanol Extract of Rat L iv e ~
Slices After Incubation with fV l] Melatonin
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Figure 2.2 Elution Profile of a LH-20 Column of a Methanol Extract 
of Rat Liver Slices After Incubation With pH] Melatonin
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2.4.1 Modified Label Preparation Method
Once the in v itro  production of pH] aMT6s from melatonin under control 
conditions had been characterized, the procedure was modified to increase the yield 
of label. The following changes in the method were made:
(i) Male Wistar rats (150-200g) were treated with phenobarbitone (0.1% 
weight/vol) in the drinking water for seven days. On the eighth day the 
rats were killed.
8(ii) 1200mg liver slices were incubated with approximately 1.2 x 10 cpm
[^H 1 melatonin in 6ml of RPMI + 2mg of NADPH, lmg niacinamide, 
300yg of PAPS, lm g of glutathione and 5mg magnesium chloride at 37°C 
under an atmosphere of 93% 02?5% CO2 for 3h.
(iii) The crude extract was purified on the LH-20 column (6g of dry powder). 
The elution profile of the LH-20 column was altered with a greater 
proportion of glucuronidated metabolites being produced (Figure 2.4).
Using this method approximately 23% of the starting pH] melatonin was 
converted to [^H ] aMT6s. This procedure is now routinely used in our laboratory to 
prepare [^H ]aM T6s.
2.4.2 Discussion of [^H 3 aMT6s Preparation
The pattern of melatonin metabolism observed in the control rats was the 
same as that reported by Kopin et al., (1961). Paper chromatographic analysis of 
the incubates gave identical results to those of Kopin and colleagues, however, 
slightly d ifferent R^ values were obtained.
Figure 2.4
20000
[3h ] aMT6s
10000
80 1004020 600
Fraction number
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Extract of Phenobarbitone-Induced Rat Liver
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A study by Wurtman and co-workers (Wurtman et al., 1968) demonstrated 
that treating rats with phenobarbitone increased the rate of disappearance of 
radioactive melatonin from plasma. This suggested that phenobarbitone induction of 
liver enzymes increased the rate of melatonin metabolism. Therefore to increase 
the yield of aMT6s label, rats were pre-treated with phenobarbitone.
Aromatic hydroxylation by microsomal mixed-function oxidases requires 
NADPH and molecular oxygen as co-factors. In the in v itro  metabolizing system the 
concentration of co-factors is likely to be lim iting, therefore NADPH and PAPS 
were included in the incubate to act as co-factors for the phase I and phase II 
reactions, respectively. Glutathione was included in the incubate following a report 
by Gregory (1962) that maximal activ ity  of sulphate transferring enzymes in v itro  
only occurred in the presence of a sulphydryl compound such as glutathione. 
Magnesium chloride and niacinamide were added to the incubate in sim ilar 
concentrations to those used in Kopin’s (1961) rat liver microsomal system for the 
metabolism of melatonin. Phenobarbitone treatment and the inclusion of the co- 
factors in the incubate increased the yield of aMT6s by about 30%. Phenobarbitone 
treatment changed the pattern of melatonin metabolism to give a greater yield of 
glucuronidated metabolites than under control conditions.
The performance of a RIA depends largely on the specific ity of the 
antibody and the purity of the label. The label gave one peak when screened in four 
d ifferent chromatographic systems (Figure 2.3). No evidence for the presence of the 
sulphate conjugate of NAS was obtained.
2.5 Assay Buffer
The buffer used was the tricine buffer described by Fraser and colleagues 
(1983a) for the direct plasma assay of melatonin.
Stock assay buffer consisted of tric ine (17.9g/l, pH 5.0) containing sodium 
chloride (9.0g/l) and gelatine (1.0g/l). Assay buffer was made up in glass doubly- 
distilled water, heated at 55°C for lh  and then stored at 4°C fo r up to ten days.
Disposable glassware was used where possible, or else glassware was 
sonicated in doubly-distilled water prior to use.
2.6 Separation of Bound and Free [^H ] aMT6s
Bound and free t ^ H ]  aMT6s were separated using dextran coated
charcoal.
The minimum concentration of charcoal which gave non-specific binding 
of less than 5% was determined and found to be lOOyl of 2% charcoal w ith 0.02% 
dextran T70, in tric ine buffer. Charcoal was defined before use by mixing i t  w ith 
tricine for 15min. I t  was then centrifuged at lOOOrpm for 5min before discarding 
the supernatant. The charcoal was resuspended in tricine buffer, dextran was added 
and the charcoal suspension stored at 4°C for up to a week.
Prior to use the charcoal suspension was mixed on ice fo r at least 30min. 
Bound and free aMT6s were separated by the rapid addition of charcoal. Tubes were 
incubated on ice for 15min. Following centrifugation at 2000g fo r 15min (4°C) 
aliquots (500yl) of supernatant were taken, 4.5ml of scin tillant was added and the 
vials counted.
2.7 Estimation of Titre
In RIA a lim ited number of binding sites are incubated w ith an excess of 
radiolabel. I t  is essential to know how far each antiserum has to be diluted to fu lf i l  
these crite ria . An antiserum dilution which binds 40-50% of the added radiolabel is 
usually employed, but 100% binding of radiolabel to antiserum is rarely achieved
because of various non-specific factors. The titre  of an antiserum can be defined as 
the final dilution of antiserum which binds 50% of the maximum label bound.
2.7.1 Detection of Antibodies
Fixed amounts of radiolabel were incubated overnight at 4°C with 
decreasing concentrations of antiserum.
Nine days a fte r the firs t booster injection [ ^ H l  aMT6s binding antibodies 
were detected in all six sheep (bleed date 11.11.82)
2.7.2 Selection of Antisera
Antisera from the three sheep (1118, 1119, 1120) which had the highest 
titres were selected for further characterization. Antiserum dilution curves were 
constructed for each antiserum, both with and without the addition of lOOpg of cold 
aMT6s standard. The displacement obtained by adding cold aMT6s was compared.
The most sensitive antiserum was 1118. This antiserum also had the 
highest t itre  and was chosen for further characterization. The antiserum dilution 
curve for this antiserum, both w ith and without the addition of lOOpg of cold aMT6s 
standard is shown in Figure 2.5.
2.7.3 Booster Injections of the Sheep
A ll six sheep have been boosted at intervals, w ith 200yg of conjugate and 
antiserum collected nine days a fter injection. The best antiserum remains that 
obtained from 1118. The titres  of the antisera obtained from 1118 are presented 
graphically in Figure 2.6. The highest titre  observed for sheep 1119 and 1120 were 
1:1000 and 1:1800 (final dilutions), respectively.
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2.8 RIA in Buffer
Standards (5-400jj1) (see Section 2.9.5) or samples in buffer were pipetted 
into LP3 plastic tubes and made up to 500pl with buffer. Antiserum 1118 (11.11.82) 
(200pl; final dilution 1:1000) in buffer was added and the tubes mixed and incubated 
at room temperature for 30min. Radiolabel (lOOpl; 4500cpm) in buffer was added 
and, a fter mixing, tubes were either incubated at 37°C for 20min followed by 90min 
on ice or they were incubated at 4°C overnight. Identical results were obtained 
with either incubation method. Bound and free fractions were separated as 
described in Section 2.6. Aliquots (500]il) of the bound fraction were counted in 
4.5ml of scintillant. The binding of standard samples was calculated (B/B^), fitted  
to a spline function and the results of unknown samples determined by interpolation.
2.9 Quantitation of aMT6s Standard
No international quantitated aMT6s standard, against which our standard 
could be compared, exists. The method chosen to quantitate our standard was a 
radiolabel self-displacement technique. This technique is usually used for the 
estimation of the specific activ ity  of RIA tracers (Roulston, 1979) and was adapted 
for the quantitation of cold aMT6s standard.
The principle is as follows: increasing amounts of labelled antigen are
incubated with a constant amount of antibody under similar conditions to those
employed routinely in the assay (Gocke et al., 1969). The mass of tracer present in 
the tubes is calculated knowing the specific ac tiv ity  of the radiolabel and the 
efficiency of the counter for the label. A radiolabel standard curve is then 
constructed. A standard curve with increasing concentrations of cold antigen is also 
constructed and the cold antigen is quantitated by comparison with the radiolabel 
standard curve.
The following assumptions are made. F irstly, it  is assumed that labelled 
and unlabelled ligand are chemically identical with respect to antibody a ffin ity . 
Secondly, separation of bound and free fractions is assumed to be 100% and th ird ly, 
no loss of label is assumed to occur during the biological transformation of [^H ] 
melatonin.
2.9.1 Experiment 1
The radiolabel used to construct the label displacement curve was 
methoxy- [^H ] melatonin (79.8Ci/mmol). The calculation to convert a given number 
of counts into a mass of aMT6s is given below:
Specific activ ity  = 79.8Ci/mmol 
Efficiency of counter for [^H ] = 40% 
1 Ci = 2.22 x 1012dpm 
Molecular weight aMT6s = 328
/ .  A tube with y cpm has 100/40^ x 328mg aMTfis
2.22 x 101Z x 79.8
A standard curve with increasing concentration of pH  ] aMT6s was 
constructed together with a standard curve with increasing concentrations of cold 
aMT6s. The results are presented in Table 2.1 and in Figure 2.7. The mass of tracer 
added to the standard curve constructed with cold aMT6s is taken into account. The 
potency of the cold aMT6s standard was compared to the displacement achieved by the 
known amounts of aMT6s in the label displacement curve and hence the aMT6s 
standards was quantitated.
2.9.2 Experiment 2
A standard curve was constructed using the aMT6s standard quantitated in 
Experiment 1. The displacement observed was compared to that achieved in another 
radiolabel self-displacement curve. The radiolabel used was derived from l^H  1 
melatonin labelled on the side-chain (acetyl-5-methoxytryptamine-N- 2-aminoethyi-2- 
[ ^ H ] ;  26.4Ci/mmol).
The results are given in Table 2.2. The standard curve and radiolabel 
displacement curve are plotted in Figure 2.8. Identical curves were obtained.
2.9.3 Comparison With Other aMT6s Standards
Once the aMT6s RIA had been established, aMT6s standards from other 
research groups were donated to us. aMT6s standards were kindly donated by the
following: Dr D 3 Kennaway, Department of Obstetrics and Gynaecology,
University of Adelaide, Australia, Dr A M Leone,- Department of Reproductive 
Physiology, St Bartholomew's Hospital, London, Dr G E Webley, Institute for 
Hormone and F e rtility  Disorders, Hamburg, West Germany, Dr G M Brown, 
Department of Neurosciences, McMaster University, Hamilton, Ontario, Canada. 
These standards were synthesized by the method of Fellenberg et al., (1980) w ith or 
without modification, or by that of Leone et al., (1987b).
A ll standards were used to generate standard curves in order to assess 
their relative potency. The chromatographic properties of the standards were 
investigated by TLC in cellulose with eluents of n-butanol/glacial acetic acid/water 
(4/1/1.3 by vol) and propan-2-ol/5% ammonia (4/2 by vol).
The displacement curves obtained using the d ifferent standards are 
illustrated in Figure 2.9 . A ll the standards gave displacement parallel to that of 
our standard, however, the relative potency of the d ifferent preparations varied 
approximately two-fold. A ll the standards were chromatographically identical.
Mass of Unlabelled Mass of Tracer % Bound
Antigen Added (pg) Added (pg)
lOOx 8.2 3.9
lOx 8.2 . 10.9
5x 8.2 17.4
2x 8.2 31.0
x 8.2 43.6
0.5x 8.2 50.6
0.2x 8.2 55.2
O.lx 8.2 56.3
O.Olx 8.2 ' 56.7
0 362.9 6.0
0 181.0 9.5
0 90.0 16.0
0 41.0 30.0
0 18.6 46.3
0 9.6 54.5
Table 2.1 Percentage Binding with Increasing Concentrations
of Cold aMT6s and for Self-Displacement Curve Using
Methoxy- [ ] Melatonin Label (79.8Ci/mmol)
Mass of Unlabelled Mass of Tracer % Bound
Antigen Added (pg) Added (pg)
0 35.5 38.5
2.3 35.5 36.1
3.5 35.5 35.1
7.0 35.5 31.4
14.0 35.5 28.0
23.3 35.5 23.6
35.0 35.5 21.0
70.0 35.5 14.0
140.0 35.5 8.9
280.0 35.5 5.8
0 36.4 36.1
0 40.9 33.9
0 46.5 29.7
0 55.1 26.0
0 64.2 22.7
0 74.1 19.8
0 88.9 17.8
0 107.8 14.4
0 144.5 11.4
0 210.2 10.2
Table 2.2 Percentaqe Bindinq for Cold aMT6s Standard Curve, and
3
for Radiolabel Self-Displacement Curve Using [ H3 Melatonin 
Labelled on the Side-Chain (26.4Ci/mmol)
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Figure 2.9 Standard Curves Generated by Different aMT6s Standards
2.9.4 Discussion of aMT6s Quantitation
In the absence of an international aMT6s standard or a pure crystalline 
preparation, a radiolabel displacement technique was used to quantitate our aMT6s 
standard. Using tracers labelled in d ifferent positions identical results were 
obtained. The relative potency of the different aMT6s standards from various 
research groups varied considerably. One possible, explanation is differences in the 
efficiency of desalting in some cases. A ll the standards did, however, give parallel 
displacement indicating that they were immunoreactively identical.
When an international aMT6s standard is made available some adjustment 
of the absolute levels reported in this thesis may be necessary.
2.9.5 Standard Curve
Aliquots of standard, diluted with assay buffer were stored at -20°C at a 
concentration of 290ng/ml. For each assay an aliquot was diluted in assay buffer to 
provide standard solutions over the range 2.5-200pg/tube (5-400]il). Non-specific 
binding was always less than 10%.
2.9.6 Sensitivity
The lim it of sensitivity of the assay, defined as two standard deviations 
from the zero standard, (Feldman and Rodbard, 1971) was 2.1pg/tube.
r
2.10 Cross-Reactivity
The specificity of the 1118 antiserum was assessed by comparing the 
ability of d ifferent compounds to displace 50% of the maximum antibody-bound t^H 1 
aMT6s, under the conditions routinely employed in the assay. The percentage cross- 
reactiv ity is expressed as a ratio of the concentration of aMT6s to the concentration 
of cross-reactant (multiplied by one hundred). The other urinary melatonin 
metabolites; 6-glucuronide melatonin, 5-sulphatoxy-N-acetylserotonin and 5- 
glucuronide-N-acetylserotonin, were kindly donated by Dr A M Leone (St 
Bartholomew's Hospital, London) and were tested for cross-reactivity.
The percentage cross-reactivity of d ifferent compounds is given in Table 
2.3. The percentage cross-reactivity was very low, maximum cross-reactivity
occuring with 5-glucuronide-N-acetylserotonin (0.4%).
2.10.1 Antibody A ffin ity  Constant
The antibody a ffin ity  constant (K) was calculated by the method of Muller 
(1980) to give a value of K = 2 x 1 0 ^  litres/m ol (calculations not shown).
2.11 Plasma aMT6s Assay
2.11.1 Procedure to Define Charcoal
Activated charcoal was washed with doubly-distilled water, centrifuged at 
lOOOrpm for 5min and the supernatant discarded. This was repeated three times. 
The charcoal was again washed with doubly-distilled water, le ft to settle under 
gravity and the supernatant discarded. This was repeated four times. The charcoal 
was finally washed with acetone and le ft to dry at 60°C in a water bath.
2.11.2 Preparation of Charcoal-Stripped Plasma
10% (weight/vol) defined charcoal was added to a pool of normal human 
plasma and was mixed at 4°C for 60h. The plasma was then centrifuged for 15 min
Compound Cross-Reactivity (%)
aMT6s 100
5-glucuronide-N-acetylserotonin
6-glucuronide melatonin
5-sulphatoxy-N-acetylserotonin
6-hydroxymelatonin 
melatonin
0.4
0.03
0.003
0.004
0.001
5-methoxyindoleacetic acid
3-hydroxyindoleacetic acid
N-acetyl-tryptamine
N-acetylserotonin
N-acetyl-tryptophan
tryptamine
tryptophan
5-hydroxytryptophan
indole acetic acid
N-methyl-tryptamine
5-methoxy tryptamine
N-acetyl-5-methoxytryptophan A ll <0.0004
5-methoxy tryptophan
5-hydroxy tryptamine
vanillylmandelic acid
phenylacetic acid
homovanillic acid
3,4-dihydroxyphenylacetic acid
androsterone sulphate
estriol 3-sulphate
dehydroisoandrosterone sulphate
Table 2.3 Cross-Reactivities of Antiserum 1118 Determined
at 50% Displacement of [ ] aMT6s
at 4000rpm, filte red once throught a Whatmann No 1 f ilte r  and twice through a 
Zeiss filte r.
2.11.3 Preparation of A ffin ity-Stripped Plasma
aMT6s-free plasma was prepared by a ffin ity  chromatography, with the 
antiserum (1118 23.8.84) linked to cyanogen bromide (CNBr) activated Sepharose 4B, 
following the manufacturer's recommended procedure (Pharmacia, 1983).
Briefly, the required amount of CNBr activated Sepharose 4B was weighed 
out and swollen in ImM hydrochloric acid and washed on a sintered glass f ilte r  with 
the same solution. lgG obtained from 1118 (23.8.84) was dissolved in sodium 
hydrogen carbonate coupling buffer (0.1M, pH 8.3) containing sodium chloride (0.5M) 
to give 5-10mg of protein per ml of gel, when a gel/buffer ratio of 1/2 was used. 
This protein solution and gel suspension were mixed overnight at 4°C in an end-over- 
end mixer. The remaining active groups were then blocked by mixing the gel with 
0.2M glycine, pH 8.0, for 2h at room temperature. Excess adsorbed protein was 
subsequently removed with four alternate washes with coupling buffer and acetate 
buffer (0.1M, pH 4.0) containing sodium chloride (0.5M). The a ffin ity  columns were 
stored ready for use in a bicarbonate storage buffer (0.1M), containing sodium 
chloride (0.5M) and 0.1% sodium azide at 4°C.
Plasma was collected from apparently healthy volunteers during the 
afternoon. A ll samples which measured <3pg/ml against a standard curve 
constructed in charcoal-stripped plasma were pooled. A ffin ity  columns were 
prepared from 1ml of slurry, residual buffer was removed by applying slight positive 
pressure. To each column 2ml of plasma was added and the columns were mixed on 
a roller mixer for 15min at room temperature. The plasma was then collected. Up 
to 10ml of plasma could be processed on each column before regeneration. Columns
were regenerated by washing with 10ml of doubly-distilled water followed by 3 x 
2ml washes with methanol/water (9/1 by vol) and were finally washed with storage 
buffer.
The measurement of samples spiked with cold aMT6s showed that 85-90% 
of the aMT6s was removed. When standard curves were constructed with either 
affin ity-stripped or charcoal-stripped plasma identical results were obtained. The 
a ffin ity  columns retained binding activ ity  for at least eighteen months.
2.11.4 Procedure for Plasma Assay
The RIA procedure for plasma samples was identical to that given in 
Section 2.8 except for the following modifications: 200-500j.il of plasma sample
were assayed directly and the standard curve was constructed in an equivalent 
volume of affin ity-stripped plasma.
2.11.5 Validation of Plasma Assay
2.11.5.1 Parallelism
Parallelism was assessed when up to 500pl of plasma was assayed d irectly 
by comparing the displacement curve obtained when pooled human plasma collected 
at night-time was serially diluted with affin ity-stripped plasma, w ith the standard 
curve.
Parallelism was achieved with unextracted plasma and is demonstrated in 
Figure 2.10.
2.11.5.2 Recovery
Analytical recovery studies were performed by adding known amounts of 
analyte and assaying the spiked samples. The results are given in Table 2.4.
2.11.5.3 Assay Performance
The sensitivity of the plasma assay varied between 5.0pg/ml and 
12.5pg/ml depending on the volume of plasma assayed directly.
The precision of the assay was determined by intra-assay and interassay 
analysis. To determine interassay variation, quality control samples were measured 
in successive assays. The intra-assay and interassay coefficients of variation (CVs) 
are given in Table 2.5.
2.11.5.4 Collection of Samples
Blood samples were collected into heparinised tubes and were centrifuged 
immediately. Plasma was frozen and stored at -20°C.
2.11.5.5 Storage of Samples
The stability of aMT6s in plasma under various storage conditions was 
determined. Plasma samples were stored without preservative or w ith boric acid 
(1.0g/l) or ascorbic acid (1.0g/l) at -12°C and -20°C for up to two years. The e ffect 
of freeze-thawing was also assessed. aMT6s was measured by RIA a fte r one day, 
one week, one, six, twelve, eighteen and twenty-four months.
aMT6s was found to be very stable in plasma. No differences were found 
between samples stored with or without preservatives, or on freeze-thawing. aMT6s 
was stable in plasma for up to five days when stored at 4°C and for up to two years 
when stored at -20°C or -12GC. Figure 2.11 compares samples stored for up to two 
years at -20°C, either with or without preservatives. The interassay CVs for plasma 
samples stored for up to two years are given in Table 2.6.
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Figure 2.10 Parallelism Between aMT6s Standard Curve in
Affinity-Stripped Plasma and Increasing Amounts of 
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Table 2.4 Recovery by RIA of aMT6s Added to Human Plasma Pools
pg/ml % CV n
Intra-assay 17.8 6.7 5
Data 77.4 5.2 5
248.8 3.1 5
Interassay 23.4 10.6 18
Data 61.0 8.8 18
130.8 6.8 18
Table 2.3 Precision Data for the Plasma Assay
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Figure 2.11 Concentrations of aMT6s in Plasma Samples Stores
Storage Condition Mean - SD 
(pg/ml)
n CV
(%)
Neat, -12°C 60 - 5.5 8
Neat, -20°C 59.0 - 7.0 9
Neat, -20°C, Freeze thaw 57.0 - 7.5 9
Boric Acid, -20°C 56.5 - 10.0 9
Boric acid, -20°C, Freeze thaw 52.5 - 6.5 9
Ascorbic acid, -20°C 57.5 - 10.0
Table 2.6 CVs for Plasma Samples Stored Under
Various Conditions For Up To 2 Years
9.8
12.0
13.0
18.3
12.3
17.5
2.12 Urine aMT6s Assay
2.12.1 Preparation of Charcoal-Stripped Urine
5% (weight/vol) defined charcoal (Section 2.12.1) was added to a pool of 
normal human urine, collected during the afternoon, and was mixed overnight at 
4°C. The urine was centrifuged at 3000rpm for 15min, then filte red  once through a 
Zeiss f ilte r . The charcoal-stripped urine was stored frozen at -20°C in 500yl 
aliquots.
2.12.2 Procedure for Urine Assay
The RIA procedure for urine samples was identical to that given in 
Section 2.8 except fo r the following modifications: urine samples were diluted 1:50 
in assay buffer and 200 yl were assayed d irectly. The standard curve was 
constructed in an equivalent volume of charcoal-stripped urine, diluted 1:50 in assay 
buffer.
2.12.3 Validation of Urine Assay
2.12.3.1 Parallelism
Parallelism was assessed by comparing the displacement curve obtained 
with a pool of human urine samples collected in the early morning serially diluted 
with charcoal-stripped urine, w ith the standard curve. The urine was diluted 1:50 
with assay buffer and volumes of 1.5-200yl were made up to 200yl w ith charcoal- 
stripped urine diluted 1:50 with assay buffer. Parallelism was established by 
superimposing the urine dilution curve onto the standard curve and is demonstrated 
in Figure 2.12.
2.12.3.2 Recovery
Analytical recovery studies were performed by adding known amounts of
analyte and assaying the spiked samples. The results are given in Table 2.7.
2.12.3.3 Assay Performance
The sensitivity of the urine assay was 0.65ng/ml.
The precision of the assay was determined by intra-assay and interassay 
analysis. The quality control samples used to determine the interassay variation 
'cover a time period of fifteen months. The intra-assay and interassay CVs are given 
in Table 2.8. Figure 2.13 demonstrates that there was no d rift of the quality control 
samples over a period of fifteen months.
2.12.3.4 Collection of Samples
Urine samples were collected in plastic containers and 5ml aliquots were 
frozen as soon as possible after collection. The volume of each collection was 
recorded.
2.12.3.5 Storage of Samples
The stability of aMT6s in urine under various storage conditions was 
determined. Urine samples were stored without preservative or with boric acid 
(1.0g/l) or ascorbic acid (1.0g/l) for up to five days at 4°C and room temperature 
(20°C) and for up to two years at -12°C and -20°C. The effect of freeze-thawing 
was also assessed. To determine the stability of aMT6s in urine at room 
temperature, aMT6s was assayed immediately after collection, and on the second, 
third, fourth and fif th  days after collection. To determine its long-term stab ility , 
aMT6s was measured by RIA after one day, one week, one, six, twelve, eighteen and 
twenty-four months.
aMT6s has been found to be very stable in urine. No differences were 
found between samples stored with or without preservative or on freeze-thawing. 
aMT6s is stable for up to five days when stored at room temperature or 4°C and for 
up to two years when stored at -12°C or -20°C. Figure 2.14 compares the measured
aMT6s concentration in three urine samples stored at room temperature (20°C) for 
five days without preservative. Figure 2.15 compares samples stored for up to two 
years at -20°C, either with or without preservatives. The interassay CVs for urine 
samples stored for up to two years are given in Table 2.9.
2.12.3.6 Chromatographic Identity of Immunoreactivity
The chromatographic identity of immunoreactivity was determined in 
three systems. Two TLC systems were used; cellulose plates with n-butanol/glacial 
acetic acid/water (4/1/1.5 by vol) and silica gel plates with chloroform/methanol 
(9/1 by vol) as the respective solvents. The paper chromatography system used was 
Whatmann No 3MM with propan-2-o 1/5% ammonia (4/2 by vol) as the solvent. A ll 
plates were sprayed with methanol 0.1% ascorbic acid and dried before use.
The migration of standard aMT6s, l^H 1 aMT6s and the urinary 
immunoreactivity were compared. Urine was spotted directly onto the baseline. An 
equivalent volume of urine was spotted onto each track to control for the e ffect of 
urinary salts on the migration of aMT6s.
To test for immunoreactivity, the plate was cut up into 1cm portions and 
eluted with tricine buffer. The immunoreactivity was measured by RIA. The 
position of the aMT6s standard was detected by spraying the plate w ith Ehrlich's 
reagent (10% weight/vol in concentrated hydrochloric acid: diluted 1:5 w ith 
acetone), while the portion of the plate containing [^H ] aMT6s was cut up, eluted 
with 500|il of methanol and counted in a scintillation counter.
The results are illustrated in Figure 2.16. The migration of the urinary 
immunoreactivity was identical to that of aMT6s standard and [ ^H] aMT6s in each 
chromatographic system. Over 90% of applied immunoreactivity was recovered 
from all chromatograms.
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Figure 2.12 Parallelism Between aMT6s Standard Curve in
Charcoal-Stripped aMT6s-Free Urine Diluted 1;5Q 
in Assay Buffer, and Increasing Amounts of Pooled 
Urine Collected in the Early Morning, Initially 
Diluted 1:50 in Assay Buffer and Further Diluted 
with Charcoal-Stripped Urine
aMT6s Added % Recovery
(ng/ml)
2.2 115.1 -
8.5 102.6 -
30.6 83.7 - .
Values are mean - SEM; n=5
Table 2.7 Recovery by RIA of aMT6s Added to Human Urine Pools
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Figure 2.13 Concentrations of aMT6s in Quality Control
Samples for the Urine Assay Measured 
Over a Period of 13 Months
The arrows indicate where new radiolabels were used.
ng/ml %CV n
Intra-assay 2.3 3.5 5
data 12.0 3.3 5
28.2 3.4 5
Interassay 2.3 16.3 81
data 7.2 11.9 81
19.5 13.6 81
Table 2.8 Precision Data for the Urine Assay
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Figure 2.14 The aMT6s Concentration in 3 Urine Samples Stored 
at Room Temperature for 5 Days Without Preservative
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Figure 2.15 Concentrations of aMT6s in Urine Samples
Stored Without Preservative, With Boric Acid, 
or With Ascorbic Acid for up to 2 Years at -20 C
Storage Conditions Mean - SD n
(ng/ml)
Neat, -12°C 36.0 ^ 3.3 9
Neat, -20°C 33.8 ± 4.2 9
Neat, -20°C, freeze-thaw 33.7 - 3.3 9
Boric acid, -12°C 37.2 - 4.3 8
Boric acid, -20°C 34.8 - 2.6 8
Boric acid, -20°C, freeze-thaw 33.5 - 3.6 9
Ascorbic acid, -12°C 36.3 - 5.0 9
Ascorbic acid, -20°C 37.9 ^ 6.6 9
Ascorbic acid, -20°C, freeze-thaw 36.2 - 4.0 9
Table 2.9 CVs for Urine Samples Stored Under Various
Conditions for up to 2 Years
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Figure 2.16 Migration of Urinary Immunoreactivity in 3 
Chromatographic Systems
The arrows indicate the position of cold aMT6s standard
2.12.3.7 GC/MS Validation of the Urinary Assay
One hundred urine samples from both normal volunteers and patients were 
assayed for both to ta l and free 6-hydroxymelatonin by the GC/MS method of Tetsuo 
et al., (1981a). The assays were performed by Mrs M C Shih and Dr S P Markey of 
the National Institute of Mental Health, Bethesda, USA. The samples were then 
measured on a single-blind basis by RIA.
Least-squares regression analysis was used to calculate the slope and 
intercept of the best line through the data points. The standard error of regression, 
which gives a measure of the scatter of the points about the 'best-fit' line 
(Cornbleet and Gochman, 1979) was also calculated.
The correlation between the two methods was good (r = 0.94, n = 100) and 
was highly significant (p<0.001). Regression analysis of the data gave the equation y 
= 0.47x + 0.64ng/ml (where y is RIA) w ith a standard error of regression of 2.72. 
The results are presented graphically in Figure 2.17.
2.13 Discussion
The method described in this thesis is the firs t RIA developed for the 
measurement of aMT6s. The classical validation techniques employed for the 
measurement of urine and plasma samples show the method to be sensitive, specific 
and reproducible. The aMT6s synthesized in our laboratory is immunoreactively 
identical to other aMT6s standards. The availability of an internationally agreed 
quantitated standard is highly desirable in the interests of comparing results from 
different groups.
The radiolabel was prepared by the biological transformation of 
melatonin, labelled in two different positions, and the radiolabels produced were 
immunoreactively identical. No differences have been found between d iffe rent
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Figure 2.17 Correlation Between Total 6-Hydroxylated Melatonin
Metabolites Measured by GC/MS and aMT6s Measured by RIA
batches of radiolabel and no problems with stability of the label have been 
encountered for periods of up to one year. The antiserum has been shown to be 
extremely specific with negligible cross-reactivity w ith other indoles. The 
specificity of the antiserum allows plasma and urine samples to be assayed d irectly, 
therefore lengthy extraction procedures are avoided. The cross-reactivity w ith the 
other urinary metabolites of melatonin is so negligible that it  can be discounted in 
physiological studies.
The a ffin ity  column method employed to produce aMT6s-free plasma 
pools has the considerable advantage that consistent pools can be generated. There 
are no other reported methods for the measurement of aMT6s in plasma with which 
our assay can be compared. Unfortunately, the aMT6s levels in plasma are too low 
to investigate the chromatographic identity of the immunoreactivity.
In addition to validation using chromatographic procedures, the urine 
assay has been validated by comparison with an established GC/MS method. As 
expected, the RIA for aMT6s generated consistently lower values than the GC/MS 
method for tota l 6-hydroxylated melatonin metabolites. In the samples measured by 
both methods the to ta l excreted as the sulphate conjugate was not consistent - this 
may be due to a variable proportion being excreted as the glucuronide conjugate. 
Genetic differences in the conjugating enzymes or possible drug interactions w ith 
the enzymes (Weinshilboum, 1986) may account for this difference.
aMT6s has been shown to be extremely stable. The stab ility  of aMT6s in 
urine samples at room temperature is particularly important as it  enables samples to 
be collected from volunteers in their normal social environments. The sensitivity of 
the assay is such that only very small volumes of urine (< lm l) need be stored for 
analysis.
The reported method has considerable advantages over the other methods 
for the measurement of urinary melatonin metabolites. It requires a minimal 
amount of sample with no prior extraction, it  is rapid, inexpensive, requires basic 
equipment and no specially trained personnel. The ease with which large numbers of 
samples can be processed is essential for the measurement of the large number of 
samples associated with clin ical and circadian rhythmn studies. No other RIAs exist 
for the measurement of urinary melatonin metabolites and the reported method is 
considerably more rapid and robust than the reported RIAs for urinary melatonin.
Some report, a sea-maid spawned him. Some, 
that he was begot between two stockfishes. But it  is 
certain that when he makes water, his urine is con­
gealed ice; that I know to be true.
W. Shakespeare, Measure for Measure, 3,2,104
CHAPTER 3
BASIC PHYSIOLOGICAL STUDIES ON aMT6s PRODUCTION IN HUMANS
3.1 Diurnal Variation in aMT6s Excretion
3.1.1 Introduction
Previous workers (Fellenberg et al., 1980; Tetsuo et al., 1980) have 
demonstrated a marked diurnal rhythm in the rate of excretion of urinary melatonin 
metabolites. We carried out a preliminary study to confirm these findings.
3.1.2 Procedure
Four sequential six-hourly urine samples were collected from eight 
healthy volunteers (four men and four women; age range 23-27 years). aMT6s was 
measured by RIA.
3.1.3 Results
The values for aMT6s excretion are summarized below and in Figure 3.1.
Time aMT6s Excretion, jig/Collection Range, pg/Collection
Mean - SD (n = 8)
1200 - 180Oh 0.73 - 0.23 0.32 - 1.09
1800. - 2400h 0.85 - 0.18 0.55 - 1.16
2400 - 0600h 4.53 - 2.06 2.10 - 8.19
0600 - 1200h 2.58 - 0.87 0.80 - 3.84
Total 24h 8.70 - 2.85 4.40 - 12.66
82% of the tota l aMT6s excretion occurred between midnight and midday.
3.1.4 Discussion
The pattern of excretion of urinary aMT6s determined w ith our RIA is 
very similar to that reported by Fellenberg and Tetsuo. Fellenberg and colleagues
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(1980) reported that over 80% of the total 24h aMT6s production was present in the 
firs t sample voided after awakening. We found 82% of to ta l aMT6s production was 
present between midnight and midday.
The aMT6s excretion rates reported (4.4-12.7pg/24h) are very sim ilar to 
the previously published values. Fellenberg and co-workers (1981) reported aMT6s 
excretion rates of 6.3-30.9yg/24h, whereas Tetsuo at al., (1981a) quoted 6- 
hydroxymelatonin excretion rates of 6.2-18.8pg/24h.
The highest levels were found in the 2400-0600h collection when plasma 
melatonin and urinary melatonin levels are highest. High levels were also found 
between 0600-1200h. This is likely to be due to a delay in clearance and metabolism.
3.2 Intra-Individual Variation in aMT6s Excretion
3.2.1 Introduction
The excretion of 6-hydroxymelatonin over three consecutive days in seven 
male volunteers has been studied by Tetsuo et al., (1980). Over the three days the CV 
for consistency of 6-hydroxymelatonin excretion over 24h for all seven volunteers was
18.7 - 20.3% (mean - SD). In a similar study Fellenberg £ t al., (1981) collected urine 
from a single volunteer for five days. The CV for consistency of aMT6s excretion over 
24h was 14%.
In the above studies the total urine voided over 24h was collected and the 
volume recorded. The urinary excretion of a compound is often expressed as the 
'substance'/creatinine ratio. This overcomes the inconvenience involved in collecting 
24h urine samples. In a study by Boyce (1985), the urinary aMT6s levels of melancholic 
patients have been expressed as both the total excreted (jig), and also as a creatinine 
ratio (jig aMT6s/g creatinine).
The following experiment was designed to further investigate the intra- 
individual variation in aMT6s excretion. Both the consistency of to ta l aMT6s 
excretion and of aMT6s excretion when expressed as a creatinine ratio were 
investigated.
3.2.2 Procedure
Eighteen apparently healthy volunteers (nine men and nine women; age 
range 17-67 years) collected urine over 12-hourly time periods, 1000-2200h and 2200- 
lOOOh for four consecutive days. Samples were collected under normal conditions of 
work, activ ity , diet and sleep. A ll subjects were drug free apart from five women 
taking oral contraceptives.
aMT6s was measured by RIA. A ll the samples from any one individual 
were measured in the same assay. The creatinine measurements were carried out on a 
Cobas Bio auto-analyser using a Boehringer Mannheim k it (number 124 192). The 
measurements depend on the colour reaction produced when creatinine reacts w ith 
picric acid in an alkaline medium. The interassay CV of this method is <3%.
Two-way analysis of variance was used to analyse the data. The CVs for 
day-to-day differences in the urinary excretion of total aMT6s, and of aMT6s 
expressed as a creatinine ratio, were calculated for each subject. The percentage of 
the total 24h aMT6s production excreted at night was also calculated.
3.2.3 Results
Two-way analysis of variance of the urinary excretion of aMT6s over four 
consecutive days showed a significant variation between the to ta l urinary aMT6s levels 
of the d ifferent subjects, for the daytime (F = 6.34, p < 0.001, df 17, 51), n ight-tim e (F 
= 23.79, p < 0.001, df 17, 51) and 24h samples (F = 26.62, p < 0.001, df 17, 51).
There was no significant within-group variation showing that for any one individual the 
total excretion of aMT6s was consistent within the four-day period.
Two-way analysis of variance of the urinary excretion of aMT6s over the 
four days, when expressed as a creatinine ratio, showed a significant variation between 
the urinary levels of the d ifferent subjects for the daytime (F = 1.90, p < 0.04, df 17, 
51), night-time (F = 2.23, p < 0.02, df 17, 51) and 24h samples (F = 2.31, p < 0.01, df 17, 
51). There was no significant within-group variation.
The means and the ranges of the tota l urinary aMT6s production are 
shown in Table 3.1, together with the mean CVs for consistency of to ta l aMT6s 
excretion over the four days and the ranges of the CVs observed. The corresponding 
values for urinary aMT6s excretion, when expressed as a creatinine ratio  are shown in 
Table 3.2.
The mean - SD aMT6s production over the four-day period for all eighteen 
volunteers is shown in Figure 3.2. Figure 3.3 illustrates the aMT6s excretion in four 
individual volunteers over the 96h period.
Of the tota l 24h urinary aMT6s excretion 80.7 - 6.1% (mean - SD, n = 18) 
was excreted between 2200-1000h. The proportion of aMT6s excreted at night by each 
individual subject was remarkably consistent. The mean CV for the proportion of 
aMT6s excreted at night by each volunteer over the four days was 7.40 - 4.7% (mean - 
SD, n = 18). One-way analysis of variance showed no significant differences between 
sexes, in the meaned tota l aMT6s excretion for the daytime, night-tim e and 24h 
samples.
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Figure 3.3 Urinary aMT6s Excretion, Determined at 12h Intervals 
for 96 Consecutive Hours in 4 Subjects
3.2.4 Discussion
The marked diurnal variation in aMT6s excretion has been confirmed and 
the excretion profile of to ta l aMT6s has been shown to be consistent fo r any individual 
over four days. Consistency of excretion was greatest for the n ight-tim e values. 
Daytime values are often at, or near, the detection lim it of the assay; in this study no 
restriction was made on flu id  intake and slight assay variations may be magnified by 
large urine volumes and the subsequent m ultip lication factors.
The mean CV for consistency of to ta l 24h aMT6s excretion in eighteen 
volunteers over four consecutive days was 13.7 - 3.3% (mean - SD). This is very 
sim ilar to the CVs fo r 24h urinary metabolite excretion reported by Tetsuo and 
Fellenberg (for details see Section 3.2.1) which were 18.7 - 20.3% (mean - SD, n = 7) 
over three days, and 14% (n = 1) over five days, respectively.
The aMT6s values obtained are again in agreement w ith those previously 
reported. Urinary levels of aMT6s excretion in both males and females were sim ilar 
and ranged from 2.47-30.11]jg aMT6s/24h. There were very large inter-individual 
differences in aMT6s excretion which were highly significant.
When aMT6s excretion was expressed as a creatinine ra tio , the variab ility  
in aMT6s excretion from day-to-day for each individual subject, became unacceptably 
high. The mean CV for consistency of 24h aMT6s excretion over the four days, when 
expressed as a creatinine ratio  was 40.2 1 30.0% (mean - SD, n = 18), which compares 
with a CV of 13.7 - 5.3% (mean - SD, n = 18) for tota l 24h aMT6s excretion.
The reasons why there is a large variab ility  in aMT6s excretion rates when 
expressed as a creatinine ratio are two-fold. F irstly , there can be considerable day- 
to-day variations in the urine creatinine content and therefore its use as an index of
completeness of 24h urine collections is misleading. Secondly, there is a small 
circadian rhythm in creatinine excretion. The diurnal variation in aMT6s excretion is 
opposite in phase to that of creatinine and therefore using the 'creatinine ratio ' again 
gives rise to misleading results (Daly, 1978).
In conclusion, the experiment has shown that the excretion of to ta l aMT6s 
for any one individual is consistent over a four-day period. A single 24h sample is 
sufficient to give a representative measure of the aMT6s excretion of a particular 
subject. There are, however, large inter-individual variations in aMT6s excretion. A ll 
the urine excreted has to be collected and the volume recorded. Expressing the aMT6s 
excretion as a creatinine ratio is not a viable alternative due to the high variab ility  of 
the results obtained.
3.3 The Correlation Between Plasma Melatonin Levels,
Plasma aMT6s Levels, and Urinary aMT6s Excretion
3.3.1 Introduction
It is now well established that there is a marked diurnal rhythm in plasma 
concentrations of melatonin in humans. In normal volunteers daytime plasma 
melatonin levels are very low, usually undetectable by RIA technology. Melatonin 
secretion increases at night and reaches a peak at approximately 0100-0300h (for 
review, see Arendt, 1986b). In order to obtain meaningful results, hourly blood 
samples need to be taken at night.. This is obviously an extremely d iff ic u lt 
undertaking. If the measurement of a urinary metabolite of melatonin is to be a viable 
alternative, the exact relationship between plasma concentrations of melatonin and 
urinary aMT6s has to be established.
Fellenberg and co-workers (1981) administered deuterated-melatonin (50- 
lOOOjjg doses) intravenously to two male volunteers and found that 99.7% of tracer
was excreted within 24h. About 42% of the administered dose was excreted as 
deuterated aMT6s confirming the significance of this pathway as a major route of 
excretion of melatonin and confirming that the estimation of endogenous aMT6s was a 
good index of melatonin production.
The firs t study to determine the correlation between plasma melatonin 
and levels of urinary melatonin metabolites was carried out by Markey et al., (1985). 
A significant correlation (r = 0.76, p = 0.00004) was found between night-time peak 
plasma melatonin levels (samples taken at 3h intervals) and the 24h urinary excretion 
totals for conjugated 6-hydroxymelatonin for a group of twenty-two women.
The experiment described here was carried out to determine the 
correlation between concentrations of plasma melatonin and urinary aMT6s. No 
plasma assays for melatonin metabolites have been reported and this is the firs t study 
to investigate the diurnal changes in the plasma concentrations of aMT6s.
3.3.2 Procedure
Blood was sampled (July) from eighteen apparently healthy volunteers 
(twelve men and six women) at two-hourly intervals from 1200-2000h and at hourly 
intervals from 2000-1000h with one final blood sample at 1200h. Blood was sampled by 
venepuncture during the day, whereas an indwelling cannula inserted into the 
antecubital vein was used for the night-time sampling. N ight-tim e samples were taken 
using a dim red torch (< 1 lux). Simultaneously with blood sampling subjects collected 
timed six-hourly urine samples, 1200-1800h, 1800-2400h, 2400-0600h and 0600-1200h.
Four additional male volunteers were also included in the study. From 
2000-1000h blood was sampled (May) at hourly intervals, no blood samples were 
collected during the day. Simultaneous urine samples were collected 2000-2400h, 2400 
-1200h and 1200-2000h. The samples obtained from these four male volunteers were 
the 'controls' in a collaborative study (Bojkowski et al.,1987).
The age range of all the volunteers was 18-47 years. During the day 
subjects remained in their normal working environments and were kept at the C linical 
Investigation Unit, St Luke’s Hospital, Guildford, overnight. Subjects were sent to bed 
at 2330h and were awakened at 0700h.
A ll plasma samples were assayed for both melatonin (Fraser et al., 1983a) 
and aMT6s. Urine samples were assayed for aMT6s. The area under the curve (AUC) 
of the 24h, plasma profiles was calculated by the trapezium method (Cornish-Bowdem, 
1981). For the purposes of calculation all values below the detection lim it of the assay 
were set at the detection lim it, as were the daytime samples of the four volunteers 
sampled in May. In normal volunteers daytime plasma melatonin levels are very low, 
usually undetectable by RIA technology (Arendt, 1986b). The quantitative 
relationships between urinary aMT6s and plasma concentrations of melatonin and 
aMT6s were determined by the coefficient of linear regression.
3.3.3 Results
Plasma aMT6s was found to have a marked circadian rhythm, closely 
related to that of melatonin. Figure 3.4a and 3.4b illustrates the individual plasma 
melatonin and aMT6s profiles in all the subjects. In all the volunteers except subjects 
B and G daytime melatonin and aMT6s values were low and peak values were obtained 
at night.
In the twenty-two subjects, the mean concentrations of plasma melatonin 
varied from 8.0pg/ml (1400-1800h) to 49.6pg/ml (0400h) while the mean plasma aMT6s 
levels varied from ll.O pg/m l (1600-2100h) to 85.2pg/ml (0500h) (Figure 3.5). There 
were large inter-individual differences in peak melatonin values (range 10.0 - 
180.0pg/ml) and peak aMT6s values (range 18.6 - 233.0pg/ml). The mean values for 
urinary aMT6s excretion were (jjg aMT6s; mean - SD, n = 18) 0.68 - 0.27 (1200-1800h),
1.24 - 0.65 (1800-2400h), 4.38 - 1.84 (2400-0600h) and 1.87 - 1.08 (0600-1200h). The 
mean tota l 24h urinary aMT6s excretion was 8.76 - 3.43yg aMT6s (mean - SD, n = 22).
The AUCs and the peak heights of the respective plasma melatonin and 
aMT6s profiles as well as the tota l 24h urinary aMT6s excretion for all twenty-two 
volunteers are given in Table 3.3. There were significant correlations between all the 
parameters (Table 3.4). The most important correlation was that between plasma 
melatonin (AUC of 24h profile) and total 24h urinary aMT6s (r = 0.75, p = 0.0002, n = 
22) (Figure 3.6). This relationship is of great relevance and enables urinary aMT6s to 
be used as an index of plasma concentrations of melatonin.
The AUCs of the melatonin and aMT6s profiles and the to ta l 24h aMT6s 
excretion showed no correlation with age, height or weight (p>0.05 in all cases).
3.3.4 Discussion
There is a very good correlation between urinary levels of aMT6s and 
plasma concentrations of melatonin (r = 0.75, p = 0.0002). This validates the use of the 
urinary metabolite as an index of plasma concentrations of melatonin. A very sim ilar 
relationship between plasma melatonin and urinary 6-hydroxymelatonin (r = 0.76, p = 
0.00004, n = 22) was reported by Markey and colleagues (1985). Whether these 
correlations are maintained in various disease states or after drug treatment remains 
to be established.
In many situations the measurement of urinary aMT6s is like ly to provide 
a better index of pineal melatonin production than the measurement of plasma 
samples. Studies have been published in which single time-point sampling has been 
used. The marked diurnal variation in plasma concentrations of melatonin brings the 
valid ity of such results into question. In situations where plasma samples are not taken
at frequent intervals over 24h, the measurement of urinary aMT6s provides an 
integrated measure of pineal melatonin production over several hours and is like ly to 
yield more valuable data.
The measurement of melatonin and its major metabolites in the same 
subjects indicates that low melatonin levels are not the result of more rapid 
metabolism and clearance, but result from low pineal production. Two of the 
volunteers, B and G, had no apparent rhythm in melatonin. Subject B had no aMT6s 
rhythm while subject G had a small night-time aMT6s peak. A ll the values fo r this 
subject, however, were at or near the detection lim it of the assay. I t  is interesting to 
observe that neither of these subjects showed any apparent c lin ica l abnormalities. In 
all the other subjects the rhythmic characteristics of the night-tim e increases in 
plasma melatonin and plasma aMT6s and in urinary aMT6s excretion were very 
marked. Daytime plasma levels were at or near the detection lim it of the assays while 
the onset/decline of the night-time production of melatonin/aMT6s was very 
consistent between subjects.
Plasma aMT6s levels were very closely related to plasma melatonin 
levels. Mean peak aMT6s levels were achieved at 0500h slightly la te r than peak 
melatonin levels at 0400h, and the plasma concentrations of aMT6s remained elevated 
for about 2h longer than those of melatonin. There were changes in the ra tio  of 
melatonin to aMT6s over 24h, possibly due to a delay in clearance of aMT6s from the 
circulation compared to the rate of secretion and metabolism of melatonin. Whether 
there is a change in the rate of metabolism of melatonin or in the clearance of aMT6s 
over 24h is not known. The elimination h a lf-life  for aMT6s is greater than the 
corresponding ha lf-life  for melatonin (see Chapter 4) and this helps to explain why 
these changes in the ratio  of melatonin to aMT6s are observed. The inter-individual 
differences in plasma concentrations of melatonin which have been previously reported 
(Arendt, 1978) were reflected in the plasma and urinary aMT6s levels.
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Correlation Between Individual Levels of Plasma 
Melatonin (AUC of 24h Profile) and Total Urinary
aMT6s Excreted Over 24h (n = 22)
Subject Plasma Melatonin Plasma aMT6s Urina
aMT6
AUC
pg/ml.h
Peak Height 
pg/ml
AUC
pg/ml.h
Peak Height 
pg/ml ug/24
A 343 28 589 49 6.43
B 276 18 339 19 3.79
C 868 97 1383 138 9.68
D 334 32 632 60 8.49
E 273 20 582 58 9.62
G ' 240 8 348 25 2.99
H 351 62 701 78 7.75
J 440 42 858 73 9.15
L 398 40 800 63 7.70
M 894 81 756 68 10.53
2A 939 130 1966 233 12.11
2B 217 24 426 42 4.40
2G 592 72 948 132 9.43
2D 406 37 855 87 7.66
2E 1116 180 1138 152 12.66
2F 206 24 541 66 5.87
2G 148 21 760 75 7.80
2H 389 53 711 82 9.65
3A 546 76 846 101 12.86
3C 938 90 1340 150 18.63
3E 322 33 718 132 6.40
3F 476 55 1240 183 9.16
Table 3.3 AUCs and Peak Heights of Plasma Melatonin and aMT6s
Profiles and 24h Urinary aMT6s Excretion for 22 Subjects
Comparison r
(n=22)
AUC plasma melatonin: tota l 24h urinary aMT6s 0.75
Plasma melatonin peak height: total 24h urinary 
aMT6s 0.70
AUC plasma aMT6s: tota l 24h urinary aMT6s 0.70
Plasma aMT6s peak height: to ta l 24h urinary 
aMT6s 0.64
AUC plasma melatonin: AUC plasma aMT6s 0.76
Plasma melatonin peak height: plasma aMT6s peak 
height 0.73
Table 3.4 The Correlation Between Individual Levels of Plasma
Melatonin (AUC of 24h Profile and Peak Height), Plasma 
aMT6s (AUC of 24h Profile and Peak Height), and Total
P
0.0002
0.0005
0.0005
0.002
0.0001
0.0003
Urinary aMT6s Excreted Over 24h
3.4 Investigation of Short-Term Fluctuations in Plasma Melatonin and aMT6s
Levels
3.4.1 Introduction
Several reports have appeared in the litera ture  on the episodic secretion 
of melatonin. Coarse pulsatile rises in melatonin concentration in plasma lasting an 
hour or more have been observed with re lative ly long (20-30min) sampling intervals 
(Vaughan at al., 1978; Weinberg et al., 1979). Episodic secretion of melatonin was also 
found in daytime samples taken from pre- and postpubertal children (Penny, 1985), and 
in normal volunteers when assayed by GC/MS (Mullen et al., 1980). Pulsatile patterns 
of melatonin secretion in h u m a n s  h a y e  also been reported by Birkeland (1982) and 
Claustrat and colleagues (1986) w ith a mean of 2.5 and 4.5 peaks during the night 
respectively. Vaughan and co-workers (1979a) found pulses of melatonin about lOmin 
apart and in another study in which a sampling interval of 2-5min was used, even more 
rapid fluctuations in concentration were observed (V aughan et al., 1979b).
Further evidence for the episodic secretion of melatonin has been 
obtained from studies in sheep. Blood samples were taken at 12min intervals from 
ovariectomized ewes and rapid fluctuations of melatonin levels were observed through 
the course of the night (Bittman et al., 1983). Recently, English et al., (1987a) 
reported very rapid fluctuations in plasma melatonin levels in sheep.
The following experiment was performed to confirm the existence of very 
rapid fluctuations in plasma melatonin levels in humans and to see whether these 
changes were reflected in the plasma concentrations of aMT6s.
3.4.2 Procedure
___________ Three—volunteers-(two women-and-one man;—aged-24y—27—and-45-years----
respectively) had indwelling cannulae inserted into their antecubital vein at 2330h.
They then retired to bed in darkness. A t 2400h and 0300h the volunteers had 5ml blood 
samples taken, in darkness, with a dim red torch (<1 lux), at 30s intervals for 10 min. 
The plasma samples were assayed for melatonin and aMT6s, all samples from any one 
individual being determined in the same assay. Control or noise series were created by 
pooling the remaining aliquots of plasma from one or more of the volunteers to form 
large plasma pools. Sequential samples from these pools were then assayed in an 
identical manner. A ll measurements for a series of samples were performed in the 
same assay.
The following method was used to identify peaks in the data. A ll local 
minima and maxima were identified. The concentration at the minimum was 
multiplied by three times the concentration matched intra-assay CV to obtain the 
corresponding increment in hormone concentration. The next local maximum was 
considered a peak i f  i t  exceeded the minimum by an amount equal to or greater than 
this increment. The CV of the twenty samples in the noise series was used to identify 
peaks in that particular series and in concentration matched volunteers' samples. The 
number of peaks in the volunteers' samples was compared by paired Student's t-test 
(two-tailed) to the number of peaks in concentration matched noise series (false 
positives).
3.4.3 Results
The melatonin and aMT6s concentrations in the volunteers' and the 
control samples are shown in Figure 3.7a and Figure 3.7b, respectively. No secretory 
episodes, with short duration pulses of an amplitude significantly greater than that 
observed in the control noise series, were observed in the volunteers' samples. The CV 
for each series of samples was calculated. The mean CVs for the volunteers' samples 
-were 7.5 -  2.6%-(n-= 6) and-6.7—-1.2% (n =-6) for-melatonin-and-aMT6s respectively, 
whereas for the concentration matched noise series the mean CVs were 4.3 ^0.3% (n = 
6) and 7.9 ^0.3% (n = 6) respectively. A slightly greater variab ility was observed in the 
volunteers' melatonin samples than in the noise series.
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Using the three CV criterion, peaks were observed in both the melatonin 
noise series (eleven peaks in total) and the volunteers' melatonin samples (fourteen 
peaks in total). In the aMT6s noise series three peaks in to ta l were observed, whereas 
in the volunteers' aMT6s samples only one peak was observed. The to ta l number of 
peaks observed in the volunteers' melatonin or aMT6s samples compared to the to ta l 
number of peaks in concentration matched control series showed no significant 
difference using the paired Student's t-tes t (two-tailed).
3.4.4 Discussion
In the majority of cases where workers have reported the existence of 
episodic secretion of melatonin the same methodology has been used (the RIA of 
Rollag and Niswender, 1976) adapted for the assay of human plasma). Melatonin 
concentrations of 500pg/ml (Weinberg et al., 1979) and 3000pg/ml (Birkeland, 1982) 
have been reported, which brings into doubt whether these workers were measuring 
melatonin. Other workers have found daytime values of around 50pg/ml (Mullen et al., 
1980; Penny, 1983) and this again casts doubt on the valid ity of the methodology 
employed.
Where melatonin spikes have been reported, very l it t le  data is given on 
the intra-assay variation of the methodology used. With frequent blood sampling the 
probability of detecting false positive peaks due to assay noise is increased. It is very 
important to include data on the variab ility of repeated measurements of the same 
samples. Ideally, a more rigorous criterion than an increment from nadir to peak of 
three times the intra-assay CV should be used to identify peaks, such as m ultiple 
measurement at each time point (Ross et al., 1984). Unfortunately, w ith the volume 
of plasma required in our assay this was not possible. In only one study on the episodic 
secretion of melatonin in humans have such crite ria  been applied (Claustrat et al., 
1986).
Claustrat and colleagues (1986) reported episodic secretion of melatonin 
with a mean of 4.3 peaks per night. The amplitude of the reported peaks was low. In 
the data presented in this thesis there are no 'episodic' variations in melatonin levels 
which are of an amplitude significantly greater than that which can be accounted for 
by the intra-assay variation.
The best evidence for rapid fluctuations of melatonin levels throughout 
the night comes from experiments in sheep. These fluctuations were firs t observed by 
Bittman and colleagues (1983) and their existence was confirmed by English and 
colleagues (1987a). In both these studies, samples have been taken from the jugular 
vein. Recently, further evidence for episodic secretion of melatonin in sheep has been 
obtained by Cozzi and co-workers (1987). Blood samples were obtained from the 
rectus sinus (a blood vessel draining the pineal gland), and the jugular vein. Episodic 
release of melatonin was observed at both sampling sites. It is possible that the rapid 
changes in concentration do not result from episodic secretion of melatonin but are 
caused by changes in blood flow or by changes in clearance. It is like ly that human 
melatonin secretion is episodic but that peaks seen in the jugular vein may be 'damped' 
in the antecubital vein. In this study we have found no evidence for short duration 
pulses of melatonin or aMT6s in plasma samples taken from the antecubital vein. In 
1986, using an extensively validated assay, Webley and Leidenberger also reported no 
evidence for the episodic secretion of melatonin in humans. In their study samples 
were taken from the antecubital vein at 13min intervals.
3.3 Effect of Atenolol on Urinary aMT6s
3.5.1 Introduction
It is now well established that the production of melatonin by the pineal 
gland is dependent on the stimulation of post-synaptic pineal 6-adrenoceptors 
(Axelrod, 1974). Studies have shown that pineal 6-adrenoceptors in the rat are of the 
6-subtype (Zatz et al., 1976) and lie outside the blood-brain barrier (Arendt et al., 
1981b).
Previous work in humans has demonstrated that propranolol reduces the 
nocturnal increase in plasma melatonin (Vaughan et al., 1976b; Hanssen et al., 1977). 
Propranolol is a non-selective 6-adrenoceptor antagonist which crosses the blood-brain 
barrier (Cruickshank et al., 1980). Taking plasma samples at 1400h and 2400h Cowen 
and colleagues (1983) were able to demonstrate that atenolol, a selective 62- 
adrenoceptor antagonist which crosses the blood-brain barrier poorly (Cruickshank et 
al., 1980), caused a significant reduction in midnight melatonin concentration. The 
results suggested that human 6-adrenoceptors were of the 62-subtype.
The experimental protocol of Cowen and colleagues (1983) was adapted in 
order to investigate the effect of atenolol on urinary aMT6s production.
3.5.2 Procedure
Six apparently healthy subjects (three men and three women; age range 
24-37 years) took lOOmg atenolol or placebo (ascorbic acid) at 1800h in a single blind 
cross-over protocol, either on consecutive days (n = 4) or with one day between doses. 
Subjects had been told that the order of administration was randomized, however, in 
all cases they received placebo on the firs t day. Subjects kept to the same routine on 
each of the test days but no other social or dietary restrictions were applied.
Six-hourly urine samples were collected for 24h from 1200h on each of the 
test days. Urine samples were assayed for aMT6s and statistical significance was
determined by the paired Student's t-test (one-tailed). Ethical committee approval for
this study was obtained from the Ethical Committee of St Luke's Hospital, Guildford.
3.3.3 Results
The aMT6s values are shown in Table 3.5 and in Figure 3.8.
When the results were compared by paired Student's t-tes t significant 
reductions were obtained in aMT6s excretion following atenolol administration for the 
time periods between 2400 - 0600h (p<0.005) and 0600-1200h (p<0.005) and for the 
total 24h aMT6s excretion (p<0.0025).
Atenolol treatment to ta lly abolished the night-time peak in aMT6s 
excretion, however, there were no significant differences in the daytime values.
3.5.4 Discussion
Our results confirm the observations made by Cowen and colleagues 
(1983) and show for the firs t time the abolition of the diurnal rhythm in urinary aMT6s 
excretion following a single oral dose of atenolol. In previous studies where single 
night-time samples have been taken, any decreases in observed plasma melatonin 
levels, may be due to marked phase-shifts in melatonin production, induced by the 
administered drug. The urinary data presented represents an integrated measure of 
melatonin production, therefore a decrease in aMT6s excretion following atenolol 
administration is due to a decrease in melatonin secretion. It may be argued that 
atenolol affects melatonin metabolism, however, the previously published data on 
plasma melatonin levels negates this hypothesis.
Time
Placebo 
aMT6s (pg/collection) 
Mean - SD
Atenolol 
aMT6s (yg/collection) 
Mean - SD
1200 - 1800h 0.51 - 0.10 0.55 - 0.11
1800 - 2400h 0.85 - 0.71 0.59 - 0.25
2400 - 0600h 6.47 - 3.63 0.82 - 0.44
0600 - 1200h 2.80 - 1.35 0.63 ± 0.32
Total 24h 10.63 - 4.45 2.59 - 0.96
Table 3.5 The Effect of Atenolol on Urinary aMT6s Levels
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This experiment confirms the suggestion that pineal melatonin production 
in humans is under the control of 8-adrenoceptors which lie outside the blood brain 
barrier. Chronic treatment of hypertensive patients with atenolol has been shown to 
lead to lowered melatonin levels at midnight, when compared to hypertensive patients 
treated with diuretics (Cowen et al., 1985). It is open to speculation as to whether any 
of the clinical effects of 8-adrenoceptor blocking drugs are due to a decrease in 
melatonin production.
3.6 General Discussion
The experiments described have confirmed that there are marked diurnal 
variations in aMT6s excretion. The excretion of aMT6s for any individual has been 
shown to be very consistent and a single 24h urine sample is suffic ient to give a 
representative measure of an individual's aMT6s production. The urinary aMT6s levels 
we report are in close agreement with previously published values and indirectly 
confirm the accuracy of the method which was used to quantitate our standard 
(Section 2.9).
In normal volunteers, urinary aMT6s has been shown to be a good index of 
plasma concentrations of melatonin, thus for most purposes, nocturnal blood sampling 
can be avoided. Plasma aMT6s levels are very closely related to those of melatonin 
and plasma aMT6s measurements may prove to be a very useful tool in backing-up 
plasma melatonin data.
aMT6s is stable in urine and samples can be collected w ith ease. 
However, the accuracy of the measurements depends largely on the compliance of the 
volunteers. There are very large inter-individual differences in aMT6s excretion. 
Thus, for statistica l reasons, large populations are required in cross-sectional studies 
or individuals must act as their own controls.
She found a lit t le  bottle on it, ('which certainly was 
not here before,' said Alice,) and round its neck a 
paper label, with the words 'DRINK ME' beautifully 
printed on i t  in large letters.
L. Carrol, Alice's Adventures in Wonderland, 
Chapter 1.
CHAPTER 4
PHARMACOKINETICS OF MELATONIN AND aMT6s
4.1 Introduction
There is considerable interest in a possible therapeutic role of melatonin 
in man. In rodents, pharmacological doses of melatonin w ill entrain the rest- 
ac tiv ity  cycle (Redman et al., 1983) and accelerate the re-entrainment of the 
circadian rhythm in corticosterone (Murakami et al., 1983). Acute hypnotic-like 
effects have been observed in humans after large doses of exogenous melatonin 
(Vollrath et al., 1981; Lieberman et al., 1984) and timed doses of melatonin given at 
1700h were found to have a significant e ffect on self-reported drowsiness (Arendt et 
al., 1984) and to sh ift the endogenous melatonin rhythm. Recently timed 
pharmacological doses of melatonin have also been shown to alleviate the symptoms 
of jet-lag (Arendt et al., 1986; Arendt et al., 1987). In order to interpret the results 
of experiments where melatonin has been administered to human subjects, i t  is 
essential to know the pharmacokinetic profiles of the preparations used.
There is l it t le  information on the pharmacokinetics of melatonin in man. 
Preliminary data was reported by Wetterberg et al., (1978) and Matthews et al.,
(1981) following the oral administration of melatonin, however, no pharmacokinetic 
parameters were determined. Following the intravenous injection of lOpg of 
melatonin in normal volunteers, the distribution ha lf-life  was found to be 5.6min and 
the elimination ha lf-life  was 43.6min (Iguchi et al., 1982a). Waldhauser and co- 
workers (1984b) reported the kinetic parameters following the oral administration of 
80mg melatonin in gelatine capsules. The elimination ha lf-life  was 48min and large 
variations were reported in the fraction of ingested melatonin that was absorbed. 
The plasma concentrations of melatonin after oral ingestion of d iffe rent 
preparations were investigated by Aldhous and colleagues (1985). The elim ination 
ha lf-life  varied from 32-40min. The plasma samples obtained in the la tte r study 
were assayed for aMT6s and the results form the basis of this Chapter.
4.1.1 Pharmacokinetic Principles
To exert an e ffec t, exogenously administered melatonin must be present 
in appropriate concentrations at its site of action. This w ill be a function of the 
amount administered and also the extent and rate of absorption, d istribution, binding 
or localization in tissue, biotransformation and excretion. Many factors w ill a ffect 
the absorption of a compound; these include molecular size and shape, solubility at 
the site of absorption and relative lip id solubility. Drugs given in aqueous solution 
are more rapidly absorbed than those in oily solution, suspension or solid form 
because they mix more readily w ith the aqueous phase at the site of absorption. For 
drugs given in solid form, for example, as a gelatine capsule, the rate of dissolution 
may be the lim iting  factor in the absorption (Mayer et al., 1980).
The route of administration of a drug has a major e ffec t on the blood 
levels observed. I f  intravenous administration is used the to ta l dose injected enters 
the circulation, however, if  oral administration is used many other factors have to 
be considered. Drugs in the gastrointestinal tract may be metabolized by the 
enzymes of the mucosa, the intestinal flora or the liver before they gain access to 
the general circulation. When a drug is administered subcutaneously, 
intramuscularly or intravenously into a peripheral vein, i t  enters the peripheral 
venous circulation and is distributed into tissues and organs though less than 30% of 
the dose passes through the liver during the firs t passage through the body (Gibaldi 
and Perrier, 1975). When a drug is given orally, access to the peripheral venous 
circulation is almost exclusively via the hepatic portal system. A compound such as 
melatonin, which is rapidly metabolized by the liver, may undergo substantial 
biotransformation before reaching the peripheral circulation when administered 
orally. This phenomenon is known as the first-pass e ffec t (Gibaldi and Perrier,
Once present in the circulation a drug is then distributed around the body. 
The pattern of distribution w ill depend on physiological factors and physico­
chemical properties of the drug. Drugs w ill enter various tissues and organs and 
may accumulate in certain tissues. The action of a drug is usually terminated either 
by metabolism or by renal or b iliary excretion of the unchanged drug from the body 
(Mayer et al., 1980).
Pharmacokinetic principles relate specificially to the variation of drug 
concentrations with time, particularly in the blood or plasma, as a result of 
absorption, distribution and elimination. Many pharmacokinetic models used to 
describe the time course of drugs and/or metabolites are based on the assumptions 
that the systems are linear with respect to drug distribution (ie, any changes in the 
plasma level of a drug quantitatively reflects any changes in the tissue levels of the 
drug within the same compartment) and that drug elimination is governed by firs t-  
order kinetics and occurs exclusively from the compartment containing the plasma 
(the central compartment). It is assumed that the central compartment is directly 
accessible to administered drugs regardless of the route of administration (Gibaldi 
and Perrier, 1975; Mayer et al., 1980).
It is important to realise the lim itations of pharmacokinetic models when 
applied to data obtained from the oral administration of drugs. The proportion of 
the dose absorbed is unknown, as is the amount of drug eliminated by the first-pass 
effect. For a compound such as melatonin, the disappearance of melatonin in 
plasma is the result of renal excretion, liver metabolism, metabolism in other organs 
and distribution between d ifferent 'compartments' of the body. In a complex system 
the rate constant for the disappearance from plasma is a hybrid rate constant and 
the ha lf-life  calculated can be referred to as the biological ha lf-life . As long as the 
lim itations of the data are considered, sim ilar pharmacokinetic parameters can be
determined for metabolites. If drugs are administered intravenously considerably 
more pharmacokinetic parameters can be determined. However, the intravenous 
administration of drugs to volunteers solely for the purposes of pharmacokinetics 
poses ethical problems.
Ms M Aldhous, Ms C Franey, Dr J Wright and Dr 3 Arendt are responsible 
for devising the protocol fo r oral administration of melatonin and for the 
organization of the clinical tria ls. The assays to determine melatonin levels 
following oral ingestion of d ifferent preparations were performed by Ms M Aldhous 
and Ms C Franey.
The plasma samples obtained following the intravenous administration of 
[n C ] melatonin were generously supplied by Dr B Claustrat, University of Lyons. 
Thanks also go to Dr D Le Bars (Lyon) who synthesized the [^ C ] melatonin and to 
the sta ff of the MRC Cyclotron Unit, Hammersmith Hospital.
4.2 Methods
4.2.1 Oral Administration of Melatonin
Melatonin was obtained from Sigma Chemical Company Lim ited and made 
up in two formulations. 0.04% weight/vol of melatonin was dissolved in corn oil 
containing 2% vol/vol ethanol (a). Five ml of this preparation thus provided 2mg of 
melatonin, and for ingestion was dispersed in 50ml of m ilk. Gelatine-coated 
capsules containing 2mg of melatonin dispersed in 250mg of lactose were 
manufactured by St Luke's Hospital pharmacy, Guildford (b). For ingestion these 
were taken with approximately 50ml of water.
Ten normal healthy volunteers (five men, five women) aged 21 to 39 years 
and weight range 50-85kg, were assigned to two groups. A group of four were given
the corn oil preparation, and a group of six were given the gelatine preparation. 
Ethical approval for this study was obtained from the Guildford Ethics Committee, 
St Luke's Hospital.
On the morning of the study subjects ate a standard breakfast consisting 
of a small bowl of cereal, two slices of toast, and tea , before 0800h. A basal blood 
sample was taken at 0900h and the melatonin preparation was taken immediately 
after a second basal sample at lOOOh. Blood samples were taken from an indwelling 
venous cannula 15, 20, 45, 60, 120, 180, 240, 300, 360 and 420min after dosing.
A ll plasma samples were assayed for melatonin (Fraser et al., 1983a) and 
for aMT6s. The interassay CVs for the melatonin assay were 8% (25pg/ml), 7.1% 
(108pg/ml), 12% (141pg/ml) and 4.9% (526pg/ml). The interassay CVs for the aMT6s 
assay were 32.2% (35pg/ml), 12% (150pg/ml) and 2.0% (673pg/ml).
4.2.2 Intravenous Administration of l^C lM ela ton in
In order to study the distribution of melatonin in vivo in man by positron 
emission tomography (PET), [~^C ] melatonin was synthesized by Dr D Le Bars et 
al., (1987). [n c] melatonin (41pg, ^  12mCi) was injected as a bolus into the 
antecubital vein of a male volunteer, aged 26 years. Two basal samples were taken 
and twenty-three blood samples were taken at frequent intervals from an indwelling 
venous cannula for 75min after injection. The plasma samples were assayed for 
melatonin and for aMT6s.
4.2.3 Analysis of Results
The logarithm of plasma indole concentration was plotted against time. 
Areas under the plasma concentration curve (AUC) and the biological h a lf- life  fo r 
elimination of the terminal phase were calculated using an interactive computer
programme w ritten for the BBC microcomputer. The AUCs of each subject's plasma 
indole versus time curve were compared to get a measure of the to ta l amount of 
administered melatonin which was absorbed and which was also metabolized to 
aMT6s.
4.3 Results
Following oral administration of melatonin the plasma aMT6s levels were 
much higher and remained elevated for much longer than the plasma melatonin 
levels. The increases in plasma melatonin levels and in plasma aMT6s following an 
oral dose of melatonin were simultaneous. The mean plasma melatonin and aMT6s 
concentrations (- SEM) following gelatine and corn oil preparations are shown in 
Figures 4.1 and 4.2, respectively . Following the absorption phase, the elim ination 
of melatonin and of aMT6s fitted  a one-compartment model. Both preparations 
gave melatonin levels above baseline for 4-7h after oral administration. aMT6s 
levels were well above baseline until the end of the experiment (7h a fte r oral 
administration) in all the volunteers. Highest melatonin and aMT6s values were 
observed 15-120min and 30-120min, respectively, a fte r ingestion.
There were very large inter-individual differences in the maximum plasma 
melatonin concentrations achieved, these being th irty  seven-fold in the case of the 
gelatine capsules and eight-fold for the corn-oil preparation. In contrast the 
maximum plasma aMT6s levels achieved were remarkably consistent. The maximum 
difference in peak levels between subjects was a two-fold difference in the case of 
the gelatine capsule. Similar results were found for the AUCs of each subjects 
plasma indole versus time curve. These results are summarized in Table 4.1. For 
the AUC of the plasma melatonin data there was a th irteen-fold and nine-fold 
difference between subjects for the gelatine and corn-oil preparations respectively. 
For the AUC of the plasma aMT6s data the maximum difference between subjects
was two-fold in the case of the gelatine capsule. The ratio of AUC aMT6s/AUC 
melatonin varied between subjects from a two-fold difference to a fifty - fo ld  
difference.
The biological half-lives for the elimination of melatonin and aMT6s are 
summarized in Table 4.2. The ha lf-life  for each compound was consistent between 
subjects irrespective of the preparation administered. The overall calculated mean 
- SD ha lf-life  for melatonin was 44.0 - 6.6min (n=10) whereas the ha lf-life  for aMT6s 
was slightly longer at 58.2 ^8.2min (n=10).
The plasma concentrations of melatonin and aMT6s following intravenous 
administration of [ ^ C  ] melatonin are shown in Figure 4.3. Melatonin 
disappearance showed a biphasic pattern with a rapid distribution phase and a slower 
elimination phase. The ha lf-life  of the elimination phase was 48.5min. aMT6s was 
detectable in the plasma 3.5min after injection of melatonin and peak aMT6s 
concentrations were achieved after 17.5min. The elimination of aMT6s from the 
plasma could be described by a one-compartment model and the biological ha lf-life  
of aMT6s was calculated to be 53.5min.
4.4 Discussion
The results presented demonstrate the effect of first-pass hepatic 
metabolism. Following the oral administration of melatonin the amount reaching 
the systemic circulation is substantially less than the dose administered (Waldhauser 
et al., 1984b). Lane and Moss (1985) applied hepatic clearance concepts to existing 
data, on the intravenous and oral administration of melatonin to man, and predicted 
a very high hepatic extraction ratio for melatonin with reduced bioavailability of an 
oral dose. This prediction has been substantiated by the experimental data 
presented in this Chapter.
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Figure 4.2 Mean 5EM, n = 4) Plasma Melatonin and
aMT6s Concentrations After 2mg Melatonin Taken as a 
Corn Oil/Milk Preparation
AUC AUC
Melatonin aMT6s Factor Factor Ratio
(ng/ml.min) (ng/ml.min) AUC AUC aMT6s AUC aMT6s
Melatonin AUC Melatonin
JW O il/M ilk 133.7 2365.4 2.1 1.2 17.7
MB O il/M ilk 468.4 2753.0 7.4 1.4 5.9
JE O il/M ilk 594.8 2021.8 9.4 1.0 3.4
NB O il/M ilk 63.5 3120.9 1.0 1.5 49.2
Mean - SD O il/M ilk 315.1 - 256.9 2565.3 - 475.8
CB Gelatine 806.5 2315.0 8.7 1.6 2.9
DC Gelatine 92.5 1453.8 1.0 1.0 15.7
AH Gelatine 1211.0 2238.6 13.1 1.5 1.8
CF Gelatine 652.0 2825.9 7.0 1.9 4.3
WA Gelatine 230.9 2187.0 2.5 1.5 9.5
MA Gelatine 492.8 2262.8 5.3 1.6 4.6
Mean - SD Gelatine 580.9 - 405.4 2213.8 - 439.6
The factor was determined by assigning a value of 1 to the subject w ith the lowest 
AUC for each preparation and expressing the other AUCs as a multiple of that area.
Table 4.1 The Area Under the Plasma Indole Versus Time Curves
for Each Subject Following the Ingestion of
Different Oral Preparations
Biological H a lf-L ife  for Elimination (min)
Subject and Preparation Melatonin aMT6s
JW Com O il/M ilk 48.0 60.1
MB Corn O il/M ilk 39.5 63.6
JE Corn O il/M ilk 44.8 58.2
NB Corn O il/M ilk 55.7 44.2
Mean - SD Corn O il/M ilk 47.0- 6.8 56.5 - 8.5
CB Gelatine 38.3 61.4
DC Gelatine 44.7 44.1
AH Gelatine 38.1 66.6
CF Gelatine 47.5 60.6
WA Gelatine 49.8 67.0
MA Gelatine 34.0 55.7
Mean - SD Gelatine 42.1 - 6.2 59.2 - 8.5
Overall Mean - SD (n=10) 44.0 - 6.6 58.2 - 8.2
Table 4.2 Biological Half-Lives for the Elimination of Melatonin
and aMT6s Following the Ingestion of
Differential Oral Preparations
Figure 4.3
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Plasma Melatonin and aMT6s Concentrations After 
Intravenous Administration of 41yqj^C3 Melatonin
In view of the very rapid increases in aMT6s levels following oral (and 
intravenous) administration and the very high concentrations measured, this study 
confirms that the live r is a major site of melatonin metabolism in man. The 
importance of the route of administration on the subsequent blood levels of a drug is 
emphasized by the d iffe rent plasma profiles obtained when melatonin was 
administered either orally or intravenously. Oral administration leads to a large 
proportion of melatonin being metabolized immediately whereas following 
intravenous administration all the administered dose is available for distribution 
around the body. A fte r intravenous injection of melatonin, aMT6s does not appear 
in the plasma until a fte r 3-5,min and only about 30% of the administered dose is 
subject to hepatic metabolism on the firs t passage through the body (Gibaldi and 
Perrier, 1975). When investigating the pharmacological actions of melatonin i t  is 
important to consider the route of administration. In a study conducted by Vollra th  
and colleagues (1981) melatonin was administered intranasally. The concentrations 
of melatonin obtained, particularly in the brain are like ly to be considerably higher 
than those achieved following the intravenous or oral adm inistration of sim ilar 
doses.
The peak aMT6s levels measured and the AUCs of the aMT6s 
concentration time curves were remarkably consistent between subjects, whereas 
there were very marked differences in the same parameters fo r the measured 
melatonin levels. A large dose of melatonin was administered in this study and 
absorption of the drug varied between subjects. I t  is likely that fo llow ing absorption 
of such a large dose of melatonin the metabolizing liver enzymes are saturated and 
the relatively constant amount of aMT6s produced enters the circula tion, whereas 
the amount of unmetabolized melatonin entering the circulation is very variable due 
to the differences in absorption. These findings support the idea that the large 
inter-individual differences found in plasma melatonin and in plasma aMT6s
concentrations in normal volunteers are due to differences in the secretion of 
melatonin from the pineal rather than differences in metabolism.
It is of interest to consider how the proportions of the conjugated
metabolites may vary with d ifferent doses of melatonin. Many melatonin
metabolites have only been demonstrated following the administration of exogenous 
melatonin (Young et al., 1985; Vakkuri et al., 1987) and the importance of many of 
these metabolic pathways for endogenously produced melatonin has yet to be 
established. The proportion of the different metabolites produced is likely to vary
depending on both the dose and the route of administration. English et al., (1987b)
have shown that, in the ewe, aMT6s is produced i f  melatonin is given orally whereas, 
following subcutaneous implantation of melatonin, no aMT6s is measurable in the 
plasma, ie, the metabolic pathway varies depending on the route of administration.
The biological ha lf-life  for the elimination of melatonin 44.0 - 6.6min 
(mean - SD, n=10) is in close agreement with that of 48min reported by Waldhauser
H"and colleagues (1984b) and that of 43.6 - 3.3min (mean - SD, n=5) reported by Iguchi 
et al., (1982a). The distribution of intravenously administered melatonin also 
followed the two-phase distribution pattern described by Iguchi et al., (1982a). The 
calculated biological ha lf-life  for aMT6s 58.2 - 8.2mins (mean - SD, n=10) is longer 
than the corresponding figure for melatonin. This difference in the ha lf-life  helps to 
explain why the proportion of melatonin to that of aMT6s in the plasma varies over 
24h.
The samples were originally collected to investigate the pharmacokinetics 
of melatonin. A t the end of the experiment melatonin concentrations had reached 
base-line levels, whereas aMT6s concentrations were s till elevated. I f  samples were 
collected over a much longer period of time, the endogenous night-time production
of aMT6s would then be superimposed on the aMT6s elim ination profile . The 
disappearance of aMT6s fitte d  a one-compartment model. Since plasma sampling 
was not continued until aMT6s reached base-line levels however, i t  is possible that 
aMT6s elimination may be accounted for by a two-compartment model w ith the last 
phase having an elim ination ha lf-life  greater than that calculated.
No evidence for the enterohepatic recirculation of melatonin was obtained as 
no secondary peaks were observed. I t  is like ly that w ith the high dose of melatonin 
administered a large proportion w ill be excreted unmetabolized, not only in the 
urine but also in the bile and faeces. The enterohepatic recirculation of melatonin 
therefore remains a possibility.
This w ill last out a night in Russia
When nights are longest there. I'll take my leave,
And leave you to the hearing of the cause;
W. Shakespeare, Measure for Measure 2, 1, 133
CHAPTER 5 
ANNUAL VARIATIONS IN aMT6s EXCRETION
5.1 Introduction
The work of Rosenthal et al., (1986) has shown that ligh t has an important 
role in human physiology. Experiments on subjects in environmental isolation have 
demonstrated another important e ffect of light: that of entraining human circadian 
rhythms (Wever et al., 1983). Bright ligh t can also phase-shift the human melatonin 
rhythm (Lewy et al., 1987; Broadway et al., 1987) and the human temperature and 
cortisol rhythms (Czeisler et al., 1986). Work from our laboratory has shown that 
man is even more sensitive to light than previously thought. When ligh t is 
administered under the right conditions, ligh t of an intensity as low as 300 lux can 
suppress nocturnal plasma melatonin in normal volunteers (Bojkowski et al., 1987). 
This recent evidence of the effects of light on human physiology, together with 
inconsistent reports in the litera ture  concerning seasonal changes in melatonin (see 
Section 1.16.1.6), prompted this study on the annual variation in aMT6s excretion.
5.2 Procedure
5.2.1 Subjects
Sixteen apparently healthy volunteers (nine men and seven women, aged 
19-29 years at the beginning of the experiment, mean - SD, 25.5 - 3.3 years) 
recruited from the laboratory sta ff collected six-hourly urine samples fo r 24h, 
starting at midday. During the collection period subjects remained in the ir normal 
social environments. A ll the volunteers had sim ilar daytime routines and were all 
subjected to approximately the same domestic and natural ligh t intensity. Natural 
daylength varies from 16.4h in June to 7.5h in December at 52°N (Guildford, UK). 
Throughout the year in the late evenings normal domestic intensity (300-500 lux) 
a rtific ia l lights were used. The samples were collected at local tim e between the 
10th and 16th day of each month over a period of thirteen months, commencing in 
November 1985.
Subjects were asked to abstain from alcohol on sampling days and to 
record any medication taken on or up to a week before sampling days. Three of the 
female subjects were taking oral contraceptives. One of the subjects was prescribed 
8-blockers fo r two months; no samples were collected during this period and the 
mean of the two adjoining months was used for the purposes of calculation. Three 
subjects took flights across several time zones; in these cases, samples were 
collected three weeks after the return to England.
5.2.2 aMT6s Assay
A ll samples were measured by RIA at the dilution of 1:50; where 
necessary samples were re-assayed at a dilution of 1:100. A ll the samples from any 
one subject were measured in the same assay. The order in which the samples for 
each month were measured in successive assays was formally randomized for each 
assay, to eliminate any within-assay trends. The interassay CVs were 11.0%, 8.4% 
and 9.7% (n = 32 each) at concentrations of 3.5, 7.8 and 25.7ng/ml, respectively.
5.2.3 Statistical Analysis
The 24h aMT6s excretion data was analysed by a two-way analysis of 
variance with replication. Close examination of the raw data demonstrated large 
differences in the variances within one particular time period throughout the year. 
A Bartlett's test for homogeneity of variances was performed (Steel and Torrie, 
1981a). A significant difference was found, therefore the six-hourly aMT6s 
excretion data and the total 24h aMT6s excretion data were analysed non- 
parametrically using the Friedman two-way analysis of variance (Siegel, 1956a).
In order to eliminate the effect of the considerable inter-individual 
differences in aMT6s excretion, the monthly aMT6s excretion values were converted 
to percentages of the individual annual means. This transformed data was analysed 
as described above.
In order to estimate the parameters of the aMT6s rhythm fo r each subject 
in each month, cosine curves were fitted  by a least-squares method to each set of 
four x six-hourly samples (Monk and Fort, 1983). For each 24h tim e span the 
rhythmic characteristics of the excretion are described by the follow ing parameters; 
the acrophase (the estimated peak of the rhythm data); the amplitude (the 
measurement of the peak of the rhythm above the mean level); and the mesor (the 
mean value of the fitte d  cosine curve).
The cosinor parameters for the urinary aMT6s data throughout the year 
were analysed by a two-way analysis of variance. Further s ta tis tica l significance 
was determined w ith the Student-Newman-Keul's test (Steel and Torrie, 1981b). In 
mid-March, British Summer Time was introduced and the clocks were advanced by 
lh  until the end of October when Greenwich Mean Time resumed. A ll cosinor 
analysis was calculated on the basis of Greenwich Mean Time. A ll other 
calculations for aMT6s excretion refer to local time.
The variab ility  in the excretion of aMT6s over 24h fo r each individual was 
calculated (CV = SD/annual mean). The group means were calculated and the results 
for the male subjects and the female subjects were compared.
5.2.4 Urinary aMT6s Measurement as an Index of the Rhythmic Characteristics
of Plasma Melatonin Secretion
The data obtained from the experiment described in Section 3.3 was re­
analysed. B riefly, blood samples were obtained from eighteen volunteers fo r 24h at 
two-hourly intervals during the day and at hourly intervals at night while 
simultaneous six-hourly urine collections were made. Melatonin was measured in 
the plasma samples and aMT6s was assayed in the urines. This data was analysed 
using the cosine-curve fitt in g  programme (Monk and Fort, 1983). The results 
obtained from the cosinor analysis of the plasma melatonin data were compared to 
the results from the cosinor analysis of the urinary metabolite data.
5.3 Results
Two-way analysis of variance w ith replication, o f the raw aMT6s 
excretion data showed a very significant time of day e ffect (F = 206, p «  0.0001, df 
3, 780) but no variation w ith months (F = 0.13, p = 0.99 df 12, 780). Bartle tt's  test 
showed that the variances in the 1200-1800h time group were not homogeneous (chi- 
squared = 46.5, p < 0.005 12 df). The results were therefore analysed non- 
parametrically. The Friedman two-way analysis of variance showed a significant 
seasonal variation in aMT6s excretion for the 1200-1800h time period (p = 0.015). 
Peaks were observed in December/January and in July, and troughs were seen in 
spring and autumn. No other significant differences were observed in any of the 
other time periods, including the tota l 24h excretion. The mean aMT6s excretion in 
each of the four x six-hourly collection periods throughout the year is shown in 
Figure 5.1.
When the data were transformed so that each monthly aMT6s level 
represented the percentage of the individual annual means, identical results were 
obtained on sta tistica l analysis. Expressed this way the mean to ta l aMT6s excretion 
over 24h was shown to be very consistent throughout the year and ranged from 94.5 
- 3.4% to 107.3 - 3.1% (mean - SEM n = 16 each).
There were good correlations between the parameters obtained from the 
cosinor analysis of the plasma melatonin data and the cosinor parameters obtained 
from the simultaneous six-hourly urinary aMT6s measurements. One subject (G) had 
no melatonin levels above the detection lim it of the assay throughout the 24h blood 
sampling period (Figure 3.4a) and was excluded from the analysis. In the remaining 
seventeen subjects the mean acrophase for the urinary aMT6s data was 3.7 t  1.3h 
(SD) and the mean acrophase for the plasma melatonin data was 3.1 - l.Oh (SD). The
correlations between the acrophases, amplitudes and mesors obtained from the four 
x six-hourly urine samples and the acrophases, amplitudes and mesors from the 24h 
plasma melatonin data were r = 0.73 (p = 0.0012), r = 0.76 (p = 0.0007) and r = 0.77 (p 
= 0.0005), respectively (n = 17 each).
A sim ilar pattern was observed in all the urinary aMT6s excretion data, 
with low levels during the day and a peak in excretion during the night. Two-way 
analysis of variance showed no significant differences in the amplitude and mesor 
throughout the year. In contrast, a very significant difference was found in the 
acrophase of the aMT6s rhythm (F = 3.66, p = 0.00015, df 12, 180). Student- 
Newman-Keul's test showed significant differences in the acrophases: December
differed from April, June, July, October (p < 0.05), August and September (p < 0.01) 
and January differed from August and September (p < 0.05). The mean monthly 
values for the acrophase, amplitude and mesor are shown in Figure 5.2. The three- 
month moving averages of the aMT6s acrophases together with the annual variation 
in night-length are illustrated in Figure 5.3. The linear correlation coeffic ient 
between the three-month moving averages of the aMT6s acrophases and the night­
time duration for each month was r  = 0.82, p = 0.002 (n = 11). The linear correlation 
coefficient between the mean monthly aMT6s acrophases and the night-tim e 
duration for each month was r = 0.76, p = 0.003 (n = 13). In December/January the 
mean acrophase was 4.69h whereas in August/September the mean acrophase was 
3.22h; a phase advance of lh  and 30min in summer.
The means - SD of the individual subjects' CVs for consistency of aMT6s 
excretion over 24h for thirteen months were 18.5 - 5.4% (n = 9) fo r male subjects, 
16.0 *1.3% (n = 7) for female subjects and 17.4 - 4.4% (n = 17) for the whole group.
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The only statistica lly significant difference in excretion during the year was 
observed for the 1200-1800h collection period (p = 0.015)
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Figure 5.2 Group Means -  SEM for the Acrophases,
Amplitudes and Mesors, Respectively of the aMT6s 
Rhythm Throughout the Period of 1 Year
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Figure 5.3 Three-Month Moving Averages 5EM) of the
Acrophases of the aMT6s Rhythm Together with the 
Night-Time Duration (From Sunset to Sunrise) 
Throughout the Period of Investigation
5.4 Discussion
The parameters of the circannual aMT6s rhythm, that is acrophase,
amplitude and mesor have been ascertained together with data on urinary aMT6s
excretion. We have shown that aMT6s measured in six-hourly urine collections 
provides a good index of the rhythmic characteristics of the nocturnal increase in 
plasma melatonin. This study also illustrates the advantages of urine collections. 
Subjects acted as their own controls and collections were made in the volunteers' 
normal social environment with the minimum of inconvenience.
Collections were made throughout the year so that any effects due to the 
extremes in day-length in winter/summer might be observed, together w ith the 
effects due to rapid changes in day-length in spring/autumn, which may be of equal 
or greater importance. An accurate measure of seasonal trends in urbanized man 
was obtained and in a sense the volunteers can be considered to be a 'wild-captured' 
species (Reiter et al., 1983).
The circannual change in the acrophase for aMT6s excretion is in
agreement with the findings of other workers (Illnerova et al., 1985; Arendt and 
Broadway, 1986; Kennaway and Royles, 1986) who all reported phase advances in 
summer. The greatest phase advance, that of 2h, occurred under the extreme 
lighting conditions found in the Antarctic (Arendt and Broadway, 1986). The
relatively small change in the phase position found in the Antarctic is surprising and 
suggests that there may be entraining cues other than light, such as social factors, 
which influence the phase position of the melatonin secretion profile. Whether the 
change in acrophase observed in this study is a masking e ffect due to the phase 
advance in the rest-activ ity cycle caused by the introduction of British Summer 
Time, has to be considered. This remains unlikely since the phase advance observed 
(lh  and 30min) was greater than the change in the rest-activ ity  cycle due to the
change in clock-time and secondly, because similar results have been observed in the 
Antarctic, where there is no manipulation of clock-time (Arendt and Broadway, 
1986). It is likely therefore that the phase-advance observed is the result of 
environmental factors.
The sh ift in acrophase correlates closely with the duration of darkness, 
suggesting that the phase-shift is a photoperiod-related phenomenon. Together with 
results from studies in the Antarctic, which have shown that the application of a 
12.5h skeleton spring photoperiod of 25001ux in winter, produces a 'summer 
melatonin profile ' (Broadway et al., 1987) the results presented in this Chapter 
demonstrate that a residual photoperiodic response, at least as far as melatonin is 
concerned, is retained in man.
Recent work on the suppression of nocturnal plasma melatonin by light 
has shown that light of an intensity as low as 300 lux can suppress melatonin 
secretion in humans (Bojkowski et al., 1987). Work in animals has shown that 
previous lighting history is likely to be an important factor in determining an 
individuals' sensitivity to light (Reiter et al., 1983). I f  this is the case, then a 
variation in the ability of light to suppress melatonin may occur throughout the year 
and the tota l aMT6s excretion would be expected to change with the seasons. 
However, the ubiquitous use of indoor lighting may prevent the observation of any of 
the above changes.
In agreement with other workers we have found no changes in to ta l 
melatonin production throughout the year (Beck-Friis et al., 1984; G riffiths  et al., 
1986; Sack et al., 1986). A seasonal variation in aMT6s excretion was observed for 
the 1200-1800h collection period, with peaks in summer and winter. This is sim ilar
to the reports made by other workers who used daytime sampling (Arendt et al., 
1979; Martikainen et al., 1985). Why there is a variation in the daytime and not in 
any of the other samples remains puzzling. It may be that during the daytime when 
aMT6s excretion is low, other factors such as dietary constituents may contribute to 
the aMT6s output. Peaks in daytime plasma tryptophan levels have been reported in 
January and July (Wirz-Justice et al., 1977). The amplitude of the observed daytime 
rhythm is low and i t  is not reflected in the 24h aMT6s excretion rhythm.
Throughout the year a very stable excretion of aMT6s over 24h was 
observed. The mean CVs for consistency of aMT6s excretion over 24h were 18.5% 
for male subjects and 16.0% for female subjects suggesting that there were no major 
menstrual cycle effects on aMT6s excretion. The CV for the whole group was 17.4% 
(n = 16), which is very similar to the CV of 13.7% previously reported when eighteen 
volunteers collected urine samples over four consecutive days (Section 3.2).
Large inter-individual differences in the aMT6s excretion were again 
observed, emphasizing the need to use subjects as their own controls. N ight-tim e 
peaks in aMT6s excretion were always observed and the acrophase for aMT6s was 
relatively stable between volunteers. The large inter-individual differences in 
aMT6s excretion, together with the marked seasonal variation in the acrophase of 
aMT6s excretion suggest that perhaps it  is the precise phase of melatonin secretion 
rather than the amplitude of the rhythm or the duration of secretion, which conveys 
messages about the environment to the human brain.
When the voices of children are heard on the green 
And whisp'rings are in the dale,
The days of my youth rise fresh in my mind,
My face turns green and pale.
Then come home, my children, the sun is gone down, 
And the dews of night arise;
Your spring & your day are wasted in play,
And your w inter and night in disguise.
William Blake, Songs of Experience, Nurse's Song.
CHAPTER 6
CHANGES IN aMT6s EXCRETION DURING CHILDHOOD AND PUBERTY
6.1 Introduction
Considerable controversy s till surrounds the possible influence of the 
pineal gland on human puberty (see Section 1.16.1.7). The prelim inary study 
described in this Chapter was carried out to investigate whether there are changes 
in aMT6s excretion related to age and pubertal development. While the study 
described in this Chapter was in progress, Young and colleagues (1986) using a 
GC/MS assay for aMT6s, reported a decrease in both the daytime and night-time 
excretion of aMT6s with age.
6.2 Procedure
6.2.1 Subjects and Sample Collection
Children of University personnel were recruited for the study. Two 
consecutive 24h urine samples were collected from fo rty  children (twenty-four 
males, sixteen females) aged 2-20 years. Twenty-four hour samples were divided 
into three fractions: early morning urine, representing nocturnal melatonin
production; midday sample, representing any carry-over of the nocturnal production; 
rest-of-day urine including a sample before bedtime, representing daytime 
melatonin production. A ll the urine passed over a 48h interval was collected and the 
volume and time of each sample collection was recorded. The detailed protocol for 
urine collection is shown in Figure 6.1. To ensure collections were carried out 
correctly, parents supervised the proceedings where appropriate.
To determine the approximate pubertal stage of the subjects, 
questionnaires were devised on the basis of the Tanner c rite ria  (Marshall, 1975). 
The questionnaires (Figure 6.2) were completed by the subjects themselves or by 
their parents. To ensure confidentiality all subjects were coded. Details of age, 
weight, height and drug status were also recorded. A ll urine samples collected were 
assayed for aMT6s.
Figure 6.1
Protocol for Urine Collection
Urine collection - I t  should be stressed that all urine passed during the 
collection period of 48h must be collected.
Day 1 Empty bladder before going to bed and discard
urine. Note down bedtime.
Day 2 Container 1 Collect any urine which may be passed overnight.
Into same container collect the firs t urine sample 
passed in the morning and note down time.
Container 2 Collect all urine passed until midday. A t midday
empty bladder ( if possible) and collect urine into 
same container.
Container 3 From midday collect all urine passed until just
before going to bed. Before going to bed empty 
bladder and collect urine into same container. 
Note down bedtime.
Container 4 Collect any urine which may be passed overnight.
Into same container collect the firs t urine sample 
passed in the morning and note down time.
Container 5 Collect all urine passed until midday. A t midday
empty bladder and collect urine into same 
container.
Container 6 From midday collect all urine passed until just
before going to bed. Before going to bed empty 
bladder and collect urine into same container. 
Note down time.
Finished.

6.2.2 Statistics
For the purposes of statistical analysis subjects were divided into four age 
groups: Group (1) 2-5.9 (n = 10), Group (2) 6-9.9 (n = 9), Group (3) 10-13.9 (n = 10) and 
Group (4) 14-20 years (n = 11). The aMT6s excretion over five collection periods was 
analysed. These collection periods were: tota l 24h excretion, night-time excretion, 
a midday sample (representing any 'carry-over' of the night-time production), to ta l 
night-time production (the night-time and midday samples combined) and the 
daytime excretion. Urine samples were collected over two consecutive days and 
each aMT6s measurement used for the purposes of calculation is a mean value of 
two separate collections.
aMT6s excretion was expressed as the tota l excretion per collection 
interval and also as a rate of aMT6s excretion over that interval. aMT6s excretion 
was also expressed as a function of body weight.
One-way analysis of variance was used to determine any s ta tis tica lly  
significant differences between age groups. Further statistica l significance was 
determined using Duncan's multiple-range test (Steel and Torrie, 1981c).
6.3 Results
There were significant differences between age groups, in the duration of 
sample collection for the daytime and night-time samples respectively because the 
older subjects retired to bed considerably later than the children. This complicated 
the analysis of results as aMT6s excretion had to be expressed as both to ta l aMT6s 
excretion (yg) over a collection period and also as a rate of excretion over that 
collection period (ng aMT6s/h).
The to ta l aMT6s excretion (yg) for the daytime collection period showed a 
significant difference between the oldest age group (group 4) and group (2) (F = 2.9, 
p = 0.04, df 3, 36 ). This difference is because the adult volunteers (group 4) retired 
to bed much later than the children (group 2), consequently, the daytime collection 
period was longer fo r the adult volunteers. I f  allowance was made fo r the 
differences in the duration of the collections and the data was expressed as a rate of 
aMT6s excretion (ng aMT6s/h) over the daytime collection period, there was no 
difference between age groups (F = 0.59, p = 0.63, df 3, 36 ). When expressed as 
either to ta l aMT6s excretion, or as a rate of aMT6s excretion, there were no other 
significant differences between age groups in any of the other collection periods. 
The to ta l aMT6s excretion for each collection period is shown in Table 6.1. Figure
6.3 illustrates the to ta l aMT6s excretion for the 24h, tota l n ight-tim e and for the 
daytime collection periods.
When aMT6s excretion was expressed as a function of body mass very 
significant differences were observed between age groups. Values in the younger 
age group were significantly greater than values in.the older age groups. Total 24h 
aMT6s excretion dropped from 18.63 - 5.64 (mean - SD) ng/h/kg in youngest children 
(2-6 years) to 12.10 1 4.38 ng/h/kg in children 6-10 years, and 5.99 1 2.73 ng/h/kg in 
children 14-20 years. Thus, 24h aMT6s excretion dropped by 65-70% through 
childhood. Similar results were obtained when aMT6s excretion was expressed as 
either ng aMT6s/kg, or as ng aMT6s/h/kg. In the la tte r case when a correction for 
slight differences in the duration of collection intervals between subjects was made, 
the levels of significance attained were greater. For the sake of c la rity  only the 
results for rates of aMT6s excretion are presented. The rate of aMT6s excretion 
over each collection period, expressed as a function of body weight is shown in Table
6.2 and the significant differences between the age groups are summarized. Figures
6.3 and 6.4 illustrate the differences in the rate of aMT6s excretion as a function of 
body mass, between age groups for the 24h, to ta l night-tim e and fo r the daytime 
collection periods.
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Figure 6.4 Variation in the Rate o f aMT6s Excretion,
Expressed as a Function of Body Weight, with Age
A fte r analysing the answers on the questionnaires, subjects were allocated 
to one of four groups: pre-pubertal < 6 years, pre-pubertal 6-10 years, pubertal or 
post-pubertal. The allocation of subjects to d ifferent groups was on the basis of the 
Tanner crite ria  fo r pubertal staging (Marshall, 1975). With the exception of four
subjects there was an identical distribution of subjects to that previously obtained
on the basis of age.
Because of the very close agreement in the distribution pattern of 
subjects when grouped by age or on the basis of pubertal development the data was 
not re-analysed in terms of 'pubertal groups'. On the basis of crude pubertal staging 
obtained from the questionnaires a very sim ilar pattern of significance to that
obtained w ith age groups would be expected. The pre-pubertal < 6 years, pre­
pubertal 6-10 years, pubertal and post-pubertal groups corresponding to age Groups 
1, 2, 3 and 4, respectively.
Total 24h aMT6s excretion showed no significant differences between age 
groups (F = 0.17, p = 0.91, df 3,36 ). When 24h aMTos excretion was expressed as a 
function of height, greater differences between age groups were observed, however 
levels of significance were not attained (F = 2.58, p = 0.07, df 3,36 ). As stated 
previously, the most dramatic differences between age groups were observed when a 
correction for differences in body weight was made. For to ta l 24h aMT6s excretion 
as a function of body mass F = 18.45, p = 6.4 x 10-^, df 3,36 .
The proportion of the 24h collection excreted in the to ta l n ight-tim e 
sample was compared between age groups (F = 2.69, p = 0.06, df 3,34 ). Although 
statistica l significance was not attained there appeared to be a trend, w ith the 
youngest age groups excreting the greatest proportion at night. Irrespective of 
whether 24h aMT6s excretion was expressed as to ta l excretion, as a rate of
excretion or as a function of body mass one-way analysis of variance showed no sex 
differences (p > 0.5 in all cases).
6.4 Discussion
This study again illustrates the advantages of urine collections. Samples 
were obtained from children aged 2-20 years relatively easily with no ethical 
problems. The children were in their normal social environments, were drug free 
and unlike many previous studies were completely healthy and were not hospitalized. 
Urines were collected over 48h to enable a mean of two values to be calculated, 
since young children in particular may not have complete control of their bladders. 
An important feature of the protocol was that collections were carried out under 
the supervision of parents to ensure that they were carried out correctly.
When the 24h and night-time aMT6s excretion was corrected for body 
weight changes, there was good agreement between our data and that of Waldhauser 
and colleagues (1984a). Highest levels were observed in the youngest age group with 
a progressive decline with age. The decline occurs from the early years of life  
throughout pre-puberty and remains relatively constant through puberty and 
adolescence. A decline in daytime aMT6s excretion was also found between children 
aged 2-6 years and children aged 6-10 years. In contrast, Waldhauser et al., (1984a) 
found no change in the daytime plasma melatonin levels. One possible explanation 
for this discrepancy, is that plasma melatonin assays are insuffic iently sensitive to 
detect a change, as many of the daytime samples are at or below the detection lim it 
of the assay.
In this prelim inary study no physical examination of the subjects was 
possible and therefore only very general conclusions can be made, as regards aMT6s 
levels and pubertal development. It is d ifficu lt to assess where exactly in relation
to pubertal development the drop in aMT6s levels occurs. I f  melatonin is an 
antigonadotrophic agent then a decrease in aMT6s levels might be expected to occur 
before the onset of puberty. The data presented in this Chapter does not refute this 
hypothesis. In order to determine the exact relationship between melatonin levels 
and pubertal development it  would be essential to carry out longitudinal studies in 
the same individuals with regular physical examination and sample collection.
The data presented is largely in agreement with the results of Young and 
colleagues (1986). These authors reported significantly higher daytime and night­
time aMT6s levels (when expressed as a function of body weight) in children than in 
adolescents and adults. These workers found a significant attenuation of the diurnal 
rhythm in adults, which was not confirmed by our results. The youngest age groups 
tended to start their collections earlier than the older age groups, therefore i t  is 
d ifficu lt to draw any definite conclusions about any possible changes in the diurnal 
rhythm.
Tetsuo and co-workers (1982b) reported a constant excretion of 6- 
hydroxymelatonin with age and we found a similar pattern for aMT6s excretion. I f  
excretion remains constant, whilst body mass increases, the blood concentration of 
melatonin would be expected to decrease, provided that the proportion of melatonin 
metabolized to aMT6s remains constant with pubertal development.
The importance of the age-related decrease in the blood concentration of 
melatonin is d ifficu lt to interpret. It is important to bear in mind that the 
measurement of urinary aMT6s in this study cannot demonstrate subtle changes in 
the melatonin secretion profile, for example, in the duration of melatonin secretion, 
which may be of equal or greater importance. In view of the considerable problems
in obtaining blood samples from young children future studies may have to 
concentrate on the collection of both saliva and urine samples.
More studies on cases with abnormal pubertal development should be 
carried out. Recently, pinealectomy has been shown not to e ffect pubertal 
development in male rhesus monkeys (Plant and Zorub, 1986). More studies on 
primates should be undertaken, in particular, the effects of melatonin 
administration on subsequent pubertal development should be investigated.
Do not go gentle into that good night,
Old age should burn and rave at close of day; 
Rage, rage against the dying of the light.
Do not go gentle into that good night.
Dylan Thomas
CHAPTER 7
FACTORS INFLUENCING aMT6s EXCRETION IN NORMAL VOLUNTEERS
161
7.1 Influence of Age, Sex, Weight and Height on aMT6s Excretion
7.1.1 Introduction
Many conflicting reports exist concerning the relationship of melatonin 
secretion to age and body parameters (see Section 1.16.1.8). Using the urinary 
aMT6s assay i t  is possible now to assess melatonin secretion in large numbers of 
healthy people, thus increasing the re liab ility  of the results. Investigations into the 
relationships between a number of variables and urinary aMT6s levels in normal 
apparently healthy subjects are reported in this Chapter.
7.1.2 Subjects
Data from one hundred and th irty  subjects (sixty-eight males and sixty- 
two females) were used for this analysis. A ll subjects were in good general health 
and were drug-free, although oral contraceptives were perm itted. The age, weight, 
height and sex of each volunteer was recorded. The age range of the subjects was 2- 
80 years. The data for the youngest age group has been presented in Chapter 6.
The co-operation of Ms C Franey and Mrs M Kemp (Department of 
Biochemistry, University of Surrey) in providing the data for twenty-six of the 
subjects is acknowledged. Dr Labibe (Investigation Unit, St Luke's Hospital) kindly 
supplied the samples from twelve of the elderly subjects.
7.1.3 Procedure
No restrictions regarding diet, sleep, activ ity  or ligh t exposure were 
imposed on the volunteers and samples were randomly collected at d iffe ren t times 
of the year. Urine was collected over a 24h period into one to four containers 
depending on the study. The volume of each sample was recorded and aMT6s was 
measured by RIA. The to ta l aMT6s excretion over 24h has been used fo r the 
purposes of calculation.
The samples were measured over a period of two years. Two d ifferent 
quality control pools were used over this time period. The interassay CVs were 13.6, 
11.9, 16.3, 11.2, 11.6 and 16.7% for quality control samples which measured 19.5, 
7.2, 2.3 (n = 81 each) 25.1, 7.9 and 3.3ng/ml (n = 87 each) respectively.
7.1.4 Statistical Analysis
To assess the influence of age, body weight and height on aMT6s 
excretion, the linear correlation coefficients between each of these variables and 
to ta l 24h aMT6s excretion were determined. Linear correlation coefficients were 
calculated for the complete age range (2-80 years, n = 130), for adults (20-80 years, 
n = 90) and for the children (2-19.9 years, n = 40). The weights and heights of three 
of the elderly subjects were not obtained.
The age-related differences in aMT6s excretion were further investigated 
by a one-way analysis of variance. Statistical significance was determined with 
Duncan's test (Steel and Torrie, 1981c). The subjects were divided into ten age 
groups, which are outlined in Table 7.2. To investigate age-related changes in 
aMT6s production, the data was expressed as total excretion (jig) and also as a 
function of height (ng aMT6s/cm) and body weight (ng aMT6s/kg).
Differences in aMT6s excretion between the sexes were determined by 
unpaired t-tests for the following age ranges: 2 - 19.9, 2 - 80, 20 - 80 and 60 - 80 
years.
7.1.5 Results
The linear correlation coefficients between tota l 24h aMT6s excretion and 
age, height and weight are shown in Table 7.1. There was no relationship between 
aMT6s excretion and height or weight (Figure 7.1 and Table 7.1). In contrast, there
was a highly significant decline in aMT6s excretion with age in adult volunteers (y = 
-O .llx  + 12.8]jg, r=-0.35, p=0.001, n=90). The decline with age for the whole age 
group (2-80 years) approached significance (y = -0.04x + 9.69yg, r=-0.15, p=0.073, 
n=130). However, there was no relationship between aMT6s excretion and age in the 
children (2 - 19.9 years).
The subjects were then divided into ten age groups (Table 7.2) and a one­
way analysis of variance demonstrated age-related changes when aMT6s excretion 
was expressed as: tota l excretion (F = 2.43, p = 0.014, df 9, 120) as a function of
height (F = 1.97, p = 0.048, df 9, 117) and as a function of weight (F = 14.82, p = 1.1 
-8x 10" , df 9,117). These results are summarized in Tables 7.2, 7.3 and 7.4 
respectively and in Figures 7.2 and 7.3.
When aMT6s production was expressed as the to ta l excretion or as a 
function of height, the only significant differences were between the oldest age 
group (60-80 years) and the other age groups (Figures 7.3a and 7.3b). When 
expressed as a function of weight, significant differences were observed between 
the two youngest age groups (2-3.9, 6-9.9 years) and all other age groups and also 
between the oldest age group (60-80 years) and other age groups (Figure 7.3c).
No sex differences were observed in total aMT6s excretion by unpaired t- 
tests in any of the following age ranges: 2 - 19.9, 2 - 80, 20 - 80 and 60 - 80 years (p 
> 0.03 in all cases).
7.1.6 Discussion
The variable most closely related to urinary aMT6s production is age. 
There was a significant decline in total aMT6s excretion with age in adult volunteers 
in agreement with the work of Sack et al., (1986). Iguchi and colleagues (1982b)
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Differences between groups were assessed by analysis of variance and further 
sta tis tica l significance was determined by a Duncan's test. The capital and small 
form  of the le tte r signify a significant difference between 
these points (p<0.05, *p<0.01, **p<0.001)
found a significant decline in daytime melatonin levels in volunteers aged 1-92 years 
and in this study, the decline with age for the complete age range (2-80 years) 
approached significance. When the oldest age group was compared to the younger 
age groups the levels in the aged group were significantly lower, again confirming 
the results of previous workers, when plasma samples have been taken over 24h 
(Touitou et al., 1981; Iguchi et al., 1982b). This decline in the oldest age group was 
observed irrespective of whether aMT6s excretion was expressed as to ta l excretion 
or as a function of height/weight.
As discussed previously in Chapter 6, when aMT6s excretion is expressed 
as a function of weight, there is a very significant decline with age for the two 
youngest age groups. In addition to the precipitous drop for children up to 10 years 
old, there is a gradual decline in excretion in the adult volunteers and, fina lly, the 
levels in the elderly volunteers are significantly lower than those of some of the 
other age groups.
The decline in plasma melatonin levels described by Waldhauser and 
Steger (1986) for subjects aged 1 - 9 0  years closely resembles the decline observed 
in the urinary aMT6s excretion expressed as a function of weight. The urinary 
results confirm that the decrease observed in the plasma levels is not due to an 
increase in metabolism.
When collecting samples from elderly subjects it  is important to consider 
other factors which may influence the results. Elderly subjects are more like ly to 
have impaired bladder, kidney and liver function. However, other workers have 
demonstrated a decline in plasma melatonin levels in elderly subjects and this is 
therefore unlikely.
Although the data has been presented as to ta l 24h excretion many 
collections were divided into daytime and night-time samples. Good circadian 
rhythms were observed in all age groups. However, i t  was clear that in some of the 
elderly subjects the circadian rhythm appeared to be dampened. The tim ing of 
collections was not identical between age groups and therefore i t  is not possible to 
draw any firm  conclusions about changes in the circadian amplitude with age.
These results show conclusively that there was no relationship between 
to ta l aMT6s excretion and sex, height or weight. The data was not analysed in 
terms of other body measures such as obesity index. Most volunteers were of 
normal height and weight and a parameter such as the obesity index would fa ll 
within too narrow a range to give meaningful results.
Very large inter-individual variations in aMT6s excretion were again 
observed, underlining the importance of large sample numbers in this kind of study.
7.2 . Pineal Calcification
7.2.1 Introduction
The pineal glands of many species including humans, sheep, rats, gerbils 
and guinea-pigs ca lc ify w ith age. Skull radiography has shown tha t in humans 2% of 
the glands are calcified in the firs t decade of life , 12% in the second decade, 44% in 
the third and 61% after the age of 30 years. A fte r 30 years of age, the amount of 
pineal calcium is re la tive ly constant, with the proportion of ca lc ifica tion  being 
higher in females than males (Welsh, 1983).
The functional significance of pineal calcification remains a mystery. I t  
has been suggested that pineal concretions are an indication of degenerative changes 
in the pineal gland. Another hypothesis is that the formation of pineal concretions
is related to the functional ac tiv ity  of the gland. Recently, Commentz and co- 
workers (1986) measured night-time urinary melatonin levels in eighteen subjects 
w ith pineal ca lcification and compared the levels to the night-tim e melatonin 
excretion of an age and sex matched control group with no evidence of calcification. 
The night-time melatonin excretion was the same in the two groups suggesting that 
calcification does not a ffec t melatonin production.
In view of the large differences in aMT6s production observed in our 
normal subjects, i t  was of great interest to investigate any possible relationship 
between urinary aMT6s production and the degree of pineal ca lc ifica tion.
7.2.2 Procedure
Twenty-six adult volunteers (age range 20-30 years, seventeen males and 
nine females) gave informed consent to take part in the study. A ll volunteers were 
Caucasian, apart from one male volunteer of Asian origin. A la tera l skull X-ray of 
each subject was taken at the Royal Surrey County Hospital. A ll X-rays were 
performed by the same radiographer using the same equipment (the co-operation of 
Dr Broadbridge and Mrs V Weir, X-ray Department, Royal Surrey County Hospital, is 
gratefully acknowledged). The degree of pineal calcification was assessed on a blind 
basis by Dr Broadbridge, Consultant Radiologist, Royal Surrey County Hospital. 
Each subject was given a score of 0-4 based on the degree of ca lc ifica tion: 0 = none 
visible, 1 = minimal, 2 = moderate, 3 = heavy, and 4 = unusually extensive. The 24h 
urinary aMT6s excretion of each subject was known and, in addition, the 24h plasma 
melatonin and aMT6s profiles of sixteen of the volunteers had been obtained in 
previous studies. The age, sex, weight and height of the subjects was recorded.
7.2.3 Statistics
The correlations between the degree of calcification and a number of 
variables were calculated using Spearman's rank correlation coefficient (Siegel, 
1936b). These variables were: 24h urinary aMT6s excretion (pg), AUC of the 24h 
plasma melatonin profile (pg/ml.h), melatonin peak height (pg/ml), AUC of the 24h 
plasma aMT6s profile (pg/ml.h), aMT6s peak height (pg/ml), age, weight and height. 
Differences in the degree of calcification between the sexes were assessed by an 
unpaired t-test (two-tailed).
7.2.4 Results
Seven volunteers showed no calcification, six showed minimal 
calcification, eleven moderate calcification and two heavy calcification. There 
were no subjects with unusually extensive calcification. Thus, in the population
selected, a range of calcification was observed. There was also a large range in the
24h aMT6s excretion (3.79-28.03pg) and in the AUC of the plasma melatonin (148- 
938pg/ml.h) and plasma aMT6s (339-1338pg/ml.h) profiles. Figure 7.4 illustrates the 
relationships between pineal calcification and these measures of pineal function. 
There was no correlation between the degree of calcification and any of the 
variables studied (p>0.1 in all cases).
An unpaired t-tes t demonstrated that the female subjects had 
significantly greater pineal calcification (p = 0.03).
7.2.3 Discussion
Wurtman and colleagues (1964) measured the activ ity  of IHIOMT in human 
pineal glands obtained at autopsy. These authors were able to demonstrate that 
even pineal glands which were calcified were capable of synthesizing melatonin. In 
a study with five male volunteers, Pelham and colleagues (1973) used bioassay to
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investigate the variations in plasma melatonin over 24h. They reported that the 
night-time peak levels of the 'melatonin-like' substance were inversely related to 
pineal calcification and/or age. This work was carried out long before the large 
inter-individual variation in the plasma melatonin levels of normal volunteers had 
been reported (Arendt, 1978). I t  is likely therefore, that if  the study had been 
expanded to include more than five subjects, the reported relationship between 
pineal calcification and peak levels would no longer be maintained.
The results suggest that melatonin production is not influenced by pineal 
calcification and support the findings-'-of Commentz et al., (1986). Although the 
number of subjects studied was relatively small, the range of urinary aMT6s 
excretion values was considerable. I t  is likely that if  a relationship between 
function and calcification existed, a trend would have been observed in the data.
There was a large variation in the degree of calcification between the 
subjects and, with the small number of subjects studied, no correlation w ith age or 
any of the other parameters was observed. There was, however, a significant 
difference in the degree of calcification between the sexes, as previously reported 
(Welsh, 1985). No sex differences in pineal melatonin production have been 
reported, thus providing further indirect evidence that there is no relationship 
between pineal function and calcification.
We could not understand because we were too far 
and could not remember, because we were travelling 
in the night of f irs t ages, of those ages that are 
gone, leaving hardly a sign - and no memories.
Joseph Conrad, Heart of Darkness, Ch.2.
CHAPTER 8 
FINAL DISCUSSION
8.1 Critical Evaluation of Methodology
A t present no hard evidence has been produced for a major function of the 
human pineal gland. Progress in this fie ld has been greatly retarded by 
methodological constraints. In order to study pineal gland function i t  has, in 
general, been necessary to take peripheral blood samples and measure the 
circulating concentrations of the pineal hormone, melatonin. In view of rhythmic 
production of melatonin, blood samples have to be taken at frequent intervals, 
particularly at night, and this is obviously a d ifficu lt undertaking. To compound 
these practical d ifficu lties there have often been methodological problems with 
melatonin assays, some of which have lacked specificity and the necessary 
sensitivity.
To overcome these d ifficu lties the urinary output of melatonin has been 
measured (Bartsch et al., 1981; Lang et al., 1981). However, urinary concentrations 
of melatonin are extremely low and only represent a small percentage of melatonin 
secreted from the pineal gland (Kopin et al., 1961; Lang et al., 1981). Very few 
studies have been carried out to validate the use of urinary melatonin as an index of 
plasma melatonin levels. Whether or not it  is a good measure of pineal function is 
questionable.
The major urinary metabolite of melatonin in rats and humans, 
representing 40-60% of the melatonin secreted from the pineal gland, is aMT6s 
(Kopin at al., 1961; Jones et al., 1969). GC/MS methods to measure aMT6s exist 
(Fellenberg et al., 1980; Tetsuo et al., 1981a; Francis et al., 1987), however, they 
are expensive to run and have an extremely low sample throughput. The RIA 
described in this thesis, to measure aMT6s in urine and plasma, is sensitive, highly 
specific and is amenable to the measurement of the large numbers of samples 
associated with clinical work. Classical validation procedures have been employed
and the method has also been validated by comparison with an established GC/MS 
method. Urine samples are collected with relative ease and only very small amounts 
of sample need to be stored.
In addition to the validation of the assay methodology, the use of urinary 
aMT6s measurement as an index of pineal function has also been extensively 
validated. A high amplitude circadian rhythm in aMT6s excretion has been 
documented and urinary aMT6s concentrations are very highly correlated with 
plasma melatonin levels. There are, however, drawbacks in measuring aMT6s which 
have to be considered. It is imperative to remember that a metabolite is being 
measured and that factors which affect liver metabolism or kidney and bladder 
function may give rise to misleading results. Only one metabolite is measured and it  
would be important to establish techniques to measure aMT6G, the second major 
melatonin metabolite. Measurement of both metabolites in the same subjects would 
reduce misleading results due to factors interfering with the phase II conjugating 
enzymes.
The relationship between urinary aMT6s and plasma melatonin levels has 
been established in normal healthy subjects. How well this relationship is
maintained in pathological cases, w ith or without ingestion of drugs, remains to be
seen. I f  urinary metabolites are to be e ffective ly used as an index of pineal
function, the variables which affect melatonin metabolism must be extensively 
studied. It would be of great practical value as well as of academic interest to 
determine the influence of lighting history, genetic variables and time of day on 
melatonin metabolism and clearance.
Very l it t le  work has been carried out in humans to investigate the
proportion of melatonin secreted from the pineal gland which enters the CSF
(Section 1.9). The possible sites of action of melatonin remain at present unknown 
(Section 1.13) although convincing receptors have been demonstrated in the brain 
(Vanecek et al., 1987). Melatonin may enter CNS tissue from both CSF and from the 
blood. Thus, the levels of CSF melatonin may be of considerable biological 
significance. It would also be worthwhile to investigate whether or not the 
conjugated metabolites of melatonin are present in human CSF. In view of the 
different metabolic pathway for melatonin in the CNS (Hirata et al., 1974) the 
fraction of melatonin which enters the CNS may not be accounted for by the 
measurement of urinary aMT6s. Likewise, the proportion of melatonin which is 
metabolized by pathways other than 6-hydroxylation is not accounted for by urinary 
aMT6s assays. The importance of these pathways for the metabolism of 
endogenously-produced melatonin remains to be established but is like ly to be 
relatively small.
There are problems with the use of urinary assays in general. Frequency 
of sample collection is lim ited and by their very nature, urine samples represent an 
integrated measure over a particular time period. Consequently, when using urinary 
aMT6s measurements alone, it  is very d ifficu lt to determine subtle changes in the 
melatonin profile. There is considerable interest in determining which feature of 
the melatonin secretion profile is of biological significance (Goldman, 1983). With a 
urinary assay it  w ill be almost impossible to determine subtle differences in the 
qualitative aspect of the ’melatonin sianal' such as slight differences in the tim ing 
and duration of melatonin secretion. On the other hand, differences in the 
amplitude of the melatonin rhythm w ill be reflected in urinary aMT6s 
measurements.
With any urinary measurement, the valid ity of the results depends to a 
great extent on the compliance of the volunteers. Where the tim ing of urine
collections is an important factor, as in the study on the annual variation in aMT6s 
excretion (Chapter 3), the motivation of the volunteers is of paramount importance. 
In all the studies described in this thesis, the subjects were well-motivated and 
dependable. Where members of the general public and patients are recruited to 
studies, the compliance of the subjects in collecting the samples correctly is a 
factor which has to be considered when analysing the results.
In spite of the above drawbacks, there are nevertheless considerable 
advantages with an urinary assay. In particular, the ease with which samples can be 
collected allows far more extensive tria ls to be organised. In a normal healthy 
population, urinary aMT6s has been shown to be remarkably well correlated w ith 
plasma melatonin.
8.2. Control of Human Pineal Function - Evaluation by aMT6s Assay
8.2.1 Pharmacological Manipulations
Because of the innervation of the pineal gland by peripheral
postganglionic sympathetic neurons, the secretion of melatonin from the gland has 
been used as an experimental model for the evaluation of adrenergic function. The 
synthesis of melatonin appears to be under the control of peripheral B-adrenergic 
receptors, which lie outside of the blood-brain barrier in humans. The rhythm in 
aMT6s excretion, like that of melatonin, was abolished by a 3-blocker, atenolol 
(Section 3.3). This approach has been exploited to investigate affective disorders 
(Section 1.16.1.4). In studies of this nature, either the AUC of 24h plasma melatonin 
or overnight aMT6s production has to be estimated (Boyce, 1985). The la tte r 
approach is obviously considerably easier.
The pineal gland is a particularly useful pharmacological model to study 
the effects of adrenergic drugs. The abolition of the night-time rise of melatonin by
8-blockers has already been mentioned. Checkley et al., (1987) measured urinary 
aMT6s to investigate the effects of a phosphodiesterase inh ib itor (rolipram) and 
demonstrated that cAMP was a like ly secondary messenger through which 
noradrenaline activates the synthesis of melatonin. Franey and colleagues (1986) 
demonstrated that desipramine, a noradrenaline uptake blocker, altered melatonin 
production by increasing plasma melatonin during the evening and reducing 
melatonin levels during the morning. By assaying both melatonin and aMT6s these 
authors were able to show that this change was not due to an e ffec t on hepatic 
metabolism.
Stimulation of human melatonin production during the day w ith 8-agonists 
is d ifficu lt, probably because the doses required would cause unpleasant side- 
effects. A recent area of controversy has been the e ffec t of the agonist, 
clonidine. Lewy and co-workers (1986) took blood samples at th ir ty  minute intervals 
between 2400h and 0500h and reported that clonidine reduced melatonin levels. 
However, Grasby and Cowen (1987a) used a slightly d iffe rent protocol and were 
unable to confirm these findings. In situations such as this, a urinary aMT6s assay 
may resolve the problem. Recent evidence has shown that a^-adrenoceptors are 
involved in the physiological control of melatonin secretion in man (Franey, personal 
communication). The antagonist, prazosin, significantly reduced nocturnal 
melatonin secretion. The observed e ffect was slight however, compared to that of 
8-adrenoceptor blockade.
In any study investigating the adrenergic function of the pineal gland, i t  is 
worthwhile to remember that although the sympathetic innervation of the pineal 
appears to be functionally the most important, in a number of species a central 
innervation of the gland has been documented (Section 1.4). The function of this 
central innervation of the gland remains unknown.
8.2.2 Influence of the Light-Dark Cycle on the Human Pineal
The variable which has been shown to have most e ffec t on melatonin 
secretion is the light/dark cycle. Light plays a dual role in controlling pineal 
function. Bright ligh t has an entraining e ffect on circadian rhythms (Wever et al., 
1983) and both bright and dim ligh t can suppress plasma melatonin levels (Lewy et 
al., 1980; Bojkowski et al., 1987). The manipulation of melatonin production by the 
acute administration of bright ligh t during the dark phase is a unique feature of the 
pineal gland which has been lit t le  exploited. However, this feature of the gland has 
been used by Lewy et al., (1985) to investigate whether depressives are super- 
sensitive to light.
A study to investigate annual changes in aMT6s excretion was organized 
with the subjects acting as their own controls. Large inter-individual differences 
were observed in to ta l aMT6s excretion with no annual changes. A small but highly 
significant difference in the time of peak aMT6s excretion throughout the year was 
present. These results suggest that perhaps i t  is the exact phase of melatonin 
secretion rather than the tota l amount secreted which is of importance in humans. 
The change in the aMT6s acrophase was highly correlated w ith the duration of 
darkness suggesting that this may be a photoperiod-related phenomenon.
Broadway and colleagues (1987) investigated the changes in the plasma 
melatonin rhythm in response to treatment with bright or dim ligh t during the 
Antarctic w inter. Bright, but not dim ligh t treatment in w inter induced a marked 
phase advance of the melatonin rhythm, sim ilar to that found in the summer. 
Kennaway and co-workers (1987) have also recently shown that evening exposure to 
bright light w ill phase-delay the aMT6s excretion rhythm. I f  the seasonal changes in 
melatonin secretion are indeed photoperiod-related, this opens up the possibility 
that the seasonal changes observed in other endocrine parameters are also
photoperiodic. The annual variation in melatonin secretion in response to light, 
together with evidence that a pharmacological dose of melatonin alters the rhythm 
of its own secretion (Arendt et al., 1987), suggests that the secretion of melatonin in 
man has a role to play in the organization and control of circadian and seasonal 
rhythms in humans.
It should be pointed out, however, that the evidence suggesting annual 
changes in melatonin secretion in man are related to photoperiod is very 
preliminary. The study described in Chapter 5 could be improved in a number of 
ways. The collection of urine samples at more frequent intervals and for a period of 
time longer than twelve months (preferably twenty-four) would enable the annual 
variation to be more precisely defined. Ideally, the lighting experienced by each 
individual throughout the year should be recorded. In practice, however, such 
refinements are probably not feasible.
The evidence which has emerged recently suggests that light has a far 
greater role to play in the control of the secretion of melatonin from the human 
pineal gland than previously thought. This may help to explain why there have been 
so many contradictory results in the past. In most of the published studies on 
melatonin secretion in man, lit t le  attention has been paid to the lighting conditions 
experienced by the subjects.
A ll animal studies on pineal function are carried out under very s tr ic tly  
controlled lighting conditions. In future work, lighting conditions must be carefully 
defined, particularly i f  results from d ifferent groups in different parts of the world 
are to be compared. Once this approach is adopted, then a more detailed 
examination of the other factors which may a ffect melatonin production w ill be 
possible. Extensive studies on the relevance of lighting history, and of exposure to
light of d ifferent wavelengths and intensities at d ifferent times of the day, need to 
be carried out. Further experiments under the extreme lighting conditions found in 
the Antarctic are under way. The practical d ifficu lties involved in the control of 
light exposure may prove to be insurmountable in the majority of clin ical tria ls.
8.2.3 aMT6s as a Circadian Rhythm Marker
aMT6s excretion shows a very stable circadian rhythm and an important 
use of the assay is to monitor aMT6s excretion as a circadian rhythm marker. One 
of the major problems in circadian rhythm research is the phenomenon known as 
'masking'. Changes in the rest-activ ity cycle, for example, w ill alter and 'mask' the 
underlying rhythm of body temperature. As long as subjects are drug-free and the 
lighting intensity is carefully controlled, the rhythm in melatonin production appears 
to be free of masking effects. The aMT6s assay has been used to investigate the 
control of circadian rhythms under conditions of environmental isolation w ith, and 
without, desynchronisation (Wever, 1986) and the aMT6s rhythm has been shown to 
behave more like a 'strong' oscillator variable (Arendt et al., 1983b). The rhythm in 
aMT6s excretion w ill be used in future studies to investigate the phase relationships 
between melatonin and other circadian rhythms.
aMT6s output is also very useful as a circadian rhythm marker under fie ld  
conditions. The RIA has been used as a tool to investigate the re-entrainment of 
circadian rhythms in jet-lag (Arendt et al., 1987) and would evidently serve to 
monitor circadian rhythm changes under conditions such as shift-work.
The physiological role of the pineal as a photoneuroendocrine transducer 
in photoperiodic species, such as the hamster, is well understood. Unfortunately, 
there is a paucity of information about plasma melatonin levels in rodents, largely 
due to technical d ifficu lties. Because plasma melatonin levels are so low, large
volumes of blood are required. An alternative approach is to measure the rhythmic 
variations of pineal melatonin content, however, this has obvious lim itations. The 
development of assays to measure aMT6s in rodent urine would have considerable 
importance in photoperiodic studies. In particular, repeated samples could be 
obtained from the same animal. This approach would be particularly useful in the 
study of rodent circadian rhythms where urinary aMT6s could be used as a stable 
circadian rhythm marker. However, this approach would be of lim ited value in 
species such as the sheep, where aMT6s is not a major melatonin metabolite (English 
et al., 1987b).
8.3 Establishment of 'Normal' aMT6s Levels in Humans
The urinary aMT6s assay is invaluable for the study of pineal function 
under fie ld conditions and in large-scale clinical trials. Many studies are now 
possible which would be almost impossible to carry out otherwise. Data on aMT6s 
excretion (and plasma melatonin measurements) have demonstrated very large inter- 
individual differences in absolute levels. However, a marked circadian rhythm in 
excretion is present in nearly all subjects. This emphasizes the need to organize 
studies where subjects act as their own controls. A lternative ly, large number of 
subjects have to be used.
In two healthy volunteers no rhythms in melatonin secretion were 
observed (Section 3.3). These volunteers exhibited no signs of any clinical 
abnormalities. Although no rhythm was apparent, this may largely be due to the 
lack of sensitivity of the detection methods used to measure melatonin. In one of 
these subjects, a very slight night-time rise in plasma aMT6s was observed and both 
subjects had small circadian rhythms in aMT6s excretion.
Although during the day the circulating levels of plasma melatonin are 
below the detection lim its of the current assay, this does not necessarily mean that 
melatonin is not exerting an effect during the day. When circulating levels are 
undetectable, melatonin may be present in sufficient concentration at its putative 
sites of action. This may be relevant to local neuromodulator effects, such as are 
found in the retina (Dubocovich, 1983).
The majority of subjects exhibit a good circadian rhythm in the production 
of melatonin and aMT6s. For any one individual, the night-time plasma melatonin 
secretion profile and the rhythm in aMT6s excretion are very consistent. Whether 
the reproducibility of the rhythm is of clinical significance remains to be 
ascertained. The lack of a day-to-day variation reinforces the idea that melatonin 
production is a very stable circadian output which is re lative ly unaffected by 
'masking' effects. Poor reproducibility of the melatonin 'signal' may indicate 
instability of the circadian system. As such, aMT6s may prove to be of diagnostic 
importance in diseases associated with rhythm abnormalities, such as depression, 
(Wehr and Goodwin, 1983) and serve to define rhythm disturbances in general.
A relatively constant output of total aMT6s excretion was found in the 
course of pubertal development. When aMT6s excretion was expressed as a function 
of weight, a very significant decline in the youngest age groups was observed. In an 
area of research where there have been many contradictory reports, these results 
support the work of Waldhauser et al., (1984) who found a decline in plasma 
melatonin during development. Clearly, the decline in plasma melatonin observed is 
not the result of increased metabolism. The fa ll in aMT6s excretion is most striking 
in the youngest age groups, long before the in itia tion  of pubertal development. In 
our studies, i t  was not possible to confirm any relationships which may exist 
between stage of pubertal development and aMT6s levels, as no physical 
examination of subjects was carried out.
In future studies it  would be important to determine accurately the sexual 
maturation of the subjects and to investigate how this is related to aMT6s excretion. 
Such a study should include the measurement of gonadotrophin levels in each 
subject. A t present, i t  is uncertain whether the reported inverse relationships 
between the activ ity  of the pineal gland and that of the hypothalamo-pituitary- 
gonadal axis is of biological significance or is merely coincidental. The decrease in 
plasma melatonin levels observed during childhood may simply be a result of the 
increases in body size which occur at that time. An interesting approach would be 
to study cases of delayed puberty, where body size has increased but the 
development of secondary sexual characteristics has not occurred. In normal 
subjects it  w ill only be possible to determine accurately the relationship between 
melatonin levels and pubertal development with longitudinal studies in the same 
individuals.
The variable which had most e ffect on aMT6s excretion was age. A small 
decline in total aMT6s excretion in old age was observed, whereas weight and height 
had no effect. In the elderly subjects, there also appeared to be a dampened 
circadian rhythm in aMT6s excretion. Whether these changes are of any clin ical 
significance and whether they affect the 'well being' of the subjects is open to 
speculation. It would be of great interest to try  to reinforce the melatonin 
circadian rhythm in elderly subjects by feeding them melatonin at the appropriate 
time of day. It is important to realise, however, that the changes in aMT6s 
excretion observed in elderly subjects may be the result of other factors, such as 
impaired kidney and bladder function.
8.4 Pharmacokinetic Studies
The pharmacokinetics of melatonin and aMT6s have been studied and the 
ha lf-life  of aMT6s was found to be slightly longer than that of melatonin. The very 
close relationship between plasma melatonin and plasma aMT6s levels is of interest
in view of the recent evidence that the conjugated metabolites of melatonin are 
themselves biologically active in vitro (Leone et al., 1987a). Whether or not the 
conjugated metabolites are also biologically active jn vivo in photoperiodic species 
is not known. 6-Hydroxymelatonin has low potency melatonin-like effects in some 
species (Reiter and Vaughan, 1973) which may be due to conjugated metabolites. A t 
present, the purified metabolites which are available, are too precious to be used in 
this kind of experiment. It would be possible to investigate the potency of the 
conjugated metabolites on in v itro  systems such as the melanophore bioassay 
(Section 1.18.1). Such studies would serve to define more closely the structure- 
activ ity  relationships of the melatonin receptor.
Studying the function of the pineal gland by measuring the output of 
melatonin has the obvious lim itations that only one indole is under consideration. 
An important role of melatonin has been established in photoperiodic species and, as 
a consequence, considerable emphasis has been placed in the study of human pineal 
function in measuring melatonin. Many other indoles and peptides are present in the 
pineal gland (Section 1.5) which may have an important role to play in human 
physiology.
8.5 Conclusions
The studies described in this thesis have provided essential, basic 
information on human melatonin production, as evidenced by variations in aMT6s, 
the major metabolite of melatonin in man. They suggest fru itfu l avenues of 
research into the physiological function of the human pineal.
It is the author's personal opinion that future studies may indicate that 
the total output of melatonin is not of great significance, whereas the exact phase 
of secretion is of considerable importance. More attention w ill have to be paid in
future work to the lighting conditions to which human subjects are exposed. I f  
future studies concentrate on abnormal rhythms of melatonin secretion, and on the 
phase of the rhythm, then we may begin to understand the role of the pineal gland in 
human physiology.
The mind of man is capable of anything - because 
everything is in it, all the past as well as all the 
future. /
Joseph Conrad, Heart of Darkness, Ch.2.
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ABSTRACT. An assessment of the rhythmic characteristics 
of melatonin secretion in man and other species requires the 
determination of 24-h secretion profiles. Measurement of a 
major excreted metabolite would allow noninvasive study of 
pineal function, applicable in particular to pediatric and long 
term circadian rhythm studies. This report describes a simple
MEASUREMENT of the pineal neurohormone me­latonin (MT) in human body tissues and fluids 
is of considerable interest, notably in psychiatric and 
endocrine pathology (1-3). In addition, the role of the 
pineal in the transmission of photoperiodic information 
in seasonal breeders has been intensively investigated 
using peripheral and pineal MT assays (4-7). To inves­
tigate pineal function in this way, it is necessary to 
sample pineals or blood throughout the day and night in 
view of the dark phase secretion of MT (8-11). In clinical 
practice this is difficult and has retarded progress in the 
field. A simple and rapid assay for an excreted MT 
metabolite, if it can be shown to be a good index of MT 
secretion, would greatly extend the range of physiological 
and pathological conditions amenable to study in man, 
most particularly in pediatric medicine. 6-Hydroxy­
melatonin sulfate (aMT6s) is a major MT metabolite in 
rodents (12, 13) and probably in man (14). Fellenberg et 
al. (15) described a gas chromatographic-mass spectro- 
metric (GCMS) assay for aMT6s in man, which required 
a large sample volume and extensive purification. Simi­
larly, total free and conjugated 6-hydroxymelatonin can 
be assayed by GCMS (16).
This report describes the development of a sensitive, 
specific, and reproducible RIA for aMT6s capable of 
measuring urinary and plasma levels in small volumes,
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and rapid RIA for 6-hydroxymelatonin sulfate in human plasma 
and urine. Physiological studies revealed that both plasma and 
urinary levels of 6-hydroxymelatonin sulfate were closely related 
to plasma melatonin, and that the urinary 24-h rhythm was 
abolished by the ft-adrenergic anagonist atenolol. (J  Clin En­
docrinol Metab 60: 1166,1985)
without extraction, together with preliminary informa­
tion on circulating levels in human plasma and excretion 
patterns in urine.
Materials and Methods
Materials
[3H]MT (26.4, 45.3, and 79.8 Ci/mmol) was obtained from 
New England Nuclear Corp. (Boston, MA). iV-acetyltrypto- 
phan, 5-methoxytryptophan, and 5-methoxy-iV-acetyl-trypto- 
phan were gifts from Laboratories Plan, S.A. (Geneva, Swit­
zerland). aMT6s and [3H]aMT6s were prepared as described 
below. Other indoles, steroids, and catecholamine derivates 
together with Tricine buffer and activated charcoal were ob­
tained from Sigma Chemical Corp. (St. Louis, MO). RPMI- 
1640 culture medium was obtained from Gibco Europe 
(Uxbridge, U.K.), Sephadex LH-20 and Dextran T-70 were 
purchased from Pharmacia (Piscataway, NJ), ovalbumen was 
obtained from British Drug Houses (Poole, U.K.) and Synpe- 
ronic NX was purchased from Durham Chemicals Distributors 
Ltd (Chester-le-Street, U.K.). All other chemicals were com­
mercially available and of analytical grade. Thin layer and 
paper chromatograms (Merck, Rahway, NJ) were washed in 
eluting solvent, dried, and sprayed with 0.1% ascorbic acid in 
ethanol before use.
Methods
1) Synthesis of aMT6s. aMT6s was synthesized from 6-hy­
droxymelatonin (10 mg) according to the method of Fellenberg 
et al. (15). The reaction products were purified on a Sephadex 
LH-20 column (7 g dry wt; id, 40 X 1 cm). The eluting solvent 
was KCl-saturated methanol-chloroform (1:1), and 5-ml frac­
tions were collected. aMT6s eluted in fractions 18-22, as as­
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sessed by reaction with Ehrlich’s reagent, after thin layer 
chromatography [TLC; Silica gel G, chloroform-methanol 
(9:1)]. Pooled fractions were dried (37 C; N2). After further 
purification by TLC (Silica Gel G, n-butanol saturated with 
water), recovery, by weight, was 40%. The product was taken 
up in methanol containing 0.1% ascorbic acid and stored at 
—20 C at a concentration of 48 jug/ml. Under these conditions, 
aMT6s was stable for at least 1 yr, as assessed by TLC. 
(Aliquots of this solution were further diluted 1:400 with Tri- 
cine buffer, stored at —20 C, and used for RIA standards; these 
diluted standards were stable for at least 3 months). No detect­
able indolic products other than aMT6s were present in the 
pooled eluate on further chromatography [TLC: cellulose, bu­
tanol-acetic acid-H20  (4:1:1.5); paper (Whatman 3MM, What­
man, Inc., Clifton, NJ): isopropanol-5 % ammonia (4:2)]. Qual­
itative GCMS of the product, according to the method of 
Fellenberg et al. (15) and performed by Dr. G. King, Queen 
Charlotte’s Maternity Hospital, London, showed a spectrum 
identical to that described by Fellenberg et al. (15). It should 
be noted, however, that the derivatization procedure employed 
results in loss of the sulfate group. A completely pure crystalline 
preparation was not obtained; hence, the product was finally 
quantitated by comparison of its displacement activity in the 
RIA with [3H]aMT6s of known specific activity (see section 2), 
assuming no loss of label during the biological transformation 
of melatonin. [3H]aMT6s derived from both [methoxy-3H] me­
latonin (79.8 Ci/mM) and [3H]MT labeled in the side chain 
(acetyl-5-methoxytryptamine-Af- [2-aminoethyl-2-3H]; 26.4 Ci/ 
mM) were used for this procedure with identical results.
2) Preparation of pH]aMT6s. Female Wistar rats (150-200 g) 
were used. After cervical dislocation, the liver was rapidly 
removed and cut into slices (<1 mm). Liver slices (600 mg) 
were incubated with 1.4 X 108 cpm [3H]MT (45.3 Ci/mmol) in 
3 ml RPMI-1640 at 37 C under 95% 0 2-5% C02, for 2 h with 
gentle shaking. The incubate was cooled, homogenized, and 
extracted three times with 3 ml methanol. The pooled super­
natants were dried at 37 C under N2. Chromatography of the 
crude extract [Whatman no. 3MM; isopropanol-5 % ammonia 
(4:2)] showed three radioactive peaks, corresponding to MT 
(Rf = 0.84), aMT6s (Rf = 0.67), and probably 6-hydroxymela­
tonin glucuronide (Rf = 0.45), as originally decribed by Kopin 
et al. (12), although a slightly higher Rf was found for aMT6s 
than previously reported (Fig. 1). Chromatography of 6-hy- 
droxymelatonin itself in this system resulted in decomposition.
The crude extract was purified on LH-20 (column dimen­
sions, 40 X 1.0 cm; 4.0 g dry weight) as described in section 1, 
but 2-ml fractions were collected. [3H]aMT6s-containing frac­
tions were pooled, dried, and stored as previously described. 
The product was stable for at least 3 months when stored in 
this way. Chromatography of the purified product showed one 
peak, chromatographically identical to chemically synthesized 
aMT6s and to the major reaction product of the liver slice 
incubate (Fig. 1). TLC in two further solvent systems (section 
1) again showed only one radioactive product.
3) Preparation of antigen and immunization procedure. aMT6s 
(4 mg) was conjugated to ovalbumin (55 mg) via the Mannich 
reaction (17). The molar ratio of hapten conjugated to protein 
was not directly assessed. Six Suffolk cross ewes were immu-
cpm
L iv e r -s l ic e  incubate
W hatman No. 3MM f i l te r  p ap e r 
Isopropanol -  5% NH^ (4:2)
1x10 5x10
® 20 f 30 ^ ^  40 cm
P osition  of P osition  of 
aMT6S of m elatonin
standard  standard
F ig . 1. Paper chromatograms of a methanol extract of rat liver slices 
after incubation for 2 h with [3H]MT, together with [3H]aMT6s purified 
from the incubation medium and chemically synthesized aMT6s (see 
text for details).
nized with 500 fig conjugate emulsified in 3 ml Freund’s adju­
vant-saline (2:1) by sc injection at six sites on the back and 
legs. Seven months later, 9 days after boosting with 200 ng 
conjugate, [3H]aMT6s-binding antibodies were detected in all 
six sheep by RIA. The most sensitive antiserum (1118) was 
chosen for further characterization.
RIA. The assay procedure was based on that decribed for direct 
plasma assay of melatonin by Fraser et al. (18), except for the 
modifications described below. Antibody 1118 (final dilution, 
1:1000), [3H]aMT6s, standard aMT6s, compounds tested for 
cross-reactivity, dextran-coated charcoal (2% charcoal and 
0.02% Dextran T-70 in buffer), and urine were all diluted in 
assay buffer 0.1 M Tricine, pH 5, containing 0.9% NaCl and
0.1% gelatine). Antibody-bound [3H]aMT6s was counted in a 
cocktail consisting of 12 g PPO (2,5-diphenyloxazole) and 0.225 
g POPOP (l,4-bis-[2-(5-phenyloxazolyl)]benzene) in toluene to 
which Synperonic was added (750 ml Synperonic to 1500 ml 
toluene scintillant).
Cross-reactivity studies: The specificity of the antiserum was 
assessed by comparing the displacement of antibody-bound 
[3H]aMT6s by a number of indoles, catecholamine metabolites, 
and steroids.
Plasma aMT6s assay: aMT6s-free plasma was prepared by 
charcoal-stripping. Dextran-T coated charcoal (10%) was in­
cubated for 60 h with pooled heparinized human plasma taken 
from normal subjects, and the charcoal was separated by cen­
trifugation.
To 200 n\ antibody (1118; initial dilution, 1:250), 200 gl 
plasma sample and 300 /il buffer or standard were added. 
Standard curves were constructed using 200 g\ charcoal- 
stripped aMT6s-free plasma, and the standards were included 
in the buffer volume. After incubation at 4 C for 15 min, 100 fd 
[3H]aMT6s (4500 cpm) were added to give a final volume of 
800 fd. The tubes were further incubated for 20 min at 37 C 
and 90 min at 4 C. Bound and free aMT6s were separated by 
the addition of 100 /A dextran-coated charcoal suspension, 
incubation for 15 min at 4 C and centrifugation (2000 X g; 4 C;
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15 min). Supernatant (500 pi) was counted in 4.0 ml scintillant, 
and the results were determined by interpolation.
Parallelism was assessed by comparing the displacement 
curves obtained with pooled nighttime human plasma, serially 
diluted with charcoal-stripped plasma, with the standard curve. 
A direct chromatographic validation of the plasma assay was 
not possible due to the low values recorded, the nonextracted 
nature of the assay, and the lack of sufficient sensitivity of 
current TLC and HPLC techniques.
Urine assay: The same procedure as that described for plasma 
was used, except that 200-pl aliquots of 1:50 diluted urine were 
assayed. Standard curves were initially constructed using 200 
pi charcoal-stripped aMT6s-free urine diluted 1:50 or 1:100. 
Thereafter, urine collected from normal subjects in the midaf­
ternoon was screened in the assay, and those samples with 
undetectable aMT6s were pooled and used for the construction 
of standard curves.
Parallelism was assessed by comparing the displacement 
curves obtained with pooled early morning human urine sam­
ples, serially diluted with charcoal-stripped urine, with the 
standard curve.
Sufficient immunoreactivity was present in early morning 
urine to assess the chromatographic specificity of the assay. 
Pooled early morning urine (5-50 pi) was chromatographed 
in three different systems [TLC, Silica Gel G, chloroform- 
methanol, (9:1); cellulose, N-butanol-acetic acid-H20  (4:1:1.5); 
Whatman 3MM, isopropanol-5 % ammonia (4:2)]. The immu­
noreactivity of each section (1 cm) of the chromatograms was 
determined after elution in Tricine buffer, and the migration 
was compared to those of aMT6s and [3H]aMT6s. The latter 
substances were chromatographed in an equivalent volume of 
urine.
5) Physiological studies. In a preliminary experiment, blood was 
sampled (November) at hourly intervals for 25 h during the 
day by venipuncture and during the night by indwelling cannula 
from nine normal subjects (seven men and two women), aged 
22-46 yr. Plasma was decanted and stored at — 20 C before 
assay for melatonin, by the method of Fraser et al. (18), and 
aMT6s. The volunteers remained in their normal social envi­
ronment during the day and mostly slept throughout the night­
time sampling (2400-0700 h). Dark phase samples were taken 
under very dim light (>1 lux).
In a separate experiment, blood was sampled (July) at hourly 
intervals for 25 h, as described above, from another 10 normal 
subjects (8 men and 2 women; aged 23-47 yr). Plasma was 
stored and assayed for melatonin and aMT6s as described 
above. Simultaneously with blood sampling, urine was collected 
for 6-h intervals for 24 h from all 10 subjects. After collection, 
urine was stored at —20 C and assayed for aMT6s within 3 
weeks of collection.
The quantitative relationships among plasma melatonin, 
plasma aMT6s and urinary aMT6s were determined by coeffi­
cient of linear regression using areas under the 24-h profile 
(AUC) for plasma melatonin and plasma aMT6s and total 
urinary aMT6s per 24 h.
6) Pharmacological studies. Six normal subjects (three men and 
3 women), aged 24-37 yr, took 100 mg atenolol or placebo 
(ascorbic acid) at 1800 h in a single blind cross-over protocol,
either on consecutive days (n = 4) or with 1 day between doses. 
Although the subjects were told that the order of administration 
was randomized, in fact placebo preceded atenolol in all cases. 
Urine was collected for 6-h intervals for 24 h from 1200 h on 
each experimental day. No social or dietary restrictions were 
applied during the study. After collection, urine was stored at 
—20 C and assayed for aMT6s within 2 weeks of collection.
Results
Cross-reaction with potential interfering compounds
Table 1 shows the relative abilities of different indoles, 
catecholamine metabolites, and steroids to displace an­
tibody-bound aMT6s. Cross-reactivity with all tested 
compounds was negligible, the most important cross­
reactant being 6-hydroxymelatonin. The glucuronide 
conjugate of 6-hydroxymelatonin was not tested, as it 
was not available to us, but was excluded as an interfering 
compound, at least in urine, by chromatographic proce­
dures. Likewise, possible hydroxylated and conjugated 
derivatives of iV-acetyl serotonin (19) were not available 
and were not tested.
Parallelism
Serial dilutions of early morning urine and nighttime 
plasma gave displacement parallel to that of the standard 
(Fig. 2).
T able  1. Cross-reactivity data
Compound
pg necessary for 
50% displace­
ment of [3H] 
aMT6S
aMT6s 36
6-Hydroxymelatonin 1.00 x  106
MT 3.65 x  106
5-Methoxyindoleacetic acid
5-Hydroxyindoleacetic acid \
.ZV-Acetyl tryptamine \
iV-Acetyl serotonin \
iV-Acetyl tryptophan \
Tryptamine \
Tryptophan
5-Hydroxytryptophan
Indole acetic acid
iV-Methyl tryptamine
5-Methoxytryptamine All >1 X 107
5-Methoxy AT-acetyl tryptophan
5 -Methoxytryptophan
5-Hydroxytryptamine
Vanillylmandelic acid
Phenylacetic acid
Homovanillic acid /
3,4-Dihydroxyphenylacetic acid /
Androsterone sulfate /
Estriol 3-sulphate /
Dehydroisoandrosterone sulphate
IMMUNOASSAY OF aMT6s 1169
7c Bound
F ig . 2. A, Parallelism between aMT6s 
standard curve in aMT6s-free urine di­
luted 1:50 in Tricine buffer, and increas­
ing amounts of pooled early morning 
urine, initially diluted 1:50 in Tricine 
buffer and further diluted with aMT6s- 
free urine. B, Parallelism between 
aMT6s standard curve in charcoal- 
stripped aMT6s-free plasma and in­
creasing amounts of unextracted pooled 
nighttime plasma diluted with aMT6s- 
free plasma.
50
40 = Standard aMT6S
O = 200/d of —  urine sam ple
30
diluted with aMT6S -  free urine
20
10
L
1 1000 pg aMT6S10010
10 25 50 75 100 150 200 /zl —  diluted urine
50
B
%  Bound
50
40
a = Standard aMT6S
O = P lasm a sam ple, ser ia lly  diluted 
with aMT6S -  free  plasm a30
20
10
1000 pg aMT6S100101
Precision
The mean and SD for each point (1.2 pg to 1.2 ng/ 
tube) of 12 standard curves were assessed; the mean 
overall coefficient of variation was 9.6%. Interassay coef­
ficients of variation for urine and plasma assay are shown 
in Table 2. Scatchard analysis of the binding character­
istics of the antiserum gave an affinity constant of K =  
6 X 1010 liters/mol (not shown).
Chromatographic validation
The migration of urinary immunoreactivity was iden­
tical to that of [3H]aMT6s and aMT6s on TLC in two 
different solvent systems ([chloroform-methanol (9:1); 
n-butanol-acetic acid-H20  (4:1:1.5); Fig. 3]) and on paper 
chromatography in one solvent system [Whatman 3MM; 
isopropanol-5 % ammonia, (4:2)]. Over 80% of applied 
immunoreactivity was recovered from all chromato­
grams.
Physiological studies
In the preliminary study, aMT6s had a marked 24-h 
rhythm in human plasma, closely correlated to that of
10 15 30 50 100 200 /(I plasma
melatonin. Three individual profiles chosen to represent 
high, medium, and low values of plasma melatonin are 
shown in Fig. 4. All values for both melatonin and aMT6s 
for subject 3 in this study (Fig. 4) were at or below the 
limit of detection of each assay. Thus, while there was 
apparently a small rise of aMT6s at night without a 
corresponding rise in melatonin, more sensitive tech­
niques would be required to determine in this subject the 
true relationship between these two compounds at such 
low values.
The mean plasma levels of melatonin in the whole 
group varied from 10 ±  0.5 ( ± s e m ) pg/ml (1800 h) to 29 
±  6 pg/ml (0200 h). The mean plasma aMT6s levels in 
the whole group varied from less than 13 pg/ml (most 
time points between 1200 and 2100 h) to 52.0 ±  11.0 pg/ 
ml (0200 h). Levels below the limit of detection were set 
at the limit of detection (10 pg/ml melatonin; 13 pg/ml 
aMT6s) for the purposes of calculation. AUCs calculated 
for individual profiles of melatonin and aMT6s corre­
lated significantly (r =  0.82; P  <  0.01).
Mean plasma aMT6s levels in 10 normal subjects 
sampled for 24 h in July varied from less than 13 to 55.0 
±  9.0 pg/ml (Fig. 5). There were clear changes in the
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T able  2. RIA of aMT6s: assay performance data
pg/tube % CV n
Intraassay CV
( 8 3.5 5
Plasma < 28 3.3 5
I 74 3.4 5
r io 6.5 5
Urine < 48 3.3 5
I H3 4.1 5
Interassay CV
[ 7 16.2 6Plasma \  26 12.2 6
{ 97 11.5 6
f 9 17.7 12Urine \  38 7.9 12
[ 106 7.8 12
Sensitivity 2.6 pg aMT6s/tube
13 pg/ml plasma
0.65 ng/ml urine
Recovery of aMT6s
pg/ml pg/ml added % Recovery n
Plasma 52 130 87.8 ±  2.5 5
91 130 87.9 ±  2.9 5
1,930 4,750 95.5 ±  4.5 5
Urine 21,550 28,000 99.1 ±  12.5 5
CV, Coefficient of variation.
Immunoreactivity: 40
30
pg aMT6S 20 
10
H-aMT6S 1000 
cpm
2000
254Cellulose 
Butanol:Glacial acetic acidiHgO 
(4:1:1.5)
Position of 
aMT6S standard
0.25 0.5 0.75 1.0
F ig . 3. Migration of urinary immunoreactivity, [3H]aMT6s, and 
aMT6s on TLC [n-butanol-acetic acid-H20  (4:1:1.5)]. The migration 
of urinary immunoreactivity was also identical to that of [3H]aMT6s 
and aMT6s on TLC in chloroform-methanol (9:1), Silica gel G, and on 
Whatman 3MM in isopropanol-5 % ammonia (4:2).
ratio of melatonin to aMT6s at different times during 24 
h, a possible explanation for this phenomenon being a 
delay in the clearance of aMT6s from the circulation 
compared to the rate of secretion and metabolism of
100
90
pg/m l 
aMT6S 
or MT 60
40
0900 1200 2100 0300 0900
= Subject 1 
= Subject 2 
= Subject 3
Tim e (h)
F ig . 4. Individual plasma profiles of MT (------) and aMT6s (• • •) in
three subjects sampled at hourly intervals for 24 h. All of the recorded 
values are plotted, however, the assay limits of detection were 10 pg/ 
ml (MT) and 13 pg/ml (aMT6s). Thus, in subject 3, all MT values 
were undetectable, and all aMT6s values were at or below the limit of 
detection.
melatonin. Whether the rate of metabolism of melatonin 
to aMT6s or the clearance of aMT6s varies throughout 
24 h is not known.
Urinary aMT6s excretion determined at 6-h intervals 
for 24 h in the same 10 subjects at the same time as 
plasma melatonin and aMT6s is shown in Fig. 6. The 
values were similar to those reported by GCMS (15). As 
expected, a marked 24-h variation in urinary levels was 
found, with maximum excretion occurring between 2400 
and 0600 h. A comparison of individual AUCs for plasma 
melatonin and plasma aMT6s and total urinary excretion 
of aMT6s indicated that significant correlations were 
present among all three parameters (Table 3). The clos­
est relationship was found between plasma levels of both 
compounds (P  <  0.01). Plasma melatonin correlated with 
urinary aMT6s at P  <  0.05, an important relationship if 
aMT6s is to be useful as an index of melatonin secretion. 
It was apparent from the data, however, that the rela­
tionship was more robust at very low and very high levels 
of melatonin secretion than for values in the middle of 
the range.
Pharmacological studies
Urinary aMT6s excretion in six subjects during the 24 
h preceding atenolol administration (Fig. 7) was quanti-
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60
50
40
30
20
10
0900 1500 2100 0300 0900
Time (h)
F ig . 5. Mean ±  se m  plasma levels of MT (A—A) and aMT6s ( • —• )  
in 10 subjects (8 men and 2 women) sampled hourly for 24 h in July. 
Values recorded below the assay limit of detection were set at the limit 
of detection (10 pg/ml melatonin; 13 pg/ml aMT6s). Urine was col­
lected simultaneously from the same individuals and assayed for 
aMT6s. The results are shown in Fig. 6.
tatively and qualitatively very similar to that described 
in the previous experiment (physiological studies; Fig.
6). After administration of 100 mg atenolol, the nighttime 
rise was suppressed to daytime values (Fig. 7). Paired t 
test of individual values for 6-h period after placebo 
administration compared to that after atenolol showed a 
highly significant decrease for the periods between 2400- 
0600 h (P <  0.005) and 0600-1200 h (P <  0.005) and no 
significant change at other times. Overall 24-h aMT6s 
excretion was greatly reduced by atenolol (P <  0.005).
Discussion
The classical RIA validation procedures applied to 
aMT6s assay in plasma and urine show that this assay 
is accurate, reproducible, and sensitive to physiological 
levels of this metabolite. Further chromatographic vali­
dation of the urinary assay gave strong evidence of 
specificity by comparison of the migratory characteristics
6 .0
5 .0
4 .0
3 .0
2 .0
1.0
1200 1800 120006002400
Time (h)
F ig . 6. Mean ±  sem  urinary aMT6s excretion during 6-h intervals for 
24 h in 10 subjects (8 men and 2 women). Urine was collected simul­
taneously with the 24-h blood sampling for plasma melatonin and 
aMT6s measurement shown in Fig. 5. Samples were collected in July. 
Values recorded below the assay limit of detection (0.65 ng/ml) were 
set at the limit of detection.
T able  3. The correlation between individual levels of plasma MT 
(AUC of 24-h profile), plasma aMT6s (AUC of 24-h profile), and total 
urinary aMT6s excreted over 24 h
Comparison
Coefficient 
of linear 
regression 
(r)
P n
Plasma melatonin: plasma 0.7962 <0.01 10
aMT6s
Plasma melatonin: total 0.6730 <0.05 10
urinary aMT6s
Plasma aMT6s: total 0.783 <0.01 10
urinary aMT6s
of immunoreactivity in different solvent systems. 
Clearly, it would be of interest to compare this RIA with 
GCMS measurements in the same samples; an interna­
tionally agreed standard preparation of aMT6s is not 
available, and it is likely that some adjustment of the 
absolute levels recorded will be necessary. As yet, how­
ever, no other published method exists, for the measure-
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ment of aMT6s in plasma, and the urinary levels ob­
tained are similar to those previously reported by GCMS 
assay of aMT6s (15) or total free and conjugated 6- 
hydroxymelatonin in urine (16).
While interference by known and unknown chromat- 
ographically identical compounds cannot be excluded, 
physiological studies suggests that RIA of aMT6s will be 
a useful index of melatonin secretion in man. The assay 
requires little plasma, does not need an extraction pro­
cedure, and has better reproducibility than most current 
methods for measuring melatonin. Likewise, reported 
procedures for GCMS assay of aMT6s or free and con­
jugated 6-hydroxymelatonin in urine require large sam­
ple volumes and/or extensive preliminary sample work­
up. While urine is not in short supply, a nonextracted 
RIA method has considerable advantages over previous 
methods.
In the limited physiological studies described here, 
both plasma and urinary aMT6s were significantly cor­
related to plasma melatonin. Thus, aMT6s is likely to be 
useful as a marker of melatonin secretion. Clearly, how­
ever, the hormone-metabolite relationship in both 
plasma and urine must be studied in different physiolog­
ical and pathological situations; the assessment of me­
latonin metabolism in man is an important potential 
application of this assay.
One previous study described a dramatic reduction of 
nighttime plasma melatonin in man after administration 
of 100 mg atenolol (20). The pharmacological studies
described here show clearly, for the first time, the acute 
and complete suppression of the 24-h rhythm in urinary 
aMT6s after a single dose. Atenolol is considered to be a 
selective /3i-adreno-receptor antagonist which does not 
penetrate the blood-brain barrier extensively (21). Thus, 
these observations reinforce current opinion (20) that 
melatonin production is dependent upon /?i-adrenergic 
receptors lying outside the blood-brain barrier.
To date, only one plasma melatonin assay does not 
require an extraction procedure (18), and urinary mela­
tonin assay requires extraction and further purification 
(22). In addition to the evident advantage of a direct 
assay, the measurement of aMT6s in urine is likely to be 
at least as useful as that of melatonin, provided that 
consideration is given to possible discrepancies between 
hormone and metabolite. Various aspects of human pi­
neal function are simply not amenable to study using 
plasma melatonin measurement. Moreover, urinary me­
latonin levels are very low and represent only a small 
percentage of secreted hormone (12-14). Development of 
pineal function in neonates and long term circadian 
rhythm studies (to determine, for example, the oscilla­
tory control of melatonin secretion) require measure­
ment of a suitable urinary metabolite. RIA of aMT6s is 
likely to provide the necessary tool for such work.
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Melatonin Secretion in Humans Assessed by Measuring Its Metabolite, 6-Sulfatoxymelatonin
Christopher J. Bojkowski,1 Josephine Arendt,1 Ming C. Shih,2 and Sanford P. Markey2
Comparing a direct radioimmunoassay for 6-sulfatoxymela- 
tonin (aMT6s) with an established gas chromatographic/ 
mass spectrometric method for 6-hydroxymelatonin, we 
found a good correlation r = 0.94 (P <0.001, n = 100). 
aMT6s was stable, both in urine and plasma samples, 
without preservative, for at least two years at -2 0  °C and for 
five days at room temperature. Urinary excretion of aMT6s 
showed considerable inter-individual differences; however, 
the aMT6s excretion of any one individual was consistent 
over a four-day period, as assessed by continuous collection 
from 18 normal volunteers. Total 24-h urinary excretion of 
aMT6s was significantly correlated with the area under the 
curve of the respective profiles for plasma melatonin (r = 
0.75, P =  0.0002) and plasma aMT6s (r = 0.70, P =  0.0005) 
for 22 healthy volunteers. At 24:00 h and 03:00 h, sampling 
plasma at 30-s intervals provided no evidence for episodic 
secretion (in short pulses) of either melatonin or aMT6s.
Additional Keyphrases: radioimmunoassay • urine • seroto­
nin metabolism • 6-hydroxymelatonin • gas chromatography1 
mass spectroscopy compared • pineal function • inter- and in­
tra-individual variation • sample stability • circadian rhythm 
markers
Currently, investigations of human pineal function de­
pend largely on measurement of the methoxyindole, melato­
nin, and its major metabolites in body fluids. Melatonin is 
metabolized in the liver to 6-hydroxymelatonin and N- 
acetylserotonin, both of which are excreted as the sulfate 
and glucuronide conjugates (1, 2). As in other species, the 
melatonin rhythm in humans is endogenously generated 
(3), the bulk of secretion occurring at night in normal light- 
dark cycles. Because both the timing and the amplitude of 
melatonin secretion may be important to its possible physio­
logical functions and its pathological relationships, it is 
essential to define the characteristics of its secretion profile.
In clinical practice, nocturnal blood sampling is difficult, 
and the recent development of assays (4-6) for melatonin 
metabolites in urine greatly increases the number of clinical 
cases amenable to study and also permits longitudinal 
studies in the same individual. However, the relationship of 
concentrations of melatonin metabolites in urine to those in 
plasma must be thoroughly established before urinary data 
can be unambiguously interpreted.
We have developed a sensitive, specific direct radioim­
munoassay (RIA) for 6-sulfatoxymelatonin (aMT6s) in urine 
and plasma (6); reportedly, aMT6s is the major melatonin 
metabolite in humans (7, 8). We now describe the perform­
ance of the assay and present data comparing the measured 
concentrations of aMT6s with those of total 6-hydroxylated 
melatonin metabolites as determined by gas chromatogra­
phy/mass spectrometry (GC/MS). We have also assessed the
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reliability of urinary aMT6s as an index of the endogenous 
concentrations of melatonin in plasma and report the char­
acteristics of individual aMT6s production.
Materials and Methods
Materials
We prepared [3H]aMT6s by biologically transforming 
[3H]melatonin (56.7, 48.2, 45.1, and 49.4 kCi/mol; New 
England Nuclear Corp., Boston, MA) as previously de­
scribed (6). A specific antiserum (1118 11.11.82; Guildhay, 
Surrey, U.K.) raised in sheep against aMT6s-ovalbumin 
was stored lyophilized at -2 0  °C. Just before use, we diluted 
the antiserum 1000-fold with assay buffer.
Standard aMT6s was synthesized in our laboratory from 
6-hydroxymelatonin according to the method of Fellenberg 
et al. (4) and purified as previously described (6). Aliquots of 
standard diluted with assay buffer were stored at -2 0  °C, at 
a concentration of 290 pg/L. Standard aMT6s was also 
generously supplied by each of the following: Dr. D. J. 
Kennaway, Department of Obstetrics and Gynaecology, 
University of Adelaide, Australia; Dr. A. M. Leone, Depart­
ment of Reproductive Physiology, St. Bartholomew’s Hospi­
tal, London, U.K.; Dr. G. E. Webley, Institute of Hormone 
and Fertility Disorders, Hamburg, F.R.G.; and Dr. G. M. 
Brown, Department of Neurosciences, McMaster Universi­
ty, Hamilton, Ontario, Canada. Each standard was tested in 
the RIA. These standards were synthesized by the method of 
Fellenberg et al., with or without modifications (4), or by 
that of Leone et al. (9).
The assay buffer contained 17.9 g of "Tricine” (iV-[tris(hy- 
droxymethyl)methyl]glycine; Sigma Chemical Co., Poole, 
Dorset, U.K.), 9.0 g of sodium chloride, and 1.0 g of gelatin 
per liter. The charcoal suspension consisted of 2.0 g of 
activated charcoal (Sigma Chemical Co.) and 0.2 g of 
Dextran T70 (Pharmacia Fine Chemicals, Uppsala, Sweden) 
per liter of assay buffer. The assay buffer and charcoal 
suspension could be used for up to 10 days if stored at 4 °C. 
Cyanogen bromide-activated Sepharose 4B was obtained 
from Sigma Chemical Co.
Procedures
aMT6s RIA. We follow the procedure originally described 
by Arendt et al. (6), but with several modifications. In brief, 
the procedure is as follows. We incubate 100 pL of 
[3H]aMT6s (4500 counts/min) with 200 pL of antiserum and 
the sample (200-500 pL of plasma or 200 pL of urine 
diluted 50-fold with assay buffer) or 5-400 pL standard 
(2.5-200 pg per tube) for 20 min at 37 °C, then for 90 min at 
4 °C. To construct the standard curves, we use either affini­
ty-stripped plasma (in place of charcoal-stripped plasma), or 
charcoal-stripped aMT6s-free urine diluted 50-fold with 
assay buffer, in volumes equivalent to those of the test 
material being measured. The final volume of each sample 
is brought to 800 pL with assay buffer. To separate bound 
and free aMT6s, we add 100 pL of dextran-coated charcoal 
suspension, incubate at 4 °C for 15 min, and centrifuge at 
2000 x g  for 15 min at 4 °C. The radioactivity of 500-/uL
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aliquots of the resulting supemates is counted in 4.5 mL of 
"Optiphase Safe” scintillant (LKB Ltd., Selsdon, Surrey, 
U.K.), from which we calculate the binding of standard 
samples, fit B/B0 to a spline function, and determine results 
for unknown samples by interpolation.
We prepared aMT6s-free plasma by affinity chromatogra­
phy, using antiserum (no. 1118 23.8.84) linked to cyanogen 
bromide-activated Sepharose 4B, according to the manufac­
turer’s recommended procedure (10). Columns were stored, 
ready for use, at 4 °C in 84 g/L bicarbonate buffer containing 
29.2 g of sodium chloride and 0.1 g of sodium azide per liter. 
We used plasma collected from normal volunteers in the 
mid-afternoon, pooling those samples that measured <5 ng/ 
L (in comparison with charcoal-stripped plasma). We poured 
1 mL of antibody-Sepharose slurry into disposable columns 
(Amicon Ltd., Stonehouse, Glos., U.K.) and removed the 
residual buffer by applying slight positive pressure. We then 
applied 2 mL of plasma sample to each column, placed the 
columns on a roller-mixer for 1 h at room temperature, and 
then collected the plasma. We could process up to 8 mL of 
plasma on each column before regenerating the columns by 
washing them with 10 mL of doubly distilled water, followed 
by three 2-mL washes with methanol/water (9/1 by vol). 
Measurement of the affinity-stripped spiked samples 
showed that 85-90% of unlabeled aMT6s was removed. 
Results were identical when standard curves were con­
structed with either affinity-stripped plasma or charcoal- 
stripped plasma. The antibody-Sepharose preparation re­
tained its binding activity for at least a year.
To assess assay parallelism, we compared the standard 
curve with the displacement curves obtained for pooled 
human plasma collected during the night and serially 
diluted with affinity-stripped plasma.
Melatonin RIA. We followed the method described by 
Fraser et al. (11). The interassay CVs were 10.0,12.6, and 
20.6% (n = 14 each) at 134.4,47.8, and 25.5 ng/L, respective­
ly. Intra-assay CVs were 3.5 and 4.4% (n = 19 each) at 48.7 
and 101.0 ng/L.
Comparison with GC/MS method for total 6-hydroxylated 
melatonin metabolites. We assayed 100 urine samples from 
healthy volunteers for total free and conjugated 6-hydroxy­
melatonin by the gas-chromatographic/mass-spectrometric 
method of Tetsuo et al. (5). We then assayed the same 
samples for aMT6s, on a single-blind basis, by RIA. We used 
least-squares regression to calculate the slope and intercept 
of the best-fit line through the data points, and also deter­
mined the standard error of regression (12).
Studies of Analytical Variables
Comparison of standards. We used six aMT6s standards 
from different sources (see Materials) to generate standard 
curves and assessed their relative potency. Their purity was 
evaluated by thin-layer chromatography on cellulose 
(Merck; supplied by BDH Chemicals Ltd., Eastleigh, Hamp­
shire, U.K.), with butanol/acetic acid/water (4/1/1.5, by vol) 
and propan-2-ol/ammonia, 50 mL/L (4/2 by vol) as eluents.
Cross-reactivity studies. The specificity of the antiserum 
has been reported previously (6), but we performed addition­
al cross-reactivity studies with 6-glucuronide melatonin, 5- 
sulfatoxy-iV-acetylserotonin, and 5-glucuronide-iV-acetyl- 
serotonin (all kindly supplied by Dr. A. M. Leone, St. 
Bartholomew’s Hospital).
Storage of samples. To determine the stability of aMT6s in 
plasma under various storage conditions, we stored plasma 
samples without preservative or with boric acid (final con­
centration 1.0 g/L) or ascorbic acid (1.0 g/L) at -1 2  °C and 
-2 0  °C for up to two years. We also assessed the analyte’s 
stability in plasma after freezing and thawing. As a routine 
procedure we froze plasma samples without delay and stored 
them at — 20 °C.
The stability of aMT6s in urine was determined as for 
plasma; i.e., samples were stored without preservative or 
with boric acid (1.0 g/L) or ascorbic acid (1.0 g/L) for up to 
five days at 4 °C and at room temperature, and for up to two 
years at -1 2  °C or -2 0  °C. As a routine procedure, urine 
samples were frozen as soon as possible after collection and 
stored frozen at — 20 °C. The total volume of each collection 
was recorded.
We measured aMT6s in the stored urine and plasma 
samples after one day, one week, and one, six, 12,18, and 24 
months.
Physiological Studies
Intra-individual variations in aMT6s excretion. For four 
consecutive days, 18 apparently healthy volunteers (nine 
men and nine women, ages 17-67 years) collected urine over 
12-h periods: 10:00-22:00 h and 22:00-10:00 h. The only 
restriction placed on the subjects was the timing of their 
urine collection. Five women were taking oral contracep­
tives, but the subjects were otherwise drug free.
We used two-way analysis of variance to analyze the data. 
We also calculated the coefficients of variation for day-to- 
day differences in each subject’s urinary excretion of aMT6s.
Short-term fluctuations in concentrations of melatonin and 
aMT6s in plasma. Previous workers have reported episodic 
secretion of melatonin in short pulses in humans and sheep 
(13-15). To confirm these observations and to see if the 
reported melatonin peaks were also reflected in peaks for 
aMT6s, we performed the following experiment.
Three volunteers (two women and one man) had indwell­
ing cannulas inserted into their antecubital veins at 23:30 h. 
They then retired to bed in darkness. At 24:00 h and 03:00 h,
5-mL blood samples were taken at 30-s intervals for 10 min, 
in darkness with a dim red torch (<1 lux). We assayed these 
plasma samples for melatonin and aMT6s, determining all 
samples from any one individual in the same assay. Control 
or "noise” series were created by pooling the remaining 
aliquots of plasma from one or more of the volunteers to 
form large pooled specimens of plasma. We then assayed 
sequential samples from these pools in the same manner, 
again performing all measurements for a series of samples 
in the same assay.
To identify peaks in the data, we identified all local 
minima and maxima, then multiplied the concentration at 
the minimum by threefold the intra-assay CV for that 
concentration, to obtain the corresponding increment in 
hormone concentration. The next local maximum was con­
sidered a peak if it exceeded the minimum by an amount 
equal to or greater than this increment. We used the CV for 
20 samples in the noise series to identify peaks in that 
particular series and in concentration-matched volunteers’ 
samples. We compared the number of peaks in the volun­
teers’ samples with the number of peaks in concentration- 
matched noise series (false positives) by paired Student’s t- 
test (two-tailed).
Correlation between plasma concentrations of melatonin 
and urinary aMT6s excretion. Blood was sampled (in July) 
from 18 apparently healthy volunteers (12 men and six 
women, at 2-h intervals from 12:00-20:00 h, at 1-h intervals 
from 20:00 to 10:00 h, with one final blood sample at 12:00 h.
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During the day, blood was sampled by venepuncture, where­
as at night we used an indwelling cannula inserted into the 
antecubital vein. At night, samples were taken with illumi­
nation only from a dim red torch (<1 lux). Simultaneously 
with blood sampling, subjects collected timed 6-h urine 
samples: 12:00-18:00 h, 18:00-24:00 h, 24:00-06:00 h, and 
06:00-12:00 h.
Four additional male volunteers were also included in the 
study. From 20:00 to 10:00 h blood was sampled (in May) at 
1-h intervals; no blood samples were collected during the 
day. Urine specimens were collected concurrently, at 20:00- 
24:00 h, 24:00-12:00 h, and 12:00-20:00 h intervals. The 
age range of all the volunteers was 18-47 years.
We assayed all plasma samples for both melatonin and 
aMT6s; urine samples were assayed for aMT6s. We calculat­
ed the area under the curve (AUC) of the plasma profiles by 
the trapezium method (16). For the purposes of calculation 
we set all values below the detection limit of the assay and 
all the daytime-collected plasma samples from the four 
volunteers sampled in May at the detection limit. In normal 
volunteers daytime concentrations of melatonin in plasma 
are usually so low as to be undetectable by RIA technology 
(17). We used the coefficient of linear regression to establish 
the quantitative relationships between concentrations of 
aMT6s in urine and the concentrations of melatonin and of 
aMT6s in plasma.
Results
Assay Performance
The lowest detectable concentration of aMT6s standard, 
defined as the amount of aMT6s producing a displacement of 
2 SD from maximum binding, was 2.1 pg per tube. The 
sensitivity of the urine assay was 0.65 fig/L. That of the 
plasma assay ranged from 5.0 ng/L to 12.5 ng/L, depending 
on the volume of plasma assayed directly.
Pooled human plasma collected during the night, serially 
diluted with affinity-stripped plasma, gave displacement 
parallel to that of aMT6s standard when up to 500 ;uL of 
plasma was assayed directly.
Analytical recoveries of three different concentrations of 
aMT6s (18.7, 70.0, and 238.2 ng/L) from endogenous human 
plasma pools were 113.9 ± 9.2, 101.9 ± 2.9, and 84.2 ± 
3.3%, respectively. These values are mean ± SEM (n = 5 
each).
Data for parallelism, recovery, and chromatographic iden­
tity of urinary immunoreactivity for the urine assay have 
been reported previously (6).
Precision. We determined the intra-assay and interassay 
precision of the assays.
The intra-assay CVs for the modified plasma assay were 
6.7,5.2, and 3.1% (n = 5 each) for samples with mean values 
of 17.8, 77.4, and 248.8 ng/L, respectively.
We assessed the interassay CVs for the modified plasma 
assay by measuring quality-control samples in successive 
assays. The CVs were 10.6, 8.8, and 6.8% (n = 18 each) for 
mean aMT6s values of 23.4, 61.0, and 130.8 ng/L, respec­
tively.
We assessed the interassay CVs for the urine assay from 
quality-control samples taken during 15 months. The CVs 
were 16.3, 11.9, and 13.6% (n = 81 each) for mean aMT6s 
values of 2.3, 7.2, and 19.5 pg/L, respectively. No drift in the 
quality-control samples was observed after 15 months.
The intra-assay CVs for the urine assay have been 
reported previously (6).
Comparison of standards. All the standards tested gave 
displacement parallel to that of our standard and were 
chromatographically identical. The relative potency of the 
different preparations, however, varied approximately two­
fold, possibly due to the efficiency of desalting in some cases.
Cross-reactivity studies. Original cross-reactivity studies 
with this antiserum showed it to be extremely specific but 
did not include the other urinary metabolites of melatonin:
6-glucuronide melatonin has recently become available and 
two new urinary metabolites of melatonin have been identi­
fied, 5-sulfatoxy-iV-acetylserotonin and 5-glucuronide N- 
acetylserotonin (8). They cross reacted with the antiserum 
by 0.03%, 0.003%, and 0.4%, respectively.
Storage of Samples
aMT6s is extremely stable in plasma and urine. We found 
no differences for samples stored either with or without 
preservative, or between fresh urine samples and those 
stored frozen, nor were there losses on thawing and refreez­
ing. aMT6s was stable in plasma and urine for up to five 
days at 4 °C or at room temperature, and for up to two years 
when stored at -2 0  °C or -1 2  °C. Interassay CVs for urine 
and plasma samples stored without preservative at -2 0  °C 
over a two-year period were 11.7% and 12.0% (n = 9 each) at 
concentrations of 36.0 /xg/L and 59.0 ng/L, respectively.
Comparison with GC/MS Method for Total 6-Hydroxylated 
Melatonin Metabolites
A good correlation was obtained between the two methods 
(r = 0.94, n = 100), which was highly significant (P <0.001). 
Regression analysis of the data gave the equation y  = 0.47x 
+ 0.64 fig/L (where y  is the RIA) with a standard error of 
regression of 2.72 (12). The regression line is shown in 
Figure 1.
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Fig. 1. Correlation between concentrations of 6-hydroxylated melatonin 
metabolites in urine as measured by gas chromatography/mass spec­
trometry and urinary aMT6s as measured by RIA
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Biological-Variation Factors
Intra-individual variations in aMT6s excretion. Two-way 
analysis of variance of the urinary excretion of aMT6s over 
four consecutive days showed a significant variation be­
tween the urinary aMT6s excretion by the different subjects 
for the daytime (.F = 6.34, P  <0.001, df = 17,51), nighttime 
(F = 23.79, P <0.001, df = 17,51), and 24-h samples (F = 
26.62, P < 0.001, df = 17,51). We found no significant 
within-group variation, showing that for each individual the 
excretion of aMT6s was consistent within the four-day 
period. Figure 2 illustrates the intra-individual variations 
in aMT6s excretion for four subjects during the collection 
period.
Table 1 shows the mean excretion of aMT6s, together 
with the mean CVs for consistency of aMT6s excretion 
during the four days, and the observed ranges of the CVs.
Of the mean total 24-h urinary aMT6s excretion, 80.7% 
(SD 6.1%; n = 18) was excreted between 22:00 and 10:00 h. 
This finding is in harmony with the study of Fellenberg et 
al. (4).
Short-term fluctuations in plasma concentrations of mela­
tonin and aMT6s. Figure 3 compares melatonin and aMT6s 
concentrations in representative control samples and sam-
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Fig. 2. Urinary aM T6s excretion, determined at 12-h intervals for 96 
consecutive h, in four subjects
Table 1. Mean Excretion of aMT6s, Mean CVs for 
Consistency of aMT6s Excretion during the Four-Day 
Period, and Ranges of CVs
aMT6s excretion (mean ± SD), ng CV for aMT6s excretion, %
Men Women Mean ±  SD
(n = 9) (n = 9) (n = 18) Range
10:00-22:00 h
1.69 ±  0.51 1.72 ±  1.10 31.6 ±  15.9 1 0 .5 -6 3 .5
22:00-10:00 h
7.42 ±  2 .05 8.47 ±  6.97 17.9 ±  7.9 3 .5 -3 6 .0
Total 24 h
9 .14  ±  2.35 10.18 ±  8.02 13.7 ±  5.3 5 .1 -2 6 .7
Control Volunteer
samples samples
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Fig. 3. Melatonin and aMT6s concentrations in a representative sample 
from a control (left) and a volunteer (right)
Volunteer samples were taken at 30-s intervals for 10 min, all samples from one 
individual being measured in the same assay. The control or “noise” series were 
plasma pools that were assayed identically
pies from volunteers. No secretory episodes, with short 
duration pulses, of an amplitude significantly greater than 
that observed in the control noise series were observed in 
the volunteers’ samples. We calculated the CV for each 
series of samples. The mean CVs for the volunteers’ samples 
were 7.5% (SD 2.6%, n = 6) and 6.7% (SD 1.2%, n = 6) for 
melatonin and aMT6s, respectively, whereas for the concen­
tration-matched noise series the mean CVs were 4.3% (SD 
0.3%, n = 6) and 7.9% (SD 0.3%, n = 6), respectively. We 
thus observed a slightly greater variability in the volunteer 
melatonin samples than in the noise series.
Using the three-CV criterion, we observed peaks in both 
the melatonin noise series (11 peaks in total) and the 
volunteer melatonin samples (14 peaks in total). In the 
aMT6s noise series we observed a total of three peaks, 
whereas in the volunteer aMT6s samples only one peak was 
observed. The total number of peaks observed in the volun­
teer melatonin or aMT6s samples compared with the total 
number of peaks in concentration-matched control series 
showed no significant difference by the paired Student’s t- 
test (two-tailed).
Correlation between concentration of melatonin in plasma
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and urinary aMT6s excretion. Plasma aMT6s, like melato­
nin, has a marked circadian rhythm, as previously shown by 
use of a small number of subjects (6). In the 22 subjects 
reported here, the mean concentrations of melatonin in 
plasma ranged from 8.0 ng/L (14:00-18:00 h) to 49.6 ng/L 
(04:00 h), while the mean concentrations of aMT6s in 
plasma ranged from 11.0 ng/L (16:00-21:00 h) to 85.2 ng/L 
(05:00 h) (Figure 4).
Table 2. Correlation between Individual Values for 
Plasma Melatonin, Plasma aMT6s, and Total Urinary 
aMT6s Excreted during 24-h
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Fig. 4. Mean (±  SEM ) concentrations of melatonin and aMT6s in 
plasma from 22 subjects (16 men and six women) sampled for 24 h
The mean excretion of aMT6s was (fig aMT6s; mean ± 
SD, n = 18 each) 0.68 ±0.27 (12:00-18:00 h), 1.24 ±0.65 
(18:00-24:00 h), 4.38 ±1.84 (24:00-06:00 h), and 1.87 ±1.08 
(06:00-12:00 h). The mean total 24-h urinary aMT6s excre­
tion was 8.76 ±3.43 fig aMT6s (mean ± SD, n = 22).
We used the coefficient of linear regression to establish 
the relationships between the AUC of the individual plasma 
melatonin and plasma aMT6s profiles and the respective 
peak height of the profiles, with the individual 24-h urinary 
aMT6s excretion. We observed significant correlations be­
tween all these (Table 2). The most important correlation 
was that between plasma melatonin (AUC of 24-h profile) 
and total 24-h urinary aMT6s (r = 0.75, P  = 0.0002, n = 22).
Discussion
We show that this RIA for aMT6s is sensitive, specific, 
relatively simple, and very robust. The assay is direct for 
both plasma and urine, obviating lengthy extraction proce­
dures. There is little interference in the assay by the other 
urinary metabolites of melatonin, and it can be ignored in 
physiological studies. The use of affinity-stripped plasma to 
construct standard curves has decreased the concentration
Comparison r P
24-h urinary aM T6s vs: 
Plasma melatonin AUC 0.75 0.0002
Plasma melatonin PH 0.70 0.0005
Plasma aM T6s AUC 0.70 0.0005
Plasma aM T6s PH 0.64 0.002
AUC plasma melatonin vs AUC plasma aM T6s 0.76 0.0001
Plasma melatonin PH vs plasma aM T6s PH 0.73 0.0003
AUC, area under the curve; PH, peak height, n =  22 each.
detectable in plasma from 13.0 ng/L to 5.0 ng/L, and enables 
reproducible aMT6s-free plasma pools to be generated.
The aMT6s standards supplied by other groups were all 
immunoreactively and chromatographically identical to our 
standard, although their potency varied somewhat. The 
commercial availability of a pure standard preparation of 
aMT6s would be highly desirable in the interests of compar­
ing results from different laboratories.
The RIA shows a very good correlation with the gas- 
chromatographic/mass-spectrometric method. As expected, 
the RIA for aMT6s generated consistently lower values than 
the gas-chromatographic/mass-spectrometric method, which 
measures total (free and conjugated) 6-hydroxylated melato­
nin metabolites. In the samples measured by both methods 
the proportion of 6-hydroxylated metabolites excreted as the 
sulfate conjugate was not consistent. Whether this is ascrib- 
able to a variable proportion being excreted as the glucuro- 
nide conjugate remains to be established. Possible reasons 
for this could be genetic differences in the conjugating 
enzymes or possible drug interactions with the conjugating 
enzymes (18). When we repeatedly measured the same 
sample pools by both methods, we found that the proportion 
excreted as the sulfate conjugate remained consistent (data 
not shown), implying that methodological inconsistencies 
were not the cause of the inconsistency.
The observed stability of aMT6s in urine (for up to five 
days at room temperature) is particularly important when 
one is carrying out studies on volunteers in their normal 
social environments. In such volunteers the 24-h excretion 
of aMT6s was consistent during a four-day period, the 
nighttime values being most consistent. Daytime values are 
often at or near the detection limit of the assay; in this study 
we did not restrict fluid intake, and slight assay variations 
might be magnified by larger urine volumes and consequent 
multiplication factors.
The consistency of individual aMT6s excretion very prob­
ably reflects a stable rate of melatonin production in the 
same individuals (19). One consequence of practical impor­
tance is the reliability of both compounds as circadian 
rhythm markers (17).
In this preliminary study, we found no evidence for short- 
duration pulses of melatonin or aMT6s in human plasma 
taken from the antecubital vein. If blood sampling is fre­
quent, the probability of detecting false-positive peaks due 
to assay noise is increased. It is important to include data on 
the variability in repeated measurements of the same 
samples, something that previous reports on short-duration 
pulses and episodic secretion of melatonin have omitted (13, 
14). Ideally, a more rigorous criterion than an increment 
from nadir to peak of three times the intra-assay CV should 
be used to identify peaks, such as multiple measurement at
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each time point (20). Unfortunately, with the volume of 
plasma required in our assays this was not possible. In the 
melatonin assay a slightly greater variability was observed 
in the volunteers’ samples than in the control noise series. 
In view of other reports, notably studies of sheep, it is likely 
that human melatonin secretion is episodic but that concen­
tration differences, for example, in the jugular vein (14,15) 
may be "damped” in the antecubital vein.
The correlation between urinary aMT6s excretion and 
concentrations of melatonin in plasma is a very important 
relationship, because it validates the use of the urine assay 
as an index of the endogenous concentrations of melatonin 
in plasma. Markey et al. (21) reported a correlation coeffi­
cient of 0.76 between plasma melatonin and urinary 6- 
hydroxymelatonin. This is confirmed by our correlation 
coefficient (0.75) between plasma melatonin and urinary 
aMT6s.
In conclusion: measurement of urinary aMT6s evidently 
is a very useful tool in the study of pineal function. In 
normal volunteers urinary aMT6s is a good integrative 
measure of plasma melatonin. Whether or not this relation­
ship is maintained in pathological and clinical situations 
remains to be established.
This work was supported by the Wellcome Trust. We thank Dr. J. 
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Annual Changes in 6-Sulphatoxymelatonin Excretion in Man
Christopher J.Bojkowski and Josephine Arendt
Abstract
A recently developed RIA for 6-sulphatoxymelatonin, the major urinary 
metabolite of melatonin, has been used to investigate the annual change in melatonin 
secretion in humans. Twenty plasma samples were taken from 18 volunteers 
throughout a 24h period and simultaneous 6-hourly urine samples were also collected. 
Plasma melatonin and urinary 6-sulphatoxymelatonin were measured by RIA. 6- 
sulphatoxymelatonin assayed in the urine samples was shown to be a good index of the 
rhythmic characteristics of the plasma melatonin secretion.
To study annual changes in excretion, four sequential 6-hourly urine samples 
were collected at monthly intervals from 16 normal volunteers for 13 months. Cosinor 
curves were fitted  to the 6-sulphatoxymelatonin excretion data and the 24h rhythm 
was described by the cosinor parameters; amplitude, mesor and acrophase. Significant 
differences in the acrophase were found during the year. The summer acrophase was 
phase advanced relative to the winter acrophase by about 1.5h while intermediate 
phase positions were observed in spring/autumn.
The 24h excretion of urinary 6-sulphatoxymelatonin was remarkably consistent 
and there was no annual rhythm. In contrast, the daytime 6-sulphatoxymelatonin 
excretion between 1200-1800h showed a sta tistica lly significant seasonal rhythm, w ith 
peaks in December/January and in July.
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